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ABSTRACT OF THE DISSERTATION
REGULATION OF TELOMERASE ACTIVITY BY RAB5 GUANINE NUCLEOTIDE
EXCHANGE FACTORS
by
Patric Hambleton
Florida International University, 2019
Miami, Florida
Professor Manuel A. Barbieri, Major Professor
Many cancerous cells display abnormalities in the signal transduction pathways
responsible for responding to extracellular growth factors. Growth factors, such as insulinlike growth factor I, represent a major class of mitogenic ligands that can initiate the
mitogen activated protein kinase (MAPK) pathway. The role of the MAPK pathway in
transducing growth signals to the interior of the cell and subsequently stimulating cell
growth and proliferation is highlighted by the fact that roughly one quarter of all human
tumors contain mutant forms of Ras proteins. Ras interference 1 (Rin1) is involved in key
steps of receptor mediated endocytosis and can potentially moderate signaling through the
MAPK pathway. The possible connection between Rin1, an effector of the active form of
Ras, and subsequent telomerase gene expression and activity is of particular interest as
telomerase is active in roughly 85% of all cancers. In this study, we determine the effect of
the expression of Rin1 on cellular proliferation as well as on telomerase gene expression
and activity in several different human cancer cells. MDA-MB 231, MCF7, and MCF-12A
breast cell lines expressing Rin1 exhibit reduced levels of proliferation of up to 31%
following exposure to the IGF-1 growth factor. Telomerase activity and gene expression
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were also reduced by factors of up to 1.5 and 2.55 fold in the three breast cell lines studied
when compared to control cells. Similarly, overexpression of Rin1 in human Yusik
melanoma cells leads to reduced telomerase activity. Telomerase activity was determined
by the telomeric repeat amplification protocol (TRAP) assay while gene expression was
measured by RT-qPCR. Furthermore, our observations suggest that overexpression of the
Rin1 Y561F mutant and Rin1 delta splice variant in MDA-MB 231 cells results in
increased proliferation and telomerase activity in these cancer cells when compared to
control cells. The MDA-MB 231 cells expressing wild type Rin1 displayed lowered levels
of phosphorylation for the p-44/42 (ERK), STAT3, and Ets2 transcription factors.
Additionally, overexpression of the C-terminus region of Rin1 in these cells greatly
reduced ERK phosphorylation. In summary, Rin1 may play a novel tumor suppressor role
in modulating signaling through the Ras/MAPK pathway upon IGF-1 stimulation.
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CHAPTER 1
Introduction
1.1

The Role of Telomerase in Cancer Cells
Cancer is a disorder of the cell cycle. The hallmark of any malignant tumor is the

abnormal and excessive proliferation of cells which begins to impair the normal
functioning of a tissue or organ (Buseman et al., 2012). In healthy cells, the events and
timing of the cell cycle are precisely regulated so that cells only divide under appropriate
circumstances in a controlled manner. The tight regulation of the events of the cell cycle is
largely accomplished through the use of key checkpoints (G1, G2, M) in which a cell can
temporarily halt progression through the cycle to assess if crucial events have occurred
properly to that point (Buseman et al., 2012). Many types of cancer cells have lost the
ability to arrest the cell cycle at one or more of the important checkpoints. Thus, these cells
progress atypically through the cell cycle regardless of aberrations which would otherwise
cause healthy cells to not divide. Any number of abnormal events may occur both internally
and externally that result in the loss of a checkpoint (Buseman et al., 2012). The most
common cause of many of the classic abnormalities associated with cancer cells is
mutation. A change(s) in the DNA sequence of critical cell cycle regulation genes is usually
the main culprit. For instance, mutations in the DNA of tumor suppressor genes such as
p53 or the genes which code for proteins involved in cell signaling are quite prevalent in a
variety of different cancers (Chen & Chen, 2011).
1.1 A.

Telomere Structure and Function

Telomeres are unique regions of DNA located at the very tips of eukaryotic
chromosomes. These regions of DNA typically consist of a highly repetitive sequence
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(TTAGGG in vertebrates) and are tasked with a number of important functions related to
chromosome structure and integrity. Principal among these, is the role of telomeres in
acting as a sort of molecular clock during cell division. The repetitive DNA at the telomeres
acts as a buffer which slows the erosion of important regions of DNA during successive
rounds of cell division. As most somatic cells progress though the cell cycle, a loss of
approximately 150 bp of DNA occurs at the telomeric regions with each round of division
(Dwyer et al., 2007; Liu, 1999) This loss is a result of the inability of DNA polymerase
enzymes to complete DNA synthesis on the lagging daughter DNA strand during
replication (S phase). As a consequence, the telomeres become progressively shorter with
each round of cell division and the amount of DNA loss serves to indicate the number of
divisions (Gomez et al., 2012). The telomeres are eventually eroded to a critical threshold
length at which time they become unstable and a multitude of cellular DNA damage
mechanisms are activated to initiate replicative senescence or apoptosis (Dwyer et al.,
2007). Erosion of telomeres has important meaning for aging and tumorigenesis.
Structurally, telomeric DNA is observed to exist as large duplex loops known as t-loops
(Liu, 1999). A t-loop occurs when the single stranded 3’ overhang left behind after DNA
synthesis is looped back around and inserted into the double stranded telomeric repeat
region. The formation of t-loops helps to protect the telomeres from further DNA damage,
fusion, and recombination by various cellular DNA repair enzymes, and may also be
necessary for proper replication of the telomeric DNA (Liu, 1999). A six subunit protein
complex known as “shelterin” aids in the formation of t-loops and is also thought to be
involved in regulating telomerase activity. Telomere repeat factor 2 (TRF2), a protein
essential to t-loop formation, is part of the shelterin complex along with TRF1, POT1,
2

RAP1, TIN2, and TPP1. Collectively, these telomere binding proteins, among others, are
shed during repeated rounds of cell division as a consequence of telomere shortening and
may serve to interact with signaling molecules. Reduction of telomere length may also
promote the expression of genes which are sensitive to telomere length, a phenomenon
which has been reported for the p53 tumor suppressor gene in mice (Liu, 1999).
1.1 B.

Telomerase Structure and Function

While most somatic cells will enter senescence or undergo apoptosis after roughly 50
to 70 rounds of cell division, there are certain populations of cells which can avoid these
fates. These include embryonic stem cells, adult somatic stem cells, and germ cells. A
ribonucleoprotein with reverse transcriptase ability known as telomerase is responsible for
preventing the shortening of telomeres in cells that express it. The enzyme in humans
consists primarily of a 445 nucleotide RNA template (hTR) which directs the extension
and addition of the telomeric repeat sequence (TTAGGG), and an accompanying 1132
amino acid (120 kDa) catalytic subunit with reverse transcriptase activity (hTERT). The
RNA subunit is encoded by a single gene and is integral to the function of the enzyme (Liu,
1999).
One of the major causes for the rapid rate of cell division observed in multiple types of
cancer is the overexpression of telomerase. While telomerase expression is suppressed in
the vast majority of normal somatic cells, its expression and activity can be quite significant
in many types of cancerous cells (Liu, 1999). In fact, overexpression of telomerase is
observed in approximately 85% of all human cancers and often confers an immortal
phenotype to those cells which overexpress it (Liu, 1999). The deregulation of cell
signaling pathways which results in the abnormal expression of telomerase is a hallmark
3

of most cancers and is therefore of great clinical importance. The idea that cancer cells
abnormally express telomerase is logical given that cancer cells undergo rapid and aberrant
cell division, and thus may rely on telomerase expression to prevent the excessive
shortening of chromosomes which would otherwise induce senescence or apoptosis.
1.1 C.

Signal Transduction Pathways and the Regulation of Telomerase Activity

The unique role that telomerase plays in cancer cells has been widely reported. In fact,
roughly 80% to 90% of all cancer cells display high levels of telomerase activity (Buseman
et al., 2012; Chen & Chen, 2011; Gomez et al., 2012). Therefore, telomerase is an ideal
target for cancer therapies because the enzyme is not expressed in the vast majority of
normal somatic cells and can be targeted with some specificity only in the cancerous cells.
Telomerase activity in cancer cells appears to enable these cells to maintain the length of
their telomeres above the critical threshold for triggering senescence or apoptosis. As a
consequence, cancer cells tend to escape the normal cellular mechanisms of senescence
and apoptosis, which are designed to prevent any further cell division in cells that have
unstable and/or damaged chromosomes (Bernardes de Jesus & Blasco, 2013).
Like many proteins, telomerase activity is regulated at both the protein level and the
gene level (Dwyer et al., 2007). At the protein level, a number of protein kinases and
phosphatases are involved in controlling telomerase activity (Dwyer et al., 2007). For
instance, the telomerase catalytic subunit hTERT is phosphorylated and activated by both
PCKα and Akt in human breast cancer cells (Dwyer et al., 2007). Phosphorylation of an
associated protein, TEP1, which binds to the RNA template has also been shown to
increase telomerase activity. On the contrary, telomerase activity can be greatly reduced
by the action of the protein phosphatase PP2A in breast cancer cells (Liu, 1999). The
4

importance of the reciprocal action of PKCα and PP2A in regulating telomerase activity is
underscored by the fact that there is usually an imbalance in the action of these enzymes in
cancer cells. The PKCα activity tends to exceed that of PP2A in breast cancer cells because
of stimulation by an assortment of tumorigenic compounds and growth factors such as IGF1. The PP2A activity is likewise inhibited by the combined action of growth factors such
as EGF and other tumorigenic antigens and compounds (Liu, 1999). The drug Tamoxifen
is effective against breast cancer because it inhibits PKCα (Liu, 1999). The regulatory
imbalance between PKCα and PP2A is significant because it results in elevated telomerase
activity which in turn promotes tumorigenesis in breast cancer cells. It has even been
suggested that the p53 protein may interact directly with telomerase to reduce its activity
and thus may represent one mechanism by which the p53 gene acts as a tumor suppressor
(Liu, 1999).
Besides regulation of telomerase activity at the protein level via the action of protein
kinases and phosphatases, telomerase activity can also be regulated at the gene level- that
is, at the level of gene expression or transcription. When discussing transcriptional control
of telomerase expression, it is necessary to examine the hTERT promoter. It is well
established that the c-Myc transcription factor is strongly linked to cellular proliferation,
and it comes as no surprise that telomerase expression is upregulated by c-Myc. The c-Myc
is able to interact directly with the hTERT promoter and stimulate hTERT expression.
Transcription factors such as c-Myc stimulate gene expression by binding to specific
sequences within the promoter region of a gene, and many cancer cells often accumulate
mutations within the promoters of key cell cycle regulatory genes.

5

In a large scale study of 799 tumor samples, Huang et al. (2015) identified two specific
mutations which were present in the hTERT promoter in a high percentage of the tumor
samples. Specifically, these mutations C228T and C250T occur at 124 and 146 bp upstream
of the hTERT translation start site and are prevalent in many different types of tumors
(Huang et al., 2015). The authors conclude that each mutation creates a new binding site
for the E-twenty six (Ets) group of transcription factors which subsequently results in the
upregulation of telomerase expression. Upregulation of telomerase activity has also been
reported as a consequence of the hypoxia commonly found in solid tumors, where the
enzyme may aid in the stabilization of chromosomal damaged induced by the low oxygen
environment (Seimiya et al., 1999). Increased telomerase expression has also been
observed in hepatocytes undergoing cell division in response to partial removal of liver
tissue, and this telomerase expression is stimulated by both EGF and hepatocyte growth
factor (HGF) (Inui et al., 2002). In each instance, the upregulation of telomerase expression
was a direct response to signaling through the MAPK pathway.
The central role that the MAPK signaling pathway plays in telomerase activation is
illustrated in a study by Maida et al. (2002). The effect of EGF stimulation on telomerase
expression was investigated by exposing A-431, ME180, MCF-7, and NIH3T3 cells to
EGF for various periods of time, and then assessing hTERT mRNA expression. There was
a significant increase in hTERT mRNA expression in all of the cell types between 6 to 12
hours after EGF exposure. The increase in hTERT mRNA expression in response to EGF
stimulation was confined to these cell types which constitutively express telomerase and
was not observed in telomerase negative cell types. The authors conclude the MAPK
pathway is primarily responsible for EGF induced telomerase expression. The A-431 cells
6

stimulated with different concentrations of EGF for either 15 or 30 minutes showed a
marked increase in ERK activity and hTERT expression. Exposure to the MEK inhibitor
U0126 abolished this effect but exposure to PI3K or p38 inhibitors did not. Furthermore,
the authors demonstrate that EGF exerts its influence on telomerase expression through the
MAPK pathway via activation of the Ets family of transcription factors. The Ets group of
transcription factors are phosphorylated and activated by ERK, and the hTERT promoter
contains two Ets binding motifs within it at -23 and -18. A-431 cells co-transfected with a
wild-type Ets2 expression vector and an hTERT promoter reporter plasmid revealed high
levels of EGF induced transactivation when compared to cells co-transfected with a
truncated, dominant negative Ets2 expression plasmid.
A similar result was observed in cells transfected with either a normal hTERT promoter
reporter plasmid or a plasmid containing mutations in the Ets binding motifs (Maida et al.,
2002). The MPAK pathway has also been implicated in the activation of telomerase
activity and hTERT mRNA expression in estrogen receptor α (ERα) positive endometrial
cells. Zhou et al. (2013) report that stimulation of Ishikawa ERα positive endometrial cells
with estradiol (E2) results in increased phosphorylation p44/42 MAPK and increased
hTERT mRNA expression. The hTERT promoter contains two binding sites for E2-ERα
complexes, and the stimulatory effect of E2 on hTERT expression and telomerase
activation was greatly reduced by exposure to the MEK inhibitor U0126 or ERK specific
siRNA (Zhou et al., 2013). The MAPK pathway therefore appears to play a prominent role
in the estrogen induced regulation of hTERT expression and telomerase activity.
As downstream targets of the MAPK pathway, the Ets family of transcription factors
have recently been implicated in the regulation of telomerase gene expression and activity.
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The Ets family of transcription factors consists of more than thirty closely related proteins
first identified in the E26 avain leukemia retrovirus. The Ets transcription factors display a
conserved 85 amino acid helix-turn-helix motif capable of binding to a core consensus
sequence (GGAA/T) located within the promoters of various target genes, which often
times encode key proteins involved in the regulation of the cell cycle (de Launoit et al.,
2006). The Ets group of transcription factors therefore have figured prominently into
cellular proliferation and tumorigenesis. For instance, a number of studies have indicated
that Ets1 and Ets2 are commonly overexpressed in a variety of cancers (de Launoit et al.,
2006). The Ets2 transcription factor in particular is frequently upregulated in breast cancer
cells. Dweyer et al. (2007) report that siRNA mediated silencing of Ets2 gene expression
significantly reduced telomerase gene expression and activity in MCF7 breast cancer cells.
There was also an interesting inhibition of c-Myc expression which suggests a potential
role of Ets2 as a transcriptional activator of the c-Myc gene, which is a known transcription
factor in the expression of telomerase. In this model, phosphorylation and activation of
Ets2 by ERK results in enhanced transcription of c-Myc which in turn stimulates
telomerase gene expression.
Telomerase expression is simultaneously enhanced by the binding of activated Ets2 to
the telomerase promoter and it is possible that Ets2 may even form a complex with c-Myc
(Xu et al., 2008). In colon cancer, the formation of the Ets2/c-Myc complex may be
mediated by Ruv-B like helicase 2 (Ruvbl2) which can interact with Ets2 (Flavin et al.,
2011). Similarly, Hepatitis B virus core protein has also been shown to upregulate
telomerase expression in conjunction with the Ets2 transcription factor in HepG2 cells (Gai
et al., 2013). The specificity of Ets2 for its binding sites underlies its ability to regulate
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telomerase expression. Xiao et al. (2003) investigated whether the binding of Ets2 to
different Ets binding elements within the telomerase promoter had any influence on
telomerase promoter activity. Mutagenic experiments revealed that specific Ets binding
elements were associated with increased promoter activity while others were associated
with decreased activity. Along the same line, Hsu et al. (2006) report that a single
nucleotide polymorphism (SNP) located at -245 bp upstream of the telomerase promoter
may act to increase telomerase activity in non-small cell lung cancer.
The importance of the Ets family of transcription factors in the regulation and
expression of telomerase continues to be supported by a growing body of evidence. Goueli
and Janknecht (2004) report that the Ets transcription factor ER81 is primarily responsible
for upregulation of telomerase expression in SKBR3 breast cancer cells which overexpress
the HER2/Neu receptor tyrosine kinase. The HER2/Neu receptor is overexpressed in the
majority of breast tumors and its expression is likely enhanced by ER81. The authors also
report that ER81 is capable of stimulating telomerase expression as it is a downstream
target of the MAPK pathway. Active HER2/Neu can stimulate Ras which in turn will
activate RAF1 and result in the downstream phosphorylation of ER81 by ERK. Once
activated by ERK, ER81 can then stimulate expression of telomerase. Mutation of the
ER81 binding sites within the telomerase promoter or inhibition of ER81 phosphorylation
by ERK resulted in decreased telomerase expression and activity. A similar result was
obtained by inhibition of HER2/Neu or the expression of a dominant negative form of
ER81 (Goueli and Janknecht, 2004). The ER81, also known as Etv1, belongs to the PEA3
group of Ets transcription factors. The PEA3 transcription factors are known to regulate
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the expression of several matrix metalloproteases and may therefore figure prominently in
the development of metastasis (de Launoit et al., 2006).
As mentioned previously, the overexpression of telomerase in most types of cancer cells
is usually the result of aberrant cell signaling pathways. Much research has focused on
identifying the principal molecules involved in controlling the expression of the telomerase
promoter. The goal of promoter research is to be able to target expression of the enzyme at
the transcriptional level. For example, in a study of 327 patients with urothelial cell
carcinoma of the bladder, Rachakonda et al. (2013) described the existence of common
mutations within the telomerase promoter. Mutations at 124 and 146 bp upstream of the
transcription start site were present in 65% of the samples. The mutations create new
binding sites for the Ets/TCF group of transcription factors which increase promoter
expression between two and four fold (Rachakonda et al., 2013). The presence of an
additional single nucleotide polymorphism in an existing Ets binding site of the telomerase
promoter appears to moderate the effect of these two upstream mutations. Patients without
a variant allele of the SNP but with the two upstream mutations showed reduced survival
and greater tumor recurrence when compared to patients with a variant allele of the SNP
(Rachakonda et al., 2013).
Zhao et al. (2009) report that chromosomal mutations which translocate the human
telomerase gene and its promoter (located near the telomere of chromosome 5 arm p) to
heterologous sites often results in transcriptional activation of the telomerase gene. The
gene is not normally expressed in most somatic cells due to its location within highly
condensed chromatin. However, translocation to other chromosomal sites with less

10

restrictive chromatin structure may allow the telomerase promoter to become activated
(Zhao et al., 2009).
The Wnt/beta-catenin signaling pathway has been shown to be involved in the activation
of telomerase expression in a number of different types of human cancers. The Wnt
pathway is crucial for normal cell differentiation and proliferation during embryonic
development and beta-catenin is an effector of this pathway which can help activate the
expression of Wnt target genes (Zhang et al., 2012). The Wnt/beta-catenin pathway is often
active and not properly regulated in most cancer cells. When Wnt signaling is inactive,
beta-catenin is targeted for destruction by phosphorylation. On the other hand, when Wnt
signaling is active, beta-catenin is not targeted for destruction and travels into the nucleus
where it binds to LEF/TCF transcription factors. The LEF/TCF transcription factors
normally bind to DNA and repress the expression of target genes (Zhang et al., 2012).
Beta-catenin forms a complex with TCF4 and results in the expression of many genes
(c-Myc, cyclin D1, and NOS2) which may contribute to cancer formation (Zhang et al.,
2012). Zhang et al. (2012) provide evidence that the Wnt/beta-catenin pathway can also
result in the activation of telomerase expression in human cancers. Using different cancer
cell lines, the investigators were able to demonstrate that removal of beta-catenin by RNAi
significantly reduced telomerase gene expression and activity in Wnt+ cancer cells. FH535,
a beta-catenin/TCF inhibitor, was also shown to greatly reduce telomerase activity in all of
the cancer cell lines studied (Zhang et al., 2012).
In a similar study of human colorectal carcinoma, Jaitner et al. (2012) were also able to
demonstrate the ability of beta-catenin to regulate expression of the telomerase gene. The
researchers determined that telomerase gene expression depends in part on the binding of
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the oncogene transcription factor c-Myc to the telomerase promoter, and that c-Myc
expression itself is stimulated by beta-catenin in Wnt signaling cells (Jaitner et al., 2012).
However, a more interesting discovery was made in that the telomerase enhancer/promoter
was determined to have four binding sites for beta-catenin/TCF-4 complexes. Thus, it was
shown that the telomerase gene can also be directly regulated by beta-catenin and in a way
that is independent of c-Myc.
For instance, the data suggest that the expression patterns of telomerase and beta-catenin
mirror one another but not that of c-Myc. c-Myc, while able to stimulate telomerase
expression, is present ubiquitously in cancer cells and its expression appears to be
controlled by various pathways (Jaitner et al., 2012). Zhang et al. (2012) suggest that in
normal, non-cancerous cells c-Myc induced expression of telomerase is mediated by the
suppressive effect of the E2F1 transcription factor. c-Myc promotes expression of E2F1
which then binds to the telomerase promoter and reduces the ability of c-Myc to activate
expression of telomerase. The c-Myc and E2F1 stimulate each other’s expression and this
positive feedback mechanism is regulated in normal cells through the use of miRNAs
(Zhang et al., 2012). Listerman et al. (2014) looked at whether or not telomerase itself can
bind to and activate expression of Wnt target genes. The HeLa cells and human breast
cancer cell lines were used in the study and the authors failed to find any evidence for the
ability of telomerase to interact directly with beta-catenin or the chromatin remodeling
protein BRG1. Additionally, altering the levels of telomerase in the breast cancer cell lines
had only a minimal effect on Wnt signaling and target gene expression (Listerman et al.,
2014).
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The Hedgehog signaling pathway, which is important in cell specialization and tissue
formation during embryonic development, is abnormal in a number of different types of
cancer cells (Mazumdar et al., 2013). The Hedgehog pathway results in the activation of
the GLI group of transcription factors. Mazumdar et al. (2013) investigated whether
telomerase is a target of Hedgehog signaling via GLI transcription factors. Inhibition of
GLI1 and GLI2 through various mechanisms resulted in a significant decrease in
telomerase expression in prostate cancer, Glioblastoma multiforme, and colon cancer cell
lines compared to controls. GLI1 and GLI2 were shown to interact directly with the
telomerase promoter by chromatin immunoprecipitation (Mazumdar et al., 2013). The
results indicate that telomerase expression can be influenced by abnormal Hedgehog
signaling.
The role that the deacetylase enzyme SIRT1 plays in transcriptional activation of the
telomerase promoter in hepatocellular carcinoma was investigated by Zhang et al. (2014).
Epigenetic modifications of the chromatin structure of promoter and enhancer regions of
DNA is a primary mechanism by which cells regulate activation of transcription and thus
gene expression. Acetylation of histones promotes transcription by relaxing the association
of DNA with histone proteins while methylation of histones appears to reduce transcription
by increasing chromatin condensation. The researchers hypothesized that SIRT1 plays an
important role in remodeling the chromatin of the telomerase promoter which then results
in enhanced expression of telomerase in hepatocellular carcinoma. The results indicate that
SIRT1 does not regulate telomerase expression via CpG island methylation at the
telomerase promoter (Zhang et al., 2014). Additionally, the data suggest that the inhibition
of SIRT1 in hepatocellular carcinoma SK-HEP-1 cells results in acetylation of the ninth
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lysine residue of histone H3 as well as reduced methylation at the same position (Zhang et
al., 2014). These epigenetic changes to the chromatin structure of the telomerase promoter
should increase telomerase expression. However, the researchers observed the opposite.
Telomerase expression was reduced and the authors offer no explanation for the
mechanism of action.
Yamada et al. (2012) studied the ability of Interleukin-2 (IL-2) to stimulate telomerase
expression in adult T cell leukemia (ATL) cells. The results show that IL-2 binds to its
receptor in the cell membrane and consequently stimulates a number of signaling pathways
that ultimately lead to telomerase expression. The binding of IL-2 results in
phosphorylation of tyrosine residues in Janus activated kinases 1-3. Activated JAK1 and
JAK2 then phosphorylate the transcription factor STAT5 which travels into the nucleus
and binds to the telomerase promoter, resulting in the expression of telomerase (Yamada
et
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2012).
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PI3K/AKT/mTORC1/S6K pathway in ATL cells as well. The pathway increases
telomerase expression both transcriptionally and post-translationally. Knockdown of
STAT5 by RNAi was also shown to reduce telomerase expression (Yamada et al., 2012).
Human lymphoblastoid cells were used as a positive control for the telomerase activity
assays and beta actin was used as a positive control for telomerase mRNA assessment by
RT-PCR.
Prostate cancer provides an excellent example of the influence of androgen signaling
pathways on telomerase expression. Liu et al. (2010) examined LNCaP prostate cancer
cells with the goal of determining how androgen signaling affects expression of telomerase.
A dose dependent response in telomerase promoter activity with various concentrations of
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DHT was observed. Higher concentrations resulted in greater activity. Inhibition of
androgen receptor expression by RNAi resulted in a significant reduction of telomerase
mRNA in LNCaP cells. The investigators were also able to demonstrate that the drug
methylseleninic acid (MSA) can also reduce telomerase mRNA levels by inhibiting the
synthesis of androgen receptor (AR). The fact that androgen activated AR can bind to the
telomerase promoter and facilitate transcription was confirmed by chromatin
immunoprecipitation assay.
Holysz et al. (2013) highlight the significant role that telomerase has in the etiology of
breast cancer. The authors cite numerous studies which indicate that transcriptional
activation of the telomerase gene promoter by various transcription factors such as c-Myc
or wnt appears to be a key step in the transformation of normal cells into malignant cancer
cells (Bernardes de Jesus & Blasco, 2013). The telomerase promoter has several binding
sites for transcription factors which are involved in a number of cellular pathways. For
instance, production of transcription factors induced by the binding of human epidermal
growth factor 2 (Her2) as well as the transcription factor ER81 have both been shown to
cause increased expression of telomerase in human breast tissue (Holysz et al., 2013).
Estrogen has been demonstrated to cause a similar effect by binding to and activating a
cytoplasmic receptor which then travels to the nucleus and can activate control elements
linked to the telomerase promoter.
If the telomerase promoter can be activated by various transcription factors which are
normally present in cells, why then is telomerase not expressed continuously in most
somatic cells? The answer seems to lie in the action of proteins encoded by tumor
suppressor genes. In breast tissue, the protein product of the BRCA1 tumor suppressor gene
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interacts with c-Myc and prevents it from binding to regulatory regions of the telomerase
promoter. The BRCA1 gene product has also be shown to interfere with the proteins TRF1
and TRF2 which are necessary to recruit telomerase to the telomere regions of
chromosomes (Holysz et al., 2013). The protein product of the p53 tumor suppressor gene
acts in a similar fashion by interacting with certain transcription factors which could
potentially activate the telomerase promoter. The result of the interaction is decreased
expression of the telomerase gene (Bernardes de Jesus & Blasco, 2013).
Telomerase is active and overexpressed in a number of other cancers besides breast
cancer. Small cell lung cancer as well as non-small cell lung cancer both exhibit high levels
of telomerase activity, with SCLC being telomerase positive in approximately 90% to
100% of cases (Chen & Chen, 2011). High levels of the enzyme is correlated with poor
survival in both types of lung cancer. The role that telomerase plays in gastric cancer is
less certain. A few studies have indicated that a high level of telomerase activity is
associated with the degree of malignancy of a tumor (differentiation and depth of invasion)
while other studies have been unable to arrive at such a conclusion (Chen & Chen, 2011).
However, what has been demonstrated more clearly is that the presence of telomerase in
the peritoneal fluid of gastric cancer patients is a clinical sign of advanced stages of the
disease, including metastasis (Chen & Chen, 2011).
The exact role that telomerase plays in renal and intestinal cancers is uncertain. The
tissues of these organs normally express detectable levels of the enzyme, and it is often
difficult to establish a threshold value of telomerase activity which is associated with
malignancy. Once an adenomatous polyp forms in the colon, telomerase activity has shown
some relationship to the grade and size of the polyp. However, in most colon cancers it
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seems that the presence of high levels of telomerase mRNA is a good indicator of
metastasis. Telomerase activity in renal cancer has not been shown to be correlated with
any clinical parameters or survival (Chen & Chen, 2011). Although about 90% of all
bladder cancers display high levels of telomerase activity, it is not always associated with
malignancy. Normal bladder tissue can test positive for the enzyme, which again, makes it
difficult to distinguish the fine line between normal and abnormal (cancerous) levels of
activity. Most uterine cancers fall under the same umbrella because of the fact that
endometrial cells express varying levels of telomerase activity normally depending on the
stage of the menstrual cycle (Chen & Chen, 2011).
Finally, telomerase levels and activity appear to mirror well the transition that cervical
cells undergo as they become cancerous. As cervical cells progress through the three nonmalignant stages prior to becoming malignant, there appears to be an increasing trend in
telomerase expression and activity. An estimated 90% of cervical cell carcinomas will
eventually display elevated levels of telomerase mRNA and activity (Chen & Chen, 2011).
In ovarian cancer, telomerase expression and activity have been shown to vary widely
depending on the clinical classification of the tumor (Chen & Chen, 2011). In comparison
to most carcinomas, sarcomas typically display reduced levels of telomerase activity and
seem to rely on other non-telomerase mediated mechanisms to lengthen their telomeres
(alternative lengthening of telomeres or ALT) (Chen & Chen, 2011). For example, Hu et
al. (2013) demonstrated in transgenic mice that alternative lengthening of telomeres
mechanisms linked to mitochondrial functions can even be activated in lymphomas as well.
The transgenic mice contained an inducible telomerase expression system which could be
manipulated by the researchers. Inhibition of telomerase expression in the lymphoma cells
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resulted in an initial decrease in the growth of the cancer cells but also resulted in the
subsequent activation of alternative lengthening of telomeres pathways and the survival of
the tumors.
1.1 D.

Telomerase as a Cancer Target

Telomerase inhibition in cancer cells has been active area of research because, as
mentioned earlier, a large percentage of different cancers express telomerase at high levels
compared to normal, healthy cells. This important difference offers the promise of
developing therapies that are specific to cancer cells while helping to minimize the adverse
side effects observed with many conventional therapies. There are three broad strategies
currently available to target telomerase. The first of which is the use of drugs, or
medications, which interfere with the biochemical activity of the enzyme. A classic
example is the drug GRN163L (Imetelstat). Imetelstat works by preventing the binding of
the RNA template component of telomerase with the protein portion of the enzyme. The
end result of this interaction is a nonfunctional enzyme. However, there is a lag period of
time after initial exposure of cancer cells to a telomerase inhibitor and reduced tumor
growth. This lag period is partially a result of the time it takes for telomeres to become
shortened enough in the presence of the drug to allow for activation of senescence or
apoptosis (Buseman et al., 2012). Often times, it is recommended to combine treatment
with a telomerase inhibitor with traditional therapies such as radiation and chemotherapy.
The combination therapy could prevent any further growth of the tumor during this lag
phase of time before the drug starts to have an effect. Telomerase inhibitors have also been
proposed as maintenance drugs following conventional treatment as a way of possibly
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inhibiting any residual cancer cells from causing a relapse of the disease (Buseman et al.,
2012).
The second category of telomerase inhibition is immunotherapy, or vaccination. Many
telomerase positive cancer cells express telomerase specific antigens, or peptides, on their
cell membranes. Vaccines can be developed from protein fragments of the telomerase
enzyme or from actual AP (antigen presenting) cells which display telomerase peptides on
their surfaces. A few vaccines of these types are currently in clinical trials and most show
promising results (Buseman et al., 2012).
The third type of telomerase inhibitor makes use of gene therapy. The telomerase gene
promoter has been linked to apoptotic genes such as TRAIL or a caspase. Through a viral
mechanism or some other gene delivery format, these apoptosis inducing genes under the
control of the telomerase promoter can be introduced into cancer cells. The cells will then
express these genes whenever the telomerase promoter is transcribed. Alternatively,
adenoviruses have been engineered in which two viral genes necessary for replication only
are under the control of the telomerase promoter. Viral infection of cancer cells results in
the expression of the telomerase promoter and virus genes, resulting in the lysis of the
cancer cells. A clinical trial with Telomelysin, an engineered adenovirus, is currently
underway and the preliminary results appear encouraging despite notable failures of this
approach in the past (Buseman et al., 2012).
The important role that telomerase plays in the life of most cancer cells is illustrated by
the number of research articles which have been published within the past five to six years
investigating various aspects of this enzyme with respect to cancer cell survival or
mortality. These articles can be broadly grouped according to their design as investigating
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the effects of drug inhibitors, immunotherapy/gene therapy, and RNAi on the structure
and/or function of telomerase.
Liu et al. (2012) investigated the effect of the synthetic compound CDDO-Me, an
oleanane triterpenoid, on telomerase activity in mice prostate cancer cells. The researchers
discovered that this drug exerts its anti-tumorigenic effects in two main ways. First, it
interferes with the synthesis of transcription factors such as c-Myc, SP1, and NF-kB which
are necessary to initiate transcription of the telomerase promoter. The phosphorylation
status of another necessary transcription factor, STAT3, is interfered with by the drug as
well (Liu et al., 2012). Secondly, the telomerase enzyme must be phosphorylated on serine
residues 227 and 826 to become activated. The CDDO-Me drug prevents the enzyme Akt
from performing this function (Liu et al., 2012). The Sp family of transcription factors,
which are typically found at high levels in many cancer cells, are an ideal target of the drug.
The SP1 transcription factor interacts with c-Myc to stimulate the production of telomerase
(Liu et al., 2012). The inhibition of telomerase by CDDO-Me via transcriptional and posttranslational mechanisms more than likely allows for the induction of apoptosis in prostate
cancer cells. Moreover, there appears to be a dose-dependent response with levels of the
drug in the 1.25 to 5 uM range producing a significant reduction in tumor growth (Liu et
al., 2012). Deeb et al. (2012) investigated the potential use of CDDO-Me in pancreatic
cancer cells and reported similar results to those of Liu et al. Proliferation of cells was
arrested and apoptosis was induced. Interestingly, overexpression of telomerase by
MiaPaCa-2 and Panc-1 cancer cells transfected with a telomerase expression plasmid
resulted in these cells being significantly less sensitive to concentrations of the drug than
dosages that would otherwise kill other cancer cells (Deeb et al., 2012).
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The structure of telomeric DNA is complex, with a DNA loop that gives rise to guanine
rich tetra-stranded structures called G-quadruplexes. The G-quadruplex structures found at
telomeres tend to inhibit telomerase function by preventing the attachment of the RNA
template of the enzyme to DNA in these regions (Huang et al., 2012). The ability to
stabilize these regions of telomeric DNA could therefore be very useful in reducing
telomerase activity in cancer cells. The compound, BMVC4, has been shown to do just
this. Huang et al. (2012) treated human lung cancer cells, H1299, with various
concentrations of BMVC4 and noted the expected onset of senescence. Cells which
overexpressed telomerase as well as cells which lengthened telomeres by an alternative
mechanism were tested. The fact that senescence was observed in both cell types indicates
that telomerase inhibition may not be the sole cause by which BMCV4 operates. The
investigators worked out that in addition to stabilizing telomeric G-quadruplexes, the drug
also stabilizes a G-quadruplex structure in the promoter of the c-Myc gene (Huang et al.,
2012). The drug-promoter interaction prevents the production of the c-Myc transcription
factor that plays a role in telomerase gene expression. Senescence in both cell types may
also have been triggered by the activation of the ATM kinase DNA damage pathway in
response to DNA breaks caused by exposure to the drug (Huang et al., 2012).
In a very similar fashion, Yu et al. (2012) investigated the ability of ruthenium (II)
polypyridyl complexes to stabilize G-quadruplex DNA. Two different enantiomers were
tested, alpha and delta, and it was determined that the alpha form had the greatest ability
to bind to G-quadruplex DNA and stabilize it in HepG2 cancer cells (Yu et al., 2012). This
stabilization was confirmed through a series of chemical analyses as well as TRAP
(telomeric repeat amplification protocol) assay. In HeLa cells however, the delta
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enantiomer had a greater cytotoxic effect. In fact, the degree of cytotoxicity was shown to
depend largely on the specific type of cancer cell tested. Although the study employed a
wide range of chemical tests, the results are mostly qualitative and the authors do not
identify the precise mechanism of ruthenium complex binding to G-quadruplex DNA (Yu
et al., 2012).
In a 2010 study, Marian et al. evaluated the efficacy of the drug Imetelstat (GRN163L)
on the ability to inhibit telomerase in glioblastoma tumor initiating cells. Glioblastomas
are often fatal and patients usually have only a few months to live once diagnosed. The two
year survival rate is less than five percent (Marian et al., 2010). As discussed earlier,
Imetelstat targets the RNA component of the telomerase enzyme and prevents the
formation of functional telomerase. The drug is particularly well suited to permeating
tissues because of a lipid component in its chemical structure that is able to cross the bloodbrain barrier (Marian et al., 2010). The authors report that the anti-tumorigenic effects of
Imetelstat begin to occur after about 15 to 20 rounds of cell division after exposure to the
drug, with IC50 telomerase inhibition occurring at a concentration of 0.45 uM (Marian et
al., 2010). Unfortunately, normal healthy populations of brain stem cells are also affected
by the drug. However, as a consequence of a key difference in the actual length of telomeres
between glioblastoma cells and normal stem cells, the drug has less of a negative effect on
the normal stem cells. The negative effect is reversed when treatment is stopped. The
researchers also acknowledge the fact that most of the observed results and data of
Imetelstat treatment were collected from mice subcutaneous xenografts of glioblastoma
tumor cells (Marian et al., 2010).

22

Beisner et al. (2009) report limited success in inhibiting telomerase activity with use of
antisense 2’-O- methyl-RNA. The RNA molecule was packaged into chitosan coated
PLGA nanoparticles which were readily absorbed by A549 cancerous lung cells. The RNA
molecule acts in a similar way to the drug Imetelstat in that it interferes with the RNA
template of the telomerase enzyme. However, the anti-tumorigenic effects of the molecule
as measured by a TRAP assay are not observed until after approximately fifteen weeks of
treatment (Beisner et al., 2009). An appropriate experimental design which includes a
series of controls for the delivery of the nanoparticles and for the specificity of the RNA
molecule for the telomerase RNA component is apparent. A549 cells treated with 2’-Omethyl-RNA saw an average decrease in telomere length of about 2,000 bp when compared
to control groups (Beisner et al., 2009).
Mohammad et al. (2013) looked at the therapeutic effect of a plant compound called
Diosgenin derived from the herb Trigonellafoenum graceum. The authors mention a
number of studies which have already demonstrated the telomerase inhibiting ability of
this compound, and their work seems to be mostly a repeat and confirmation of previous
studies. A549 lung cancer cells were treated with various concentrations of Diosgenin and
the ability to inhibit telomerase activity displayed a dose dependent and time dependent
function. Telomerase activity was determined by qRT-PCR using telomerase mRNA
extracted from Diosgenin treated cells (Mohammad et al., 2013). The results clearly
indicated reduced levels of telomerase mRNA in treated cells but no statistical analysis is
provided nor do the authors discuss any observed reduction in A549 cell growth. The
authors do not mention an exact mechanism for how Diosgenin could down-regulate
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telomerase gene expression other than to suggest that the drug most likely down-regulates
expression of c-Myc (Mohammad et al., 2013).
Chen et al. (2013) report that epigallocatechin gallate (ECGC) found in green tea and
sulphoraphane (SFN) found in vegetables such as broccoli can produce anti-tumorigenic
effects in ovarian cancer cells when used in combination. The researchers primarily wished
to test the inhibitory of effects of these compounds, either alone or in combination, on
cancer cells which were resistant to the chemotherapy drug Paclitaxel. The design of the
study seems fairly straightforward, but there is no real effort to explain which controls were
used when treating two cells lines of ovarian cancer with various combinations of ECGC
and/or SFN. A paclitaxel susceptible cell line (SKOV3-ip1) was compared to a resistant
cell line (SKOV3TR-ip2). The authors state that the resistant cell line trials were exposed
to Paclitaxel in their growth media, but no control was made to expose the sensitive cells
to the drug to indeed show that they are susceptible. Although each cell type was tested
according to ECGC alone, SFN alone, and ECGC + SFN and for the same periods of time
(24, 48, and 72 hours), the concentrations of ECGC alone and SFN alone were different in
each trial (Chen et al., 2013).
A possible negative control of either resistant or susceptible cells exposed to DMSO
only was included as a reference in each trial at each time interval. However, how a
statistical analysis comparing cell growth in drug conditions as a percent of DMSO control
cell growth is not clearly indicated. The investigators also assayed each cell line for the
presence of the anti-apoptotic protein Bcl-2 and for telomerase activity. The results suggest
that the expression of both proteins as well as DNA methyltransferase-1 (a chromatin
remodeling enzyme) are significantly reduced in each type of cell line when used in
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combination (Chen et al., 2013). A beta actin positive protein control was used as a
comparison for the Western blot analysis. Overall, the authors conclude the SFN alone can
significantly reduce the growth of cells in both Paclitaxel resistant and sensitive cell lines.
When used in combination with ECGC, the result is amplified; however, no substantial
detail on the mechanism of action for how these drugs affect cell growth or protein
expression is provided (Chen et al., 2013).
In an almost identical design to that of Chen et al., Nasiri et al. (2013) treated T47D
human breast cancer cells with the herbal compounds curcumin and/or silibinin. Not
surprisingly, the results indicated that a combination of the two plant compounds at high
concentrations for long periods of time had a detrimental effect on the viability of T47D
cells as measured by MTT assay (Nasiri et al., 2013). Quantitative real time PCR was
employed to assess telomerase expression as a function of treatment with curcumin and/or
silibinin. Again, the controls were not clearly defined for either part of the experiment with
only the mention that beta actin served as an endogenous control for the comparison of
telomerase expression (Nasiri et al., 2013).
While not an actual drug, the glycolytic enzyme glyceraldehyde 3-phosphate
dehydrogenase has been shown to be able to induce apoptosis in cells subjected to oxidative
stress. The enzyme is involved in limiting the formation of reactive oxygen species in
addition to its central role in glycolysis. Nicholls et al. (2012) provide evidence that
GAPDH can travel into the nucleus in response to oxidative stress and can interact with
telomeric DNA. This interaction normally stabilizes the telomeres and promotes cell
survival. The enzyme has also been shown to interact with the RNA template of telomerase
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and thus inhibits the action of telomerase. Nicholls et al. (2012) observed increased
senescence in MCF7 breast cancer cells stably expressing a recombinant GAPDH.
Another intriguing approach to investigate the role of telomerase in cancer cells is
through the use of immunotherapy/gene therapy. These techniques make use of the fact
that many cancer cells begin to express altered peptides on their cell membranes as a result
of accumulated genetic and chromosomal abnormalities. The cells of the immune system,
cytotoxic T cells in particular, are able to identify cancer cells as foreign because of their
surface molecules and can then target them for destruction. Miyazaki et al. (2013) were
able to kill adult T cell leukemia (ATL) cells using modified CD8+ T cells. The CD8+ T
cells were transfected with a retroviral expression vector containing genes which would
enable these modified CD8+ T cells to identify a very specific protein complex found on
the surface of ATL cells over-expressing telomerase. That complex is HLAA*24:02/hTERT461-469. Mice were injected with ATL cells containing this complex. The
mice were then injected with either modified CD8+ T cells, unmodified CD8+ T cells, or
no cells at all. Compared to the control groups, the mice which received the modified CD8+
T cells showed minimal levels of ATL cell growth over a six month period (Miyazaki et
al., 2013).
The ability to produce a sustained response by CD8+ T cells against telomerase
expressing tumor cells requires the assistance of CD4+ helper T cells. The helper cells play
a role in maintaining cytotoxic T cell numbers and also play a critical role in generating
memory immune responses. Liao et al. (2013) examined the effect of dendritic cell
stimulation with branched diepitope multiple antigen peptides (MAPS) on the ability to
lyse various different tumor cell lines expressing telomerase. The particular MAP used
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contained two epitopes of human telomase, one which would stimulate CD8+ cytotoxic T
lymphocytes and another which would stimulate CD4+ helper T cells. The diepitope MAP
resulted in a slight increase (8.56%) in the ability of cytotoxic T lymphocytes to lyse target
tumor cells than when cytotoxic T lymphocytes were exposed to just the CD8+ epitope of
human telomerase alone (Liao et al., 2013). A positive control of dendritic cells exposed
to a recombinant adenovirus human telomerase vector and a negative control of dendritic
cells exposed to an HIV peptides were used when comparing the ability of branched
monoepitope MAPs to cause CTL induced lysis of target cells versus their linear forms. As
already mentioned, a diepitope MAP produced the greatest immune response (Liao et al.,
2013).
Adotevi et al. (2010) researched a lentivector model for inducing the proliferation of
endogenous anti-telomerase CD8+ T cells in mice. The HLA-A*0201 transgenic HHD
mice were injected with a lentiviral expression system containing the human telomerase
gene. Mouse cells expressing an epitope of human telomerase on their surfaces then
induced the development of CD8+ T cells capable of detecting the human epitope.
Surprisingly, these cells also displayed a strong ability to target self (mouse) cells which
expressed epitopes derived from mouse telomerase (Adotevi et al., 2010). When inoculated
with B16/A2 mouse melanoma cells, mice which were immunized with the lentiviral vector
resulted in tumor regression in three out of ten mice. Seven out of ten mice were cured of
their tumors when a specific telomerase peptide epitope was injected along with the
lentiviral vector. All mice in a control group not exposed to the lentiviral vector died forty
days after tumor cell inoculation (Adotevi et al., 2010).
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Using a different lentivirus model, Yu et al. (2011) demonstrated the ability of a
lentiviral vector consisting of the cytosine deaminase (CD) suicide gene and the green
fluorescent protein (GFP) gene under the control of an optimized human telomerase gene
promoter. It was hypothesized that infection of various cancer cell lines with the vector
would result in transcription of the telomerase promoter and the expression of the CD gene,
which could be visually confirmed by the simultaneous expression of GFP. Upon
administration of the drug 5-FC, the cancer cells would convert it into 5-fluorouracil using
the cytosine deaminase enzyme. This conversion in turn would result in the death of the
cancer cells. Appropriate controls with telomerase negative cancer cells along with the use
of a vector lacking the CD gene were utilized as part of the experiment. The results indicate
that intra-tumor injection of the CD/GFP lentiviral vector results in a significant difference
in tumor volume when compared to controls (Yu et al., 2011).
In recent years, the use of RNA interference (RNAi) pathways in cells has led to a
number of important discoveries about gene expression and protein function. RNA
interference makes it possible to study the silencing of specific genes and how cellular
pathways may be affected by the reduced expression of a particular protein. The potential
therapeutic benefits of RNAi to interfere with cancer cell proliferation have become the
basis for a number of innovative cancer treatments. Cerone et al. (2011) exposed HeLa
cells to an siRNA library which contained siRNAs directed against a number of different
kinase enzymes involved in regulating telomerase activity. The authors found that RNAi
of the protein kinases MAPKAPK5 and ERK8 resulted in a significant decrease in
telomerase mRNA levels in HeLa cells when compared to cells transfected with siRNA
controls not directed against protein kinases (Cerone et al., 2011). Silencing of the enzyme
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SRC through the siRNA screen resulted in a significant increase in telomerase mRNA,
which suggests that the kinase normally has an inhibitory effect on telomerase expression.
The RNA interference inhibition of kinases such as ERK8 resulted in telomere length
reduction and DNA damage, which was detected by the presence of DNA damage proteins
TRF1 and 53BP1 at the telomeres (Cerone et al., 2011). Telomerase activity was measured
by RT-PCR using cells transfected with non-kinase directed siRNAs as a negative control.
A positive control of cells transfected with siRNA directed against telomerase was also
present.
The key role of tumor suppressor gene products such as p53 and p21 were discussed in
an earlier section of the paper. One of the hallmarks of many different types of cancer cells
is the mutational loss of these critical cell cycle control proteins. Yoon et al. (2011)
investigated whether or not the microRNA miR-296 is able to regulate expression of p53
and/or p21. Using luciferase reporter plasmids which contained either the 3’ UTR of p53
or p21, the researchers were able to demonstrate that miR-296 only weakly associates with
p53 mRNA. However, there is a very strong binding of miR-296 to the 3’ UTR of p21
(Yoon et al., 2011). As a consequence, this binding would result in a large downregulation
of p21 protein levels and thus a loss of the important tumor suppressor role of this protein.
The stability of p21 mRNA is enhanced by the binding of HU proteins to the 3’ UTR. The
miR-296 can bind to these HU sites instead and cause increased instability of the p21
mRNA (Yoon et al., 2011). The result was observed in a variety of different cancer cell
lines.
The success of RNAi modalities to limit cancer cell growth depends largely on an
appropriate delivery system of the RNAi agent. In a 2012 study, Xia et al. tested the ability
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of a modified polyethylenimine (PEI) delivery system to effectively deliver a siRNA
directed against telomerase mRNA into hepatocelluar carcinoma HepG2 cells. The use of
a cationic compound such as polyethylenimine does not elicit an immune response the way
a viral delivery vector could, and has the ability of forming nanoscale particles with siRNA
allowing for ease of transfection of target cells (Xia et al., 2012). The disadvantage of PEI
is that it is highly cytotoxic as a result of low degradability. Xia et al. modified PEI by
introducing a disulfide bond which would make it more easily degradable in cells and thus
reduce its cytotoxicity. The researchers injected HepG2 tumor cells into four different
groups of isogenic mice to induce tumor growth, with five mice in each group. Once a
tumor had formed, one group of mice received injections of disulfide PEI/siRNA, one
group received normal low molecular weight PEI/siRNA, another group received disulfide
PEI/non-telomerase siRNA, and the fourth group remained untreated. A significant
decrease in tumor volume over a seven day period was observed for the disulfide
PEI/siRNA treated group compared to the untreated group. However, the reduction was
fairly minimal and appeared to only slightly delay tumor growth (Xia et al., 2012). In a
separate experiment, the authors were able to show that rats administered low doses of
disulfide PEI (5 or 50 ug/kg) displayed no adverse effects on liver or kidney function
compared to rats administered PBS as a control (Xia et al., 2012).
Gandellini et al. (2007) report success of siRNA treatment of prostate cancer cells. Two
androgen independent prostate cancer cell lines, PC-3 and DU145, were transfected with
fourteen different siRNAs. Two siRNAs were shown to produce a large decrease in
telomerase activity in these cell lines when compared to the same cell lines transfected with
non-telomerase directed siRNA. Exposure to just the transfection agent alone also did not
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affect telomerase activity (Gandellini et al., 2007). To test whether the significant decrease
in telomerase activity seen with the two particular siRNAs was actually a result of
inhibition of telomerase mRNA translation and not some other mechanism, telomerase
negative osteosarcoma cells were transfected with the siRNAs of interest. Osteosarcoma
cell growth was not affected. The researchers were also able to demonstrate that the
observed reduction in prostate cancer cell telomerase activity was not caused by activation
of an interferon pathway as no increase in expression of an interferon response gene was
observed in siRNA treated and control cells (Gandellini et al., 2007). Lund et al. (2008)
investigated the effectiveness of a lentiviral vector system expressing a small hairpin RNA
directed against a portion of the canine telomerase RNA template molecule. The authors
state that, on the basis of their previous work, canine telomerase function and activity is
more similar to human telomerase than is murine telomerase, and is thus a better model to
study possible therapeutic effects in humans (Lund et al., 2008). Mice injected with canine
hemangiosarcoma tumor cells were used in the study. The results suggest that RNAi
directed against the canine telomerase RNA component is able to cause a rapid decrease in
tumor volume and enhance apoptosis, but a population of tumor cells became resistant and
began to grow through an alternative lengthening of telomeres mechanism (Lund et al.,
2008). The side effect has been documented in other studies and underscores the ability of
anti-telomerase therapies to possibly induce alternative lengthening of telomeres in certain
types of cancer cells.
Lastly, Uziel et al. (2010) report that miRNA expression can change as a function of
telomere length. The researchers screened for approximately 900 different miRNAs in SKN-MC cells which had normal length telomeres, shortened telomeres due to telomerase
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inhibition, and telomeres restored back to normal length with restoration of telomerase
activity. The profile of miRNA expression changed in cells with shortened telomeres
compared to the other two cell types. Most of the differentially expressed miRNAs were
related to cell growth inhibition and/or apoptosis (Uziel et al., 2010). Micro RNAs could
even be useful in interfering with the regulation of alternative splicing of the telomerase
mRNA. Wong et al. (2013) have shown that the telomerase mRNA can be spliced in
various ways, some of which result in nonfunctional enzyme. Indeed, the use of RNAi to
prevent normal splicing of telomerase mRNA could represent a novel form of
chemotherapy.
1.2

The Role of Endocytosis in Cancer Cell Migration
One of the defining hallmarks of most cancers, besides unregulated cell proliferation

and telomerase activity, is cell migration. A growing body of research is beginning to shed
light on the central role that defective endocytosis plays in promoting cancer cell migration.
Endocytosis is instrumental in a number of different tumorigenic processes ranging from
receptor tyrosine kinase internalization to regulating cell membrane dynamics. Recently,
the Rab family of small GTPases have been implicated in cancer cells as an important cause
of the altered endocytosis that may lead to enhanced cell migration. Rab5 is of particular
interest given its primary function in regulating the early endosome fusion and trafficking
events that are necessary for cancer cell migration.
A significant body of evidence suggests that Rab5 mediated endocytosis plays a crucial
role in the cellular processes that govern cancer cell migration. Endocytosis is a normal
cellular process that involves the uptake or internalization of extracellular material and cell
membrane components through the formation of endosomes. There are four primary
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mechanisms by which endocytosis occurs: clathrin-mediated endocytosis, caveolaemediated

endocytosis,

clathrin

and

caveolin

independent

endocytosis,

and

macropinocytosis (Mosesson et al., 2008).
1.2 A.

Modes of Endocytosis

Clathrin-mediated endocytosis is characterized by the uptake of activated plasma
membrane receptors via the formation of clathrin coated pits- invaginations of the cell
membrane covered in clathrin protein. The scission of clathrin coated vesicles (endosomes)
from the membrane and subsequent endosome trafficking requires the action of numerous
proteins such as the dynamin GTPases, AP2, and the Rab family of GTPases. Once
internalized, these vesicles shed their clathrin coats and fuse with other tubule-vesicular
compartments to form structures known as early endosomes that later give rise to a cargo
sorting structure known as the multi-vesicular body (Mellman and Yarden, 2013). Rab
proteins, in particular Rab5, are instrumental in the coordination of early endosome
formation and fusion events as well as the sorting of internalized cellular cargo. The
slightly acidic pH of early endosomes promotes the dissociation of ligands from their
receptors (Mellman and Yarden, 2013). Internalized membrane receptors from the surface
of the cell will be either routed to lysosomes for destruction or recycled back to the plasma
membrane through the coordinated action of the endocytic machinery involving Rab
proteins (Mosesson et al., 2008). Receptors destined for degradation in lysosomes are
typically ubiquitinated (Mellman and Yarden, 2013).
Caveolin-mediated endocytosis occurs through a similar mechanism to that of clathrinmediated endocytosis with the exception of the formation caveolin protein containing,
cholesterol rich lipid rafts from the cell membrane. These vesicles are then targeted to other
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caveolin containing organelles termed caveosomes (Mosesson et al., 2008). Clathrin and
caveolin independent endocytosis is poorly understood and may involve the uptake of
glycosylphosphatidylinositol- anchored proteins from the plasma membrane. Finally,
macropinocytosis is characterized by the bulk internalization of receptor tyrosine kinases
through the Rab5 dependent formation of circular dorsal ruffles (Mosesson et al., 2008).
1.2 B.

Rab5 and Endocytosis in Cancer Cell Migration

The role that endocytosis plays in tumorigenesis is becoming clearer. Multiple studies
have shed light on the ability of the endocytic machinery to regulate a wide variety of
cellular processes including signal transduction from activated receptors, cell morphology,
cell junctions, and cell migration/invasion. Indeed, many cancers often display
abnormalities in one or more of these endocytosis mediated events, and the essential role
of Rab proteins in determining endosome identity as well as facilitating endosome fusion
and transport has been an intense area of cancer biology research (Mendoza et al., 2014).
The Rab (Ras associated in brain) family of proteins belong to the Ras superfamily of
small GTPases and more than 60 different Rab proteins have currently been identified.
Like the Ras GTPases, the Rab GTPases are monomeric cytosolic proteins that act as
molecular switches by alternating between an inactive GDP bound state and an active GTP
bound state. The dissociation of GDP and binding of GTP is regulated by guanine
nucleotide exchange factor (GEF) proteins while the hydrolysis of GTP to GDP is regulated
by GTPase activating (GAP) proteins (Mendoza et al., 2014). Rab5 is particularly
important for the fusion of early endosomes and the routing of internalized cellular cargo
from these endosomes. Rab5 has also been implicated in cell migration through the
regulation of actin remodeling of the cytoskeleton following receptor tyrosine kinase
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activation by means of a mechanism involving integrin internalization and recycling
(Subramani and Alahari, 2010).
Integrins are transmembrane glycoproteins that are comprised of heterodimers of α and
β subunits and are major components of specialized plasma membrane regions known as
focal adhesions. Focal adhesions are characterized by collections of various integrins and
adaptor proteins that serve to link the cell to the surrounding extracellular matrix (ECM)
(Subramani and Alahari, 2010). Integrins such as α5β1 bind to fibronectin in the ECM and
the β1 integrin subunit is known to associate with activated Rab5 (Tang and Ng, 2009;
Mendoza et al., 2014). The endocytosis mediated turnover of focal adhesions through the
recycling of integrin complexes is a major driver of cancer cell migration (Mendoza et al.,
2014). In this focal adhesion model, growth factor induced cell migration consists of four
key steps: formation of circular dorsal ruffles and lamellipodia, dissolution of focal
adhesions at the rear of the cell, formation of new focal adhesions at the leading edge of
the cell, and the 3D movement of the cell to a different location (Lanzanetti et al., 2004;
Subramani and Alahari, 2010).
Growth factor stimulation of receptor tyrosine kinases promotes the activation of Rab5
through GEFS such as Rin1 or Rabex5 and promotes the formation of invasive cell
membrane protrusions known lamellipodia as well as the formation of circular dorsal
ruffles in a Rab5 dependent manner. Internalized early endosomes containing activated
receptors and integrin complexes are associated with active Rab5 which subsequently
recruits other Rab and adaptor/effector proteins to facilitate the trafficking of endosomal
cargo. The small GTPase Rac is one such protein recruited to Rab5 positive early
endosomes. Rab5 activates the Rac GEF Tiam1 which in turn activates Rac and promotes
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the remodeling of the actin cytoskeleton to form lamellipodia and circular dorsal ruffles
(Zech and Machesky, 2008). Rabs 4 and 11 are also recruited to Rab5 positive early
endosomes and facilitate the recycling of integrin complexes back to the plasma membrane
as new focal adhesions are formed (Mendoza et al., 2014).
One of the early steps in the acquisition of a motile phenotype in epithelial cells is the
loss of cell junctions that are responsible for maintaining epithelial cells in a polarized,
growth arrested state. The cells of epithelial tissues are highly polarized meaning that they
have distinct basal, lateral, and apical surfaces characterized by the specialized location of
specific membrane proteins in these regions (Mosesson et al., 2008). The loss of junctional
complexes such as tight junctions or adherens junctions along the basolateral surfaces of
epithelial cells is often a precursor to cancer cell migration. Disruption of the endocytic
machinery required to maintain tight junctions, for instance, typically involves mutations
in the Par family of polarity genes as well as mutations in an atypical protein kinase C
(aPKC) (Mosesson et al., 2008). As a consequence, tight junctional proteins are then
abnormally targeted to lysosomes for degradation. The loss of E-cadherin from adherens
junctions occurs through a similar mechanism involving mutation of the p120-Catenin
protein that prevents E-cadherin endocytosis and degradation. Inactivation of p120-Catenin
permits tyrosine phosphorylation of E-cadherin by Src which in turn promotes
ubiquitination of E-cadherin by the Cbl-like ubiquitin ligase known as Hakai. The Ecadherin is subsequently targeted to lysosomes for degradation as a result of these
modifications (Mellman and Yarden, 2013).
The connection of Rab5 with cancer cell invasion and migration has been documented
for a variety of different cancers. Igarashi et al. (2017) report that Rab5 overexpression in
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pancreatic cancer samples correlated with increased lymphatic invasion and reduced
expression of E-cadherin. A reversal of these oncogenic properties was observed with Rab5
inactivation. Similarly, Zhao et al. (2010) observed that Rab5A was significantly
overexpressed in ovarian cancer samples when compared to benign cysts; and breast cancer
samples that overexpress Rab5A also display a strong tendency to metastasize to axillary
lymph nodes (Yang et al., 2011). Additionally, hypoxia has been shown to cause the
activation and translocation of Rab5 to focal adhesions as well as significantly enhance the
migratory behavior of B16-F0 murine melanoma cells (Silva et al., 2016).
Recent evidence also suggests that Rab5A in breast cancer promotes the invasive
remodeling of the extracellular matrix by stimulating a Rab4 dependent fast recycling of
membrane type 1 matrix metalloproteinase (MT1-MMP) and β3 integrin (Frittoli et al.,
2014). The MT1-MMP has been shown to coimmunoprecipitate and colocalize with β1
integrins at regions of intercellular contact such as focal adhesions (Tang and Ng, 2009).
A similar study by Torres et al. (2009) reveals that caspase-8 expression increases cell
migration in A549 lung cancer cells through the Rab5 dependent internalization and
recycling of β1 integrins. Knockout of Rab5 inhibited the caspase-8 induced activation of
Rac and decreased cell migration. Interestingly, in a study on non-small cell lung cancer,
Liu et al. (2015) report that knockdown of the CMTM7 tumor suppressor gene results in
reduced Rab5 activation and prolonged EGFR signaling- presumably as a consequence of
reduced EGFR internalization.
The tumorigenic properties of Rab5 are intrinsically linked to its ability to influence
signaling pathways through its association with specific effector proteins. Principal among
these effectors are the lipid modifying enzymes known as phosphatidylinositol-3 kinases
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(PI3Ks) (Chistoforidis et al., 1999). The PI3Ks are well known for their roles in signal
transduction following receptor tyrosine kinase activation as well as membrane transport
and cytoskeletal remodeling. Christoforidis et al. (1999) demonstrate that PI3Ks are
recruited to Rab5 positive early endosomes and that their activity is required for Rab5
mediated docking and fusion of early endosomes. The PI3Ks are recruited to early
endosomes by active Rab5 and then modify endosomal membrane lipids in a manner
specified by Rab5 to permit the recruitment of other Rab5 effector proteins. One such Rab5
effector protein, EEA1, binds to the phosphatidylinositol lipids generated by PI3Ks and is
necessary for endosome docking and fusion.
The signaling role of Rab5 in oncogenesis is further exemplified by the Rab5 mediated
transport of APPL1 and APPL2 into the nucleus following growth factor stimulation. Both
proteins are located on a specific population of Rab5 positive endosomes and APPL1
interacts with chromatin remodeling proteins in the nucleus to promote cell proliferation
(Miaczynska et al., 2004). Similar Rab5 mediated endosomal trafficking of the MUC1
transmembrane glycoprotein has also been reported. MUC1 is frequently overexpressed in
adenocarcinomas and its cytoplasmic tail has been implicated in tumor cell proliferation.
Liu et al. (2008) report that overexpression of Rab5 in Chinese hamster ovary (CHO) cells
results in the accumulation of MUC1 containing endosomes in the perinuclear region and
that expression of the inactive Rab5 mutant (S34N) results in a more cytoplasmic
distribution of MUC1.
Clearly, aberrant endocytosis has emerged as an important cause of tumorigenesis. Rab5
mediated cancer cell migration as a function of altered endocytosis has been identified as
a major contributor to tumor progression. Defective growth factor receptor internalization
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and recycling, focal adhesion turnover, cell junction loss, and abnormal endosomal
signaling have all been associated with the oncogenic capacity of Rab5. The significance
of Rab5 mediated endocytosis to cancer cell development is clear, and future research into
the key role that endocytosis plays in cancer biology will undoubtedly reveal novel
therapeutic targets.
1.3

The Mitogen Activated Protein Kinase Pathway and Cancer
Many cancerous cells display abnormalities in the signal transduction pathways

responsible for responding to extracellular growth factors, or mitogens. As reviewed above,
mutations that alter proteins involved in these types of pathways can lead to inappropriate
or unregulated cell growth and therefore predispose the cell to becoming cancerous.
Hanahan and Weinberg (2000) in a comprehensive review of the molecular hallmarks of
cancer cells list growth factor self-sufficiency as one of the six necessary physiological
changes needed to convert a normal cell into a malignant cell. The authors also suggest that
malignancy is acquired through a series of successive mutations which fall under two broad
categories- dominant gain of function oncogenic mutations and recessive loss of function
tumor suppressor mutations.
Unlike normal cells which will only grow and divide in response to external growth
signals, many cancer cells have acquired the ability to proliferate in the absence of
extracellular mitogenic signals. The apparent autonomy is caused by three key factors: selfproduction and stimulation by growth factors in an autocrine fashion, mutant growth factor
cell surface receptors, and mutant intracellular signaling proteins (Hanahan and Weinberg,
2000). It is this third category of deregulation that appears to be found ubiquitously in most
tumors and to which mutants of the Ras/MAPK pathway fall under. The critical role of the
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Ras/MAPK pathway in transducing growth signals to the interior of the cell and
subsequently stimulating cell growth and proliferation is underscored by the fact that
roughly one quarter of all human tumors contain mutant forms of Ras proteins (Hanahan
and Weinberg, 2000). Therefore, more detailed discussion of the significance of the MAPK
pathway to cancer development is warranted in an effort to convey a more comprehensive
understanding of the tumorigenic process.
1.3 A.

Signal Transduction through the MAPK Pathway

At this point it would be helpful to review the major steps of the RAS/MAPK pathway
before proceeding to a more detailed consideration of the roles that downstream mediators
of this widespread and critical cell signaling pathway play in cancer cell biology. The
Ras/MAPK pathway is one of the principal means by which extracellular, mitogenic
signals are transduced from the surface of the cell to the cell’s interior (Fang and
Richardson, 2005). The response often culminates in the nucleus with the transcription and
expression of target genes which regulate cellular proliferation, differentiation, and
development (Seger and Krebs, 1995; Wang et al., 2002). Growth factors, such as
epidermal growth factor or insulin-like growth factor I, represent a major class of mitogenic
ligands which can initiate the Ras/MAPK pathway.
The binding of a particular growth factor to its transmembrane receptor (tyrosine kinase
receptor) sets into motion a series of events which results in the activation of several
different cytoplasmic protein kinases. Receptor activation by binding of a growth factor
ligand induces dimerization followed by auto-transphosphorylation of specific tyrosine
residues within the receptor. These phospho-tyrosine residues are then recognized and
bound by an adapter protein such as Grb2 through its SH2 domains (Seger and Krebs,
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1995). The small monomeric GTPase Ras is then activated through a guanine nucleotide
exchange factor (GEF) protein known as Sos. Sos, in turn, is activated by the Grb2 adaptor
protein. Activation of Ras through exchange of GDP for GTP then initiates the activation
of a cascade of cytoplasmic serine-threonine protein kinases which include RAF1, MEK,
and ultimately ERK (extracellular-signal regulated kinase). Each of these kinases is
activated in sequential order by the protein kinase immediately preceding it in the pathway.
Once phosphorylated and activated by MEK, ERK then proceeds to activate a number of
cytoplasmic and nuclear proteins involved in regulating cell growth and proliferation. The
regulation often occurs at the level of transcription.
One of the primary targets of activation by ERK are various types of transcription
factors, including the E-twenty six (Ets) family of transcription factors as well as cMyc and
cFos (Fang and Richardson, 2005). These transcription factors are potent stimulators of
cellular proliferation (Seger and Krebs, 1995). Mut et al. (2011) provide evidence of the
importance of the Ras/MAPK pathway in the activation of the E-twenty six like
transcription factor 1 (Elk 1) in U138 glioblastoma multiforme cells. The researchers
demonstrate that these cells have a high basal proliferative rate which can be reduced in
the presence of specific MEK or ERK inhibitors. The authors hypothesize that inhibition
of the Ras/MAPK pathway with these types of enzymatic inhibitors prevents the ultimate
phosphorylation and activation of Elk 1, which in turn prevents the transcription of specific
early cellular proliferation genes such as cFos. Activated Elk 1 exerts its effect in the
nucleus by binding to the promoters of genes containing a serum response element (SRE)
motif. The expression of a number of important cell cycle stimulatory genes, such as Egr1
and cFos, can be stimulated by Elk 1. The results also indicate that stimulation with EGF
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results in a corresponding increase in the proliferative rate, which is most likely mediated
by Elk 1 (Mut et al., 2011). For example, knockdown of Elk 1 through the use of siRNA
does not result in an increase in proliferation even after EGF stimulation in U138 cells. The
results also suggest that the PI3K/Akt pathway plays an important role in the regulation of
Elk 1 activity. Inhibitors of this pathway do not prevent the phosphorylation of either ERK
or Elk 1 in the cytoplasm following EGF stimulation, but rather prevent the movement of
these phosphorylated proteins from the cytoplasm into the nucleus (Mut et al., 2011). The
step is obviously necessary to produce the full mitogenic response to EGF stimulation.
In an intriguing study examining the role of protein kinase D1 (PKD1) in MCF-7
adenocarcinoma breast cancer cells, Karam et al. (2012) report that overexpression of
PKD1 is associated with proliferation and various other aspects of tumorigenesis. When
exposed to pharmacological inhibitors of PKD1, proliferation was reduced to levels
measured in untreated control cells which do not overexpress PKD1. The result was further
confirmed through the use of siRNA directed against PKD1, which produced a similar
reduction in proliferation as measured by an MTT assay. A major finding of the study was
that the level of phosphorylated ERK 1/2 was significantly higher in cells overexpressing
PKD1 as compared to control cells not overexpressing the enzyme. The result was
attributed to PKD1 overexpression since selective inhibition of the enzyme completely
reversed the observed increase in ERK phosphorylation. Overexpression of PKD1,
however, does not appear to affect levels of phosphorylated Akt. The amount of
phosphorylated Akt was identical in both control cells and cells overexpressing PKD1,
with or without exposure to PKD1 inhibitors (Karam et al., 2012). The investigators also
report that inhibition of either MEK or ERK slowed the proliferation rate of MCF-7 cells
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overexpressing PKD1 as well as inhibited anchorage independent growth. These effects
were observed to be dose dependent, with increasing amounts of MEK/ERK inhibitors
slowing both the growth and proliferative capacity of the MCF-7 cells to the point where
they began to resemble the non-overexpression control cells with respect to growth and
proliferation. The authors also conclude that cells overexpressing PKD1 entered into S
phase more rapidly and had a reduced dependence on serum for stimulation of proliferation
when compared to control cells (Karam et al., 2012).
1.3 B.

Cancer and the MAPK Pathway

Given the central role of the Ras/MAPK pathway in the proliferative response of cells
to growth signals, it is logical that abnormalities in any one of its molecular components
could lead to the uncontrolled cellular division characteristic of so many different cancers.
In a review article detailing the molecular mechanisms underlying colorectal cancer, Fang
and Richardson (2005) discuss the significance of the Ras/MAPK pathway in promoting
growth, proliferation, and tumorigenesis in intestinal epithelial cells. Indeed, the
importance of abnormalities in the MAPK pathway in promoting tumorigenesis is
highlighted by the fact that this pathway is deregulated in about 30% of all cancers (Fang
and Richardson, 2005). Abnormal MAPK signaling in colorectal cancer typically begins
at the surface of the cell with overexpression and activation of EGF receptors. Additionally,
protein kinase C (PKC), when activated, can also facilitate the binding of GTP to Ras which
ultimately leads to activation of the MAPK pathway.
Like many other types of cancers, the development of colorectal cancer is a multi-step
process involving mutations in specific cell cycle regulatory or signaling genes. Mutations
in Ras, specifically K-Ras, are known to be an early step in colorectal carcinogenesis along
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with mutations in certain protein kinases such as BRAF (Fang and Richardson, 2005).
Hyperactive MAPK signaling through EGFR overexpression or mutant protein kinases in
turn leads to the activation of various transcription factors, as mentioned earlier, which
promote cell growth and proliferation. Additionally, unusual MPAK signaling can also
induce the expression of VEGF which aids in tumor invasiveness and metastasis by
promoting angiogenesis. Invasiveness of colorectal cancer might also be linked to
increased synthesis of matrix metalloproteinases such as MMP7, which has been associated
with abnormal MAPK signaling (Fang and Richardson, 2005). Given the key oncogenic
role of the Ras/MAPK pathway in a variety of cancers, it is no surprise that a number of
MEK and ERK inhibitors are currently being tested as possible chemotherapeutic agents.
1.3 C.

Rin1 as a MAPK Effector

Besides anomalous cell signaling through the Ras/MAPK pathway, there is a growing
body of evidence which suggests that specific Ras interactor proteins such as Rin1 (Ras
and Rab Interactor protein 1) might be critical in modulating the cell’s response to
mitogenic signals (Wang et al., 2002). The ability of Rin1 to have a moderating effect on
signal transduction through the Ras/MAPK pathway lies in its ability to be activated by
Ras. In fact, Rin1 has been shown to compete directly with RAF1 for activation by Ras
(Wang et al., 2002) and this competition has important implications for cancer biology
research. For instance, could Rin1 be a useful target to help dampen or modify excessive
signaling through the Ras/MAPK pathway in certain cancer cell lines? If so, could one then
reduce the downstream proliferative response induced by the Ras/MAPK pathway as a
result of growth factor stimulation? Before addressing these possibilities, it is necessary to
first review the biochemical role of Rin1 in cells.
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Han et al. (1997) and Wang et al. (2002) studied the biochemical properties of Rin1 and
report that Rin1 is an important downstream effector of activated Ras. Rin1 is able to bind
to Ras through its Ras binding domain (RBD) which associates with an effector domain
within Ras. Furthermore, biochemical analysis reveals that Rin1 has a high binding affinity
for activated Ras and that it competes strongly with RAF1 for access to Ras. Molecular
studies also indicate that Rin1 binds to 14-3-3 proteins in the cytoplasm and is able to
interact with and be phosphorylated by the tyrosine kinase c-ABL.
The ability of Rin1 to bind to Ras lies in its carboxyl-terminal domain which contains a
433 amino acid sequence (between residues 294 to 727) necessary for Ras binding (Han et
al., 1997). Different Ras effector proteins, such as Rin1 and RAF1, can vary significantly
in terms of their overall primary structure but often display a high degree of similarity in
the regions required for Ras binding (Ras binding domains). The Ras binding domains of
effector proteins typically interact with a short amino acid effector sequence within Ras
itself, and this interaction is heavily dependent on Ras being in its activated GTP-bound
state. For Rin1, the carboxyl-terminal domain (Rin1C) mediates binding to both GTP-Ras
and to 14-3-3 proteins (Wang et al., 2002).
The affinity of Rin1 for Ras can be seen in experiments utilizing antibodies against Ras.
For example, Rin1 is co-immunoprecipitated with an overly active mutant allele of H-Ras
in NIH 3T3 cells when treated with a particular Ras antibody. When the same antibody is
pre-attached to Ras, Rin1 is not co-immunoprecipitated. The use of antibodies which bind
to the switch II region of Ras also prevent the binding of Rin1. Additionally, the effector
binding domain within Ras itself is equally important in mediating the proper attachment
of certain effector proteins to Ras (Han et al., 1997). The point is illustrated by the fact that
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mutations in the Ras effector binding domain can selectively inhibit the binding of certain
Ras effector proteins without affecting the binding of others. Rin1, for instance, can interact
with a constitutively active mutant form of H-Ras (H-RasV12). However, when the mutant
form of H-Ras acquires additional mutations at amino acid positions 35 or 40, Rin1 binding
is completely inhibited. The position 35 mutation on the other hand does not interfere with
RAF1 binding, while a mutation at position 37 permits Rin1 association but prevents RAF1
binding (Han et al., 1997). The ability of full length Rin1 to interact with Ras is further
highlighted by a variant form of Rin1 in which there is a 62 amino acid deletion. The
naturally occurring truncated form of Rin1, known as Rin1 delta, is the result of alternative
splicing of the Rin1 mRNA. Rin1 delta exhibits a much weaker binding affinity for Ras
when compared to full length Rin1 (Han et al., 1997).
Besides interaction with Ras, the carboxyl-terminal domain of Rin1 also mediates
binding to 14-3-3 proteins (Han et al., 1997; Wang et al., 2002). These small acidic proteins
exist as multiple isoforms in the cytoplasm (epsilon, beta, and zeta) and have been shown
to be involved in mitogenesis and malignant transformation of cells through their
interactions with signaling proteins. Both RAF1 and Rin1 share the ability to bind to 14-33 proteins via their Ras binding domains, and this binding typically results in the activation
of RAF1 through a Ras-dependent mechanism that seems to enhance signal transduction
functions (Wang et al., 2002). Since Rin1 competes directly with RAF1 for access to Ras,
the binding of Rin1 to 14-3-3 proteins would reduce its potential to bind to Ras and thus
allow for heightened signaling through the Ras/MPAK pathway. The binding of Rin1 to
cytoplasmic 14-3-3 proteins would promote the oncogenic properties of cell growth and
proliferation as a result of the increased access of RAF1 over Rin1 for activation by Ras.
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Interestingly, deletion of the Ras binding domain within the carboxyl-terminal of Rin1
prevents Rin1 from binding to all isoforms of 14-3-3 proteins, as does the 62 amino acid
deletion in the naturally occurring Rin1delta (Wang et al., 2002).
The interaction of Rin1 with 14-3-3 proteins appears to be largely controlled by a serine
residue at position 351 within the Ras binding domain. The serine residue is
phosphorylated predominantly by protein kinase D and its phosphorylation is required for
proper binding to 14-3-3 proteins (Wang et al., 2002). A mutation which substitutes alanine
at this position blocks interaction with 14-3-3 proteins and results in an increased ability to
suppress signaling through the Ras/MAPK pathway, presumably caused by an increased
capacity to compete with RAF1 for access to Ras. The phosphorylation of serine 351 of
Rin1 and subsequent attachment to 14-3-3 proteins may act as a suppression control
mechanism in cells to unlink Rin1 from activated Ras by sequestering it in the cytoplasm
(Wang et al., 2002).
An important point is raised here: in order for Rin1 to effectively compete with RAF1
for access to Ras it must be in the proper subcellular location. Wild type Rin1 in its nonphosphorylated state is weakly associated with the cell membrane and is in close proximity
to interact with Ras, which is tightly associated with the plasma membrane. Also, the
alanine substitution at position 351 in the mutant form of Rin1 allows for a significant shift
to the plasma membrane which may help to explain its suppressive effect on Ras signaling
(Wang et al., 2002). However, when phosphorylated by PKD, wild type Rin1 is confined
to the cytoplasm bound to 14-3-3 proteins. The phosphorylation of Rin1 by PKD therefore
reduces its capacity to compete with RAF1 for binding to Ras.
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The amino-terminal of Rin1, like the carboxyl-terminal, plays an important role in
mediating cell signaling through its ability to bind to the tyrosine kinase c-ABL (ABL1).
ABL tyrosine kinases are known to be involved in various cellular functions including
differentiation, division, migration, and adhesion (Hu et al., 2005). Additionally, the
amino-terminal of Rin1 contains an SH2 domain capable of interacting with
phosphotyrosine residues on an activated receptor tyrosine kinase such as the EGFR
(Barbieri et al., 2004). Rin1 interacts with c-ABL most likely through a proline rich
sequence in its amino terminal and an SH3 domain in c-ABL (Han et al., 1997). Upon
binding to c-ABL in vitro, Rin1 becomes tyrosine phosphorylated and can then
subsequently bind to an SH2 domain within c-ABL. The interaction does not seem to affect
the catalytic activity of the enzyme however, and studies have shown that Rin1 has very
little interaction with c-ABL in vivo. This reduced interaction is caused in part by the
different cellular locations of the two proteins; with c-ABL being confined mostly to the
nucleus and Rin1 to the cytoplasm (Han et al., 1997).
One interesting exception to this is the oncogenic BCR/ABL fusion protein produced
as a result of a translocation between chromosomes 9 and 22. The BCR/ABL is an
unregulated tyrosine kinase which is localized primarily to the cytoplasm where it
stimulates cellular proliferation. The BCR/ABL is therefore in the correct location to
interact with Rin1 and, indeed, Rin1 is able to bind to BCR/ABL. Rin1 appears to
accentuate the tumorigenic, transforming properties of BCR/ABL (Wang et al., 2002; Hu
et al., 2005; Afar et al., 1997). Additionally, Hu et al. (2005) report that Rin1 is an activator
of the ABL2 tyrosine kinase which is involved in the regulation of epithelial cell adhesion
and migration. Specifically, Rin1 activation of ABL2 promotes phosphorylation of the
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adaptor proteins CRK and CRKL. This phosphorylation in turn produces conformational
changes in CRK and CRKL which influence cytoskeletal elements to inhibit cell motility.
Cells deficient in Rin1 display reduced levels of phosphorylated CRKL and increased cell
motility (Hu et al., 2005).
Clearly, the biochemical profile of Rin1 suggests that it potentially plays a key role in
modulating signaling through the Ras/MAPK pathway given its ability to interact with
multiple different effector proteins. The greatest capacity for Rin1 to moderate abnormal
signaling, as detailed above, appears to lie in its ability to directly compete with RAF1 for
access to Ras. The competition, in turn, could be a useful mechanism for dampening or
attenuating signaling through the Ras/MAPK pathway by diverting the signal away from
effector proteins downstream of Ras. On the contrary, elevated levels of Rin1 may be
associated with increased tumorigenesis and lower survival as is reported by Wang et al.
(2012) for non-small cell lung cancer. It should be noted that although Rin1 is thought to
be expressed in most tissues, its expression is highest in brain tissues (Han et al., 1997).
The differential level of Rin1 expression could have important implications for research
when investigating Rin1 function in various tissues and/or cell lines.
1.3 D.

Rin1 and Rab5 in the Context of the MAPK Pathway

Before delving any further into the important role that Rin1 plays in specific cancers, it
will be useful to briefly review another significant function of Rin1 in most cells. Rin1, in
addition to its ability to moderate mitogenic signaling through the Ras/MAPK pathway,
also acts as a guanine nucleotide exchange factor (GEF) for the small monomeric GTPase
known as Rab5 (Tall et al., 2001). The Rab proteins are a diverse group of proteins which
belong to the Ras superfamily of small GTPases and play critical roles in regulating the
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steps of endocytic vesicular transport. Specifically, Rab proteins regulate vesicular traffic
from the plasma membrane by controlling cargo selection, vesicle formation, transport
along the cytoskeleton, and fusion with intracellular target membranes (Stein et al., 2003;
Hutagalung and Novick, 2011; Stenmark and Olkonnen, 2001). Certain Rab proteins also
control the sorting of molecules for return to the plasma membrane or for degradation in
lysosomes. The ability of Rab proteins to regulate the many complex steps of vesicular
transport lies in their selective activation. There are approximately 60 different Rab
proteins encoded in the human genome, each of which is selectively activated by binding
GTP. Once activated, a particular Rab protein serves as a scaffold for the attachment of
various effector proteins which then subsequently direct the completion of a specific step
in the endocytic pathway.
Rab5, which is activated by Rin1, has been shown to regulate vesicle budding and cargo
selection from clathrin coated pits as well as early endosome fusion (Stein et al., 2003;
Hutagalung and Novick, 2011; Stenmark and Olkonnen, 2001). Tall et al. (2001) report
that Rin1 and Rab5 also play a crucial role in the receptor mediated endocytosis of
epidermal growth factor receptor (EGFR) following stimulation by EGF. The receptor
mediated endocytosis of EGFR occurs through a Ras mediated mechanism involving
upstream activation of Rin1 by GTP-Ras and then subsequent activation of Rab5 by
activated Rin1.
The pivotal integrative role of Rab proteins in signal transduction is further illustrated
in a study by Barbieri et al. (2004) examining the role of Rab5 in EGFR mediated MAPK
signal transduction. Rin1 interacts with Rab5 via its Vps9 domain which also contains the
GEF activation function for Rab5. Galvis et al. (2009) have previously reported the key
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function of the Vps9 domain of Rin1 in activating Rab5 through a series of mutational
studies. Barbieri et al. (2004) demonstrate that a dominant negative mutant form of Rab5
(Rab5:S34N) is capable of inhibiting activation of the MAPK pathway in mouse NR6 cells
by preventing both the endocytosis and internalization of the EGFR. The inhibition is
particular to the MAPK pathway and does not interfere with other EGF induced kinase
pathways.
A similar inhibitory effect is observed with the overexpression of wild type full-length
Rin1. On the other hand, however, expression of wild type Rab5 or the Rin1 delta splice
variant leads to increased MAPK activity and increased cyclin D1 expression after EGF
stimulation- resulting in heightened cellular proliferation. The authors suggest that Rab5
activation is a key step in linking EGF stimulated endocytosis to signal transduction
through the MAPK pathway (Barbieri et al., 2004). Although the exact biochemical link
between Ras association and the Rab5 GEF activity of Rin1 is not entirely clear, the binding
of Ras by Rin1 appears to strongly influence EGFR endocytosis.
In a manner similar to EGFR endocytosis, the internalization of insulin receptor
following the binding of insulin may involve other steps including Rab5 activation by Rin1
(Hunker et al., 2005). It is interesting to note that Rin1 sits at the intersection between cell
signaling and receptor mediated endocytosis for mitogens such as EGF and insulin. The
increased rate of receptor mediated endocytosis potentiated by Ras stimulation of the Rab5
GEF activity of Rin1 may be an important negative feedback mechanism by which Ras can
divert signaling away from downstream effectors through Rin1. In this model, an increased
rate of receptor mediated endocytosis would favor quick removal of receptors from the
plasma membrane followed by internalization and degradation (Hunker et al., 2005). The
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end result would be an attenuation of mitogenic signal transduction much in the same way
as can be achieved by the direct competition of Rin1 with RAF1 for access to Ras.
Having examined the biochemical properties of Rin1 and how it fits into the larger
signal transduction machinery of the Ras/MAPK pathway, it would be useful to elaborate
on the possible connection between Rin1 and specific downstream effectors of the
Ras/MAPK pathway known to induce cellular proliferation. These downstream targets,
while varied, include the Ets family of transcription factors mentioned earlier as well as the
telomerase reverse transcriptase enzyme. It is intriguing to wonder if Rin1, given its ability
to compete directly with RAF1 for access to Ras, could have any influence on the cellular
proliferation associated with classical MAPK targets such as the Ets transcription factors
and/or telomerase.
The signaling pathways that have been implicated in the stimulation of telomerase
expression and activity usually involve the response to a mitogen such as EGF or IGF-1,
and subsequent activation of a number of protein kinases belonging to the Ras/MAPK and
PI3K/Akt pathways (Inui et al., 2002; Seimiya et al., 1999; Zhou et al., 2013). It is feasible
then that Rin1 could potentially have an effect on telomerase expression given its role as a
Ras effector molecule. If so, this raises the exciting idea of Rin1 as a potential therapeutic
target in specific cancers. To appreciate the role of Rin1 in a therapeutic context, it is
necessary to review what effect the regulation of the telomerase reverse transcriptase
enzyme and the Ets family of transcription factors have on cellular proliferation.
In both normal and cancerous cells, Ras effector proteins such as Rin1 may be useful
targets for modulation of signaling through the MAPK pathway. The detrimental effects of
abnormalities in the Ras/MAPK pathway are well documented for a variety of different
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cancers. Cancer, in the simplest sense, is a disease of the cell cycle and dissection of the
complex molecular interactions which govern cancer cell growth and reproduction will
ultimately shed light on instances where moderation of aberrant cell signaling may be
possible. Rin1, a known Ras effector molecule, may provide an avenue for attenuation of
signaling through the Ras/MAPK pathway. If so, it is intriguing to contemplate what effect
molecules such as Rin1 could have on downstream targets of the MAPK pathway known
to influence cellular proliferation. Telomerase, for example, is widely expressed in many
cancers and has been heavily implicated in tumorigenesis. As a target of the Ras/MAPK
pathway, it is interesting to speculate on a possible connection between telomerase
expression and the modifying ability of a Ras effector such as Rin1.
1.4

Specific Aims

Aim I
Does the expression of Rin1 affect telomerase gene expression and enzymatic
activity in breast cancer cells in response to growth factor stimulation, and is there a
correlation with cellular proliferation? The first specific aim of the research focuses on
examining the effect of Rin1 expression on telomerase gene expression and activity in
normal breast epithelial cells as well as in tumorigenic, non-metastatic and metastatic
breast cancer cells. The effect of Rin1 expression on cellular proliferation will also be
examined.
Aim II
Does the expression of different Rin1 constructs affect telomerase protein
expression and enzymatic activity in breast cancer cells? The second specific aim of
the research seeks to determine the effect of various Rin1 constructs on telomerase protein
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expression and activity in a tumorigenic, metastatic breast cancer cell line. The cellular
mechanism underlying the influence of Rin1 on telomerase protein expression and activity
will also be examined.
Aim III
Does the expression of Rin1 affect telomerase activity in other cancer cell lines?
The third specific aim of the research evaluates the role of Rin1 on telomerase activity in
different cancer cell lines, including human glioblastoma and melanoma cell lines upon
growth factor stimulation.
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Akt

c-Abl
c-Myc
E2
EGF
EGFR
ER
ERK

ETS2
GAP
GEF
hTERT
hTR
IGF-1
IGF-1R

Protein kinase B; enzyme activated by PI3K and involved in a
signal transduction pathway responsible for promoting cell
growth, proliferation and survival.
Tyrosine kinase involved in various aspects of cell cycle
regulation.
Transcription factor involved in promoting cell growth and
proliferation.
Estradiol; hormone important in promoting cell proliferation.
Epidermal growth factor; growth factor that stimulates cell
proliferation.
Epidermal growth factor receptor; binds EGF and can activate the
Ras/MAPK pathway.
Estrogen receptor; binds estradiol.
Protein kinase of the MAPK pathway that is directly activated by
MEK and translocates into the nucleus to activate various
transcription factors.
Transcription factor important in promoting telomerase gene
expression.
GTPase activating protein; protein that promotes the hydrolysis
of GTP on small, monomeric G-proteins
Guanine nucleotide exchange factor; protein that promotes the
exchange of GDP for GTP on small, monomeric G-proteins.
Human telomerase reverse transcriptase; enzyme responsible for
extending telomeres in certain cell types during cell division.
Human telomerase RNA; RNA template that binds to hTERT and
is necessary for its function.
Insulin-like growth factor I; growth factor that stimulates cell
proliferation.
Insulin-like growth factor I receptor; binds IGF-1 and can activate
the Ras/MAPK pathway.

MAPK

Mitogen activated protein kinase pathway; signaling pathway activated
by Ras in response to growth factor stimulation.

MCF-12A
MCF7
MDA-MB 231
MEK

Normal breast epithelial cell line.
Tumorigenic, non-invasive breast cancer cell line.
Tumorigenic, invasive breast cancer cell line.
Protein kinase of the MAPK pathway that is directly activated by
RAF.
microRNA; small RNA molecule involved in post-transcriptional
downregulation of gene expression.
Phosphoinositide 3-kinase; enzyme involved a signal transduction
pathway responsible for promoting cell growth, proliferation and
survival.
Small, monomeric GTPase activated by Rin1 and involved in
early endosome formation and vesicle trafficking.

miRNA
PI3K

Rab5
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RAF
Ras
Rin1

Rin1 delta
Rin1 Y561F
RPTK
Shelterin

siRNA
SP1
STAT3
Wnt/beta-catenin

Protein kinase of the MAPK pathway that is directly activated by
Ras.
Small, monomeric GTPase involved in signal transduction;
activator of MAPK and PI3K pathways.
Ras and Rab Interactor 1 protein or Ras Interference 1 protein;
full length protein containing 783 amino acids and all functional
domains (84 kDa). Involved in the formation and routing of early
endosomes.
Natural splice variant of Rin1 containing a 62 amino acid deletion
(residues 429-490, 77 kDa); reduced Ras binding.
Point mutation in Rin1 codon 561 converting tyrosine to
phenylalanine (84 kDa); reduced Ras binding.
Receptor protein tyrosine kinase; class of plasma membrane
receptors that are activated by the binding of growth factors.
A complex of telomere binding proteins consisting of TRF1,
TRF2, POT1, RAP1, TIN2, and TPP1; protects telomeres and can
regulate telomerase activity.
small interfering RNA; small RNA molecule involved in posttranscriptional downregulation of gene expression.
Transcription factor important in promoting telomerase gene
expression.
Transcription factor important in promoting telomerase gene
expression.
Proteins involved in regulating cell differentiation and
proliferation.

Table 1.1: Descriptions of key terms.
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Figure 1.1: Diagram of the proposed model for the moderating influence of Rin1 on
signaling through the Ras/MAPK pathway. The binding of a growth factor such as IGF1 to its receptor on the plasma membrane activates Ras and subsequently the MAPK
pathway. Activation of the MAPK pathway in turn activates various nuclear
transcription factors involved in telomerase expression. Rin1 competes with Raf for
binding to activated Ras.

Figure 1.2: Rin1 domains. SH2 binds phospho-tyrosine residues. Vps9 acts as a guanine
nucleotide exchange factor for Rab5. RA binds to activated Ras. Proline rich binds to
SH3 domains.
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CHAPTER 2
The Effect of Rin1 on Cellular Proliferation as well as on Telomerase Gene
Expression and Activity in Breast Cancer Cells
2.1 Introduction
Breast cancer is the most common cause of cancer in women and is the second most
common cause of cancer-related mortality among women. Roughly 20% of all breast
cancer cases are caused by triple negative breast cancers that are characterized by a loss of
the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor
2 (HER-2 or ERBB2) (Ayub et al., 2015). The significant tumorigenic role that growth
factor receptors play in the development of many types of cancers has been widely
reported, and it is especially true for breast cancer carcinogenesis. A large body of evidence
supports the involvement of receptor protein tyrosine kinases (RPTKs), such as the insulinlike growth factor 1 receptor (IGF-1R) and the epidermal growth factor receptor (EGFR),
in the development of many forms of breast cancer. Of equal importance, is the
involvement of the steroid hormone estrogen receptor (ER) in tumorigenesis. The role of
the estrogen receptor in the formation of breast cancer is also widely documented. In fact,
there is a growing body of research that indicates that cooperativity between RPTKs and
the estrogen receptor may exist and is essential for the development of the malignant
phenotype.
One of the molecular hallmarks associated with invasive breast cancer is overexpression
of the insulin-like growth factor 1 receptor. Upregulation of the IGF-1R and its ligand
binding partners is one of the principal mechanisms by which oncogenesis occurs in breast
epithelial cells. The IGF1-R is a hetero-tetrameric transmembrane protein that is
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structurally similar to the insulin receptor (IR). It is initially synthesized as a pro-receptor
that is cleaved into α2β2 subunits before insertion into the cell membrane (Riedemann et
al., 2007). When bound to the IGF-1 ligand, the receptor will undergo a conformational
change to form a catalytically active dimer that is cross-phosphorylated on specific tyrosine
residues located in the cytoplasmic C-terminal domains of the subunits (Verbeek et al.,
1998). Stimulation of the EGF receptor by epidermal growth factor occurs in an almost
identical manner.
Mitogenic signals are transduced to the interior of the cell via receptor mediated
phosphorylation of adaptor proteins that bind the receptor phospho-tyrosine residues. The
insulin receptor substrate 1 (IRS-1) and Src homology collagen (Shc) proteins typically
associate with the activated IGF-1 receptor to become phosphorylated and then relay the
growth signal to two primary intracellular signaling cascades: the PI3K/Akt pathway and
the Ras/MAPK pathway (Mawson et al., 2004). Phosphatidyl inositol 3 kinase (PI3K)
commonly binds to and is activated by phospho-IRS-1, and in turn will subsequently
activate protein kinase B (Akt). Phosphorylated Shc will form a complex with the
Grb2/SOS adaptor proteins to activate p21/Ras and ultimately the MAPK pathway. IGF-1
induction of the Ras/MAPK pathway leads to transcriptionally enhanced expression of
genes that promote cellular proliferation while activation of the PI3K/Akt pathway is
strongly related to cellular survival (Lu et al., 2003). The authors also note that
overexpression of the human epidermal growth factor 2 receptor in MCF-7 breast cancer
cells can attenuate IGF-1 induced MAPK signaling by decreasing the levels of
phosphorylated Shc.
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The reliance of most breast cancers on IGF-1 induced signaling for proliferation and
survival is highlighted by the fact that the epidermal growth factor receptor cannot
compensate for loss of IGF-1 signaling caused by the IGF-1R knockout. Riedemann et al.
(2007) demonstrated that IGF-1R knockout in the non-invasive MCF-7 breast cancer cell
line resulted in increased phosphorylation of EGFR and its effectors (JNK, extracellularsignal regulated kinases, STAT5), but that these cells were most sensitive to IGF-1R loss.
Dual knockout of IGF-1R and EGFR resulted in the same level of clonogenic survival as
IGF-1R knockout alone. Resistance to IGF-1R loss however can be conferred by the action
of the insulin receptor (IR) given the high degree of homology between the two receptors,
and the fact that IR levels are often elevated in many cancers. The IGF-1R and IR are
highly selective in their affinities for their respective ligands, IGF-1 and insulin. However,
IGF-II can bind to both the IGF-1R as well as a natural splice variant of the IR known as
IR-A. Therefore, the IR can act as an additional receptor for the proliferative signaling of
IGF-II even if IGF-1R levels are decreased (Ulanet et al., 2009; Malaguarnera and Belfiore,
2011).
The highly aggressive and invasive nature of most triple negative breast cancers and
their resistance to traditional hormonal therapies/HER-2 inhibition has driven the need to
discover selective small inhibitor molecules for IGF-1R. The approach has been difficult
however given that many of these small inhibitors also interfere with function of the insulin
receptor in normal tissues. Mukohara et al. (2009) have shown that the small IGF-1R
inhibitor NVP-AEW541 was able to decrease levels of phosphorylated IGF-1R while also
decreasing levels of phospho-Akt by disrupting the PI3K/IRS-1 complex. The effect of the
inhibitor was strongest in an MCF-7 cell line that expressed high levels of IRS-1 but was
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less pronounced in the triple negative MDA-MB 231 cell line. On the other hand, Ayub et
al. (2015) were able to demonstrate that dual inhibition of IGF-1R with NVP-AEW541 and
another small inhibitor of either PI3K, mTORC, or MEK was able to reduce the
phosphorylation of Akt and arrest the cell cycle at the G1 phase in MDA-MB 231 breast
cancer cells.
The key strategy to finding effective treatments for breast cancers is to understand the
molecular mechanisms that govern their proliferation, migration, and invasive behavior.
Badache and Hynes (2001) report that Interleukin-6 may play a pivotal role in the migration
of T47D breast cancer cells. An IL-6 treatment of T47D cells resulted in the activation of
both the Ras/MAPK and PI3K/Akt pathways, and a subsequent increase in cell migration.
The effect was abolished by treatment of cells with inhibitors of these pathways. The
activation of the IL-6 receptor by IL-6 resulted in the recruitment and phosphorylation of
the SHP-2 and Gab1 proteins- which in turn enhanced signaling through the MAPK and
PI3K pathways. Interestingly, SHP-2 and Gab1 are also associated constitutively with the
active EGFR and this may provide a cooperative link between the actions of these two
receptors (Badache and Hynes, 2001). A similar study by Park et al. (2013) revealed that
IL-32β stimulation of MDA-MB 231 breast cancer cells increased vascular endothelial
growth factor (VEGF) secretion by these cells through activation of STAT3, the outcome
of which was heightened migration and invasion.
Elevated migration and invasiveness of breast cancer cells is required for metastasis.
Metastasis of breast cancer cells to lymph nodes is common and occurs primarily by
VEGF-C induced lymph-angiogenesis. Zhu et al. (2011) treated MDA-MB 231 cells with
varying concentrations of IGF-1 and noticed that VEGF-C secretion by these breast cancer
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cells increased in a dose dependent manner up to a concentration of 400 ng/mL. The VEGFC secretion following IGF-1 stimulation was found to be mediated by both the PI3K/Akt
and MAPK pathways. Inhibition of Akt abolished the IGF-1 induced expression of VEGFC while ERK inhibition reduced it. EGF induced migration and proliferation of MCF-7
cells has also been linked to sphingosine kinase I activation. Stimulation of these cells with
EGF resulted in the activation and translocation of the enzyme to the plasma membrane
where it phosphorylates membrane sphingolipids. Specific G protein-coupled receptors
associated with the cell membrane then bind the phosphorylated sphingolipids and regulate
cellular processes such as migration and proliferation (Sarkar et al., 2005). The Src family
of kinases have also been implicated as important regulators of proliferation, migration,
and invasiveness in MDA-MB 231 cells in response to growth factor stimulation of various
RPTKs and cytokine receptors (Sanchez-Bailon et al., 2012). Additionally, exposure to the
heavy metal cadmium (Cd) has also been shown to stimulate MAPK signaling and
proliferation in MCF-7 cells (Song et al., 2015).
The migratory behavior of metastatic breast cancer cells is often driven by chemotaxis
towards growth factors and changes in the extracellular matrix (ECM). Price et al. (1999)
investigated the chemotaxis of MDA-MB 231 cells towards varying concentrations of EGF
in the environment of the cells. The directional motility of the cells toward EGF was highest
at an EGF concentration of 10 ng/mL, and the chemotactic response could be inhibited to
baseline levels through the addition of specific EGFR inhibitors. The attachment of cells
to the extracellular matrix often occurs within areas known as focal adhesions. These
regions consist of large protein complexes in which the cytoskeleton of the cell, through
transmembrane proteins such as integrins, connects to the extracellular matrix. These focal
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adhesions are critical for the transmission of mechanical forces and regulatory signals
between the cell and the ECM. A study by Taliaferro-Smith et al. (2015) revealed that the
invasiveness of MDA-MB 231 breast cancer cells is related to the activity of the
cytoplasmic focal adhesion kinase (FAK) enzyme. Inhibition of FAK by siRNA treatment
resulted in decreased levels of total and active IFG-1R as well as reduced invasiveness.
Metastasis of cancer cells is often preceded by a series of alterations to both cellular
morphology and the ECM known as the epithelial to mesenchymal transition (EMT). The
epithelial to mesenchymal transition is typically characterized by enhanced cell migration
and reduced cell adhesion to the ECM. Walsh and Damjanovski (2011) studied the role
that transforming growth factor-β (TGF-β) plays in mediating the epithelial to
mesenchymal transition in MCF-7 breast cancer cells. The TGF-β has been implicated in
tumorigenesis given its ability to regulate cellular proliferation and differentiation. MCF7 cells were treated with 100 nM of IGF-1 and then assayed for metalloproteinase activity.
A 2.9 fold increase in metalloproteinase activity was observed when compared to control
cells, and treatment with either MAPK or PI3K inhibitors could reduce this activity by as
much as 29% to 34% respectively. When treated with TGF-β immediately following IGF1 stimulation, the cells began to assume a more fibroblast-like morphology usually
associated with the EMT.
The ability of cancer cells to become mobile and invade new tissues is largely dependent
upon morphological changes mediated by rearrangement of the actin cytoskeleton. Mezi et
al. (2012) report that cortactin is necessary in the regulation of membrane dynamics and
for the formation of membrane ruffles and lamellipodia, structures frequently associated
with cell migration. The MDA-MB 231 and MCF-7 cells exhibited increased membrane
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ruffling and lamellipodia formation following stimulation with either EGF or IGF-1.
Phosphorylation of cortactin by Src and its localization to focal adhesion regions of the
plasma membrane was observed to be time dependent in both breast cancer cell lines.
Additionally, Morimura and Takahashi (2011) report that stathmin and the small
GTPase Rac1 may also help mediate invasiveness in MDA-MB 231 breast cancer cells.
The metastatic potential of MCF-7 cells appears to be regulated to an extent by a
transmembrane glycoprotein known as Mucin 1 (MUC1). The MUC1 is frequently
overexpressed in these cells but with reduced levels of glycosylation, and it is abnormally
located on the basal side of the cell membrane in close proximity to the ECM. In this
position, aberrant MUC1 is then able to interact with an ECM protein known as ICAM-1.
The interaction facilitates the attachment of migratory cancer cells to blood vessel walls
and stimulates Src activation (Liao et al., 2014). IGF-1, EGF, and estradiol (E2) have also
been shown to promote MCF-7 breast cancer cell attachment to the EMC glycoprotein
fibronectin. High levels of fibronectin in the EMC have been correlated with increased
migration and invasiveness in these cells (Voudouri et al., 2016).
The metastasis of breast cancer cells to other sites is commonly driven by chemotaxis
towards locations that will provide a suitable environment for new tumor formation. A
study by Helbig et al. (2003) reveals that NF-κB enhances expression of the chemokine
receptor CXCR4. A ligand for this receptor, stromal derived factor-1α, is abundantly
expressed at common metastatic sites and is a powerful attractant for migratory MDA-MB
231 breast cancer cells. Osseous tissue is a typical metastatic site for MDA-MB 231 cells
as it provides a conducive environment for colonization and cellular proliferation. Once in
bone tissue, these cells begin to secrete various factors such as parathyroid hormone-related
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peptide that in turn stimulate osteoclast activity. Increased bone resorption by osteoclasts
results in an elevated release of growth factors, such as TGF-β and IGFs, from the bone
matrix. A harmful cycle of cancer cell proliferation and bone destruction then ensues (Son
et al., 2010)
There is a growing body of evidence to support the idea that the development of breast
cancer may involve the cooperative action of growth factors, such as EGF or IGF-1, and
estrogen. When dually stimulated by both IGF-1 and estrogen, Mawson et al. (2004)
observed that MCF-7 breast cancer cells quickly progressed into the S phase of the cell
cycle. The progression was accompanied by an increase in the levels of c-Myc and cyclin
D1. Estrogen induced the expression of both c-Myc and cyclin D1 while IGF-1 primarily
induced the expression of cyclin D1 only. Thus, the differential regulation of c-Myc and
cyclin D1 expression by estrogen and IGF-1 may represent a point of cooperativity in the
regulation of breast cancer cell proliferation (Mawson et al., 2004).
A 2009 study by Santen et al. sheds further light on the cooperative effect of IGF-1R
and estrogen stimulation on MAPK activity in MCF-7 cells. Estradiol (E2) stimulation of
these cells resulted in a rapid phosphorylation of both IGF-1R and EGFR. Activation of
IGF-1R consequently stimulated matrix metalloproteinase activity, and in turn the release
of heparin-binding EGF (Hb-EGF) from its attachment to the plasma membrane. The
subsequent binding of Hb-EGF to EGFR was then observed to increase MAPK activation
and cell proliferation. Similarly, Fox et al. (2009) report that STAT5 is phosphorylated in
the cytoplasm in response to E2 or EGF stimulation and then translocates to the nucleus
where it regulates transcription of multiple proliferative genes. The proliferative response
to E2 can be abolished by inhibition of either EGFR, Src, or STAT5.
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The importance of the estrogen receptor (ER) in the development of breast cancer is
underscored by the fact the roughly 70% of all breast cancer cases exhibit abnormally high
levels of ER. Estrogen exerts its proliferative effect by interacting with two predominantly
nuclear receptors (ERα and ERβ) as well as with a newly discovered G protein-coupled
receptor known as GPR30. ERα, because of its increased stability and availability, appears
to play a greater role in the proliferative response of breast cancer cells to estrogen than
does ERβ (Tecalco-Cruz and Ramirez-Jarquin, 2016). Zhang et al. (2014) for instance
found that ERα36 is closely associated with the plasma membrane and is capable of
inducing rapid MAPK signaling in MCF-7 cells through the involvement of several
proteins including matrix metalloproteinases and Hb-EFG.
The expression of ERβ, on the other hand, tends to be lower in breast cancer cells than
in normal breast tissue. Lazennec et al. (2001) were able to demonstrate that overexpression
of ERβ in MDA-MB 231 cells could reduce ER stimulated proliferation and migration by
as much as 40% when compared to control. Besides the estrogen receptor, the G proteincoupled receptor GPR30 has also recently been shown to mediate estrogen induced
signaling. Prakash-Pandey et al. (2009) report that connective tissue growth factor (CTGF)
expression is strongly induced by E2 stimulation of SKBr3 breast cancer cells that contain
GPR30 but lack both ERα and ERβ. A two-fold increase in migration was subsequently
observed following E2 stimulation and this effect could be greatly diminished by either
GPR30 or CTGF inhibition.
In summary, the important role that growth factor receptors play in breast cancer
tumorigenesis is clear. Abnormalities in these receptors, as well as the estrogen receptor,
are often significant contributors to the acquisition of the cancerous phenotype- as are
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abnormalities in the signaling pathways that they regulate. The enhanced cell proliferation
and migration commonly observed in most breast cancers is therefore intimately tied to the
activity of mitogenic signaling pathways and their associated receptors.
2.2

Results
Lentiviral vectors encoding GFP and Rin1 were designed using the VectorBuilder

online platform (https://en.vectorbuilder.com/). These lentiviral vectors (Figure 2.1) were
used in the creation of the Rin1 and GFP expressing MDA-MB 231 and MCF-7 breast
cancer cell lines as described in 2.4, Creation of Cell Lines. Additionally, MCF-12A
normal breast epithelial cell lines expressing GFP and Rin1 were also created in the same
manner. Confirmation of stable Rin1 and GFP expression was accomplished by Western
blotting and immunofluorescence (IF). Western blotting (Figure 2.3) verified the
expression of GFP and Rin1 in the respective MDA-MB 231 cell lines. A light micrograph
image (Figure 2.2, B.) of the MDA-MB 231 Rin1 cell line reveals a rounded, clumped
morphology and a generally slower growth pattern for these cells. A confocal micrograph
image (Figure 2.2, A.) indicates the presence of Rin1 in the Rin1 virally transduced MDAMB 231 cell line. The spatial distribution of Rin1 throughout the MDA-MB 231 Rin1 cells
is also evident from the confocal micrograph image (Figure 2.2, A.). Rin1 appears to be
more concentrated near the plasma membrane.
A baseline experiment to assess the proliferative response of MDA-MB 231 cells to
culture media containing serum (10% FBS) was conducted to establish the normal
proliferative capacity of unaltered, non-virally transduced MDA-MB 231 breast cancer
cells (Figure 2.4). Three different concentrations of 5.0 x 104, 1.0 x 105, and 2.0 x 105
cells/mL were utilized, and each experiment was repeated in triplicate. When exposed to
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serum, all three cell concentrations resulted in an increase in proliferation as measured by
the MTT assay. However, only concentrations of 1.0 x 105 and 2.0 x 105 cells/mL displayed
a statistically significant increase in cellular proliferation when compared to a
corresponding serum free control group (p <0.05, Student’s t-test). A 22% increase in
proliferation over the serum free treatment group was observed for a cell concentration of
5.0 x 104 cells/mL, while concentrations of 1.0 x 105 and 2.0 x 105 cells/mL resulted in
increases of approximately 40% and 83%. These results demonstrate the effect of cell
concentration on serum induced cellular proliferation in the MDA-MB 231cell line.
Regression analysis (Figure 2.5) shows that the linear increase in cellular proliferation as
a function of cell concentration is statistically significant for the serum treated groups (p
<0.05).
The MDA-MB 231 cells expressing Rin1 displayed reduced levels of cellular
proliferation across a range of IGF-1 concentrations tested when compared to control cells
expressing GFP (Figure 2.6). The MDA-MB 231 GFP cells exhibited increases in cellular
proliferation over unstimulated cells ranging from 47% for treatment with 20 ng/mL of
IGF-1 to 80% for treatment with 5 ng/mL of IGF-1. Conversely, the range of increase in
cellular proliferation for the MDA-MB 231 Rin1 cells was much lower- ranging from 6%
for treatment with 100 ng/mL of IGF-1 to only 29% for treatment with 20 ng/mL of IGF1. These data suggest a suppressive role of Rin1 on cellular proliferation following IGF-1
stimulation.
In an effort to validate these findings, additional experimentation to determine the effect
of Rin1 expression on cellular proliferation in MDA-MB 231, MCF-12A, and MCF7 cells
was performed by stimulating cells with an IGF-1 concentration of 100 ng/mL for 24 hours.
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IGF-1 stimulation resulted in a significant increase in proliferation of 56% over serum
starved cells for the MDA-MB 231 non-virally transduced cell line (Figure 2.7). Similarly,
a significant increase in cell proliferation of 65% in response to IGF-1 exposure was noted
for the MDA-MB 231 GFP cell line (Figure 2.8). However, the MDA-MB 231 Rin1
expressing cell line displayed a significant increase in cellular proliferation of only 18%
when compared to the corresponding serum free group (Figure 2.9). The serum starved
condition resulted in roughly equal low levels of proliferation for all three MDA-MB 231
cell lines examined and was set equal to 1 for analysis purposes. All experiments were
conducted in triplicate using a concentration of 2.0 x 105 cells/mL.
In terms of cell viability, all three MDA-MB 231 cell lines tested showed no significant
increases in cell viability in response to IGF-1 stimulation when compared to the
corresponding serum free groups. However, similar to cellular proliferation, the MDA-MB
231 Rin1 expressing cell line exhibited the lowest level of cell viability (24%) when
stimulated by IGF-1. All viability experiments were conducted in triplicate using a
concentration of 2.0 x 105 cells/mL.
A serial dilution of a known telomerase positive HeLa cell extract was performed in
order to demonstrate the ability of the telomeric repeat amplification protocol (TRAP)
qPCR assay to accurately measure telomerase activity in diluted cell extract samples with
different concentrations of telomerase (Figure 2.11). As the dilution factor increased by
factors of 10 from 10X to 100X to 1,000X, the average cycle threshold (Ct) value increased
from 26.28 for the undiluted sample to 26.78 for the 1,000X diluted sample. The 10X and
100X dilutions produced Ct values of 26.50 and 26.70. The highest Ct value of 27.02 was
observed for the buffer only sample containing no cell extract any only the assay reagents
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(Table 2.1). The PAGE gel analysis for the undiluted telomerase positive sample reveals
the characteristic ladder of DNA bands consistent with the presence of telomerase activity
(Figure 2.10). The assay for each dilution factor was performed in duplicate.
A reverse transcriptase qPCR (RT-qPCR) assay was performed to assess the effect of
IGF-1 stimulation (100 ng/mL for 24 hours) on telomerase gene expression in the MDAMB 231 Rin1 and GFP cell lines (Figure 2.13). Telomerase gene expression for all cell
samples was normalized to that of the GAPDH housekeeping gene using the ΔCt method.
A normalized average telomerase gene expression Ct value of 10.87 in response to IGF-1
stimulation was found for the MDA-MB 231 cells overexpressing Rin1 (Table 2.3). The
corresponding IGF-1 stimulated GFP control cells displayed a normalized average
telomerase gene expression Ct value of 10.74 (Table 2.3). A 1.09 fold decrease in
telomerase gene expression was observed for the cells overexpressing Rin1 when
compared to the GFP expressing cells (Table 2.3). The fold change in telomerase gene
expression was calculated using the ΔΔCt method where fold change is equal to 2-ΔΔCt. The
ΔCt is the difference between the average sample Ct for a gene of interest and that of a
reference or housekeeping gene. The ΔΔCt, therefore, is the difference in ΔCt values for a
sample of interest and that of a particular reference sample. All samples were assayed in
duplicate. The presence and specific amplification of GAPDH and telomerase qPCR
products was confirmed through PAGE gel analysis (Figure 2.13) and melt curve analysis.
A qPCR telomerase activity assay (as described in 2.4, Telomerase Activity Assay) was
performed to determine the effect of Rin1 on telomerase activity following IGF-1
stimulation with 100 ng/mL for 24 hours (Table 2.2). Telomerase activity was assessed in
both the MDA-MB 231 Rin1 and GFP cell lines as well as in telomerase positive and
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negative controls. The MDA-MB 231 cell samples expressing Rin1 resulted in an average
Ct value of 21.14 following IGF-1 stimulation while the average Ct value of the
corresponding GFP cell samples was 20.49 (Table 2.2). A 1.56 fold decrease in telomerase
activity was observed for the cells overexpressing Rin1 when compared to the activity of
the reference GFP cells (Table 2.2). Fold change was calculated according to the ΔΔCt
method. The lowest average Ct value was observed for the HeLa cell telomerase positive
control while the heat treated negative control and buffer only samples produced average
Ct values of 20.16 and 20.23 respectively (Table 2.2). The qPCR amplification of the
TRAP products was confirmed by PAGE gel analysis (Figure 2.12). All samples were
assayed in duplicate.
Cellular proliferation and viability as well as telomerase activity of normal, nontumorigenic MCF-12A breast epithelial cells were also assayed following IGF-1 exposure.
IGF-1 stimulation of non-transduced MCF-12A cells with 100 ng/mL for 24 hours resulted
in an insignificant decrease in cellular proliferation of 20% over serum starved cells (Figure
2.15). On the other hand, an insignificant increase in cell proliferation of 41% in response
to IGF-1 exposure was noted for the MCF-12A Rin1 cell line (Figure 2.17). The MCF-12A
GFP expressing cells displayed an insignificant increase in proliferation following IGF-1
exposure of 28% when compared to the corresponding serum free group (Figure 2.16). The
serum starved condition resulted in roughly equal low levels of cellular proliferation for all
three MCF-12A cell lines examined and this value was set equal to 1 for analysis purposes.
All cellular proliferation experiments were conducted in triplicate using a concentration of
2.0 x 105 cells/mL.
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All three MCF-12A cell lines tested showed no significant increases in cell viability in
response to IGF-1 stimulation when compared to the corresponding serum free groups.
However, when compared as a whole, the MCF-12A Rin1 cell line exhibited the lowest
level of cell viability (11%) when stimulated by IGF-1. All cell viability experiments were
conducted in triplicate using a concentration of 2.0 x 105 cells/mL.
To assess telomerase activity, MCF-12A cells expressing Rin1 or GFP were serum
starved for 24 hours and then treated with 100 ng/mL of IGF-1 for an additional 24 hours.
The IGF-1 treated cell samples and corresponding untreated samples were then lysed and
prepared for the TRAP qPCR telomerase activity assay as described in 2.4, Telomerase
Activity Assay. The MCF-12A cell samples expressing Rin1 resulted in an average Ct value
of 25.76 following IGF-1 stimulation while the average Ct value of the corresponding GFP
cell samples was 25.92 (Table 2.4). A 1.1 fold increase in telomerase activity was observed
for the cells overexpressing Rin1 when compared to the activity of the control GFP cells
(Table 2.4). Fold change was calculated according to the ΔΔCt method. The heat treated
negative control and buffer only samples produced average Ct values of 25.70 and 26.06
respectively (Table 2.4). All samples were assayed in duplicate.
A reverse transcriptase qPCR (RT-qPCR) assay was performed to assess the effect of
IGF-1 stimulation (100 ng/mL for 24 hours) on telomerase gene expression in the MCF12A Rin1 and GFP cell lines (Table 2.5). Telomerase gene expression for all cell samples
was normalized to that of the GAPDH housekeeping gene using the ΔCt method. A
normalized telomerase gene expression Ct value of 5.58 in response to IGF-1 stimulation
was observed for the MCF-12A cells overexpressing Rin1 (Table 2.5). The corresponding
IGF-1 stimulated GFP control cells displayed a normalized telomerase gene expression Ct
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value of 4.23 (Table 2.5). A 2.55 fold decrease in telomerase gene expression was observed
for the cells overexpressing Rin1 when compared to the GFP expressing cells (Table 2.5).
Finally, the effect of Rin1 on cellular proliferation and viability as well as the effect on
telomerase gene expression and activity was investigated in the tumorigenic, non-invasive
MCF7 human breast cancer cell line. In the non-virally transduced MCF7 cells, a
significant increase of 26% in proliferation was observed in response to IGF-1 exposure
when compared to the corresponding serum starved cells (Figure 2.19). The trend was also
observed for the MCF7 cells expressing either GFP, 22% increase, or Rin1, 26% increase
(Figures 2.20 and 2.21). Like the MDA-MB 231 and MCF-12A cells, the MCF7 cells
expressing Rin1 exhibited the lowest level of viability following serum starvation for all
three MCF7 cell lines examined.
A reverse transcriptase qPCR (RT-qPCR) assay was performed to assess the effect of
IGF-1 stimulation (100 ng/mL for 24 hours) on telomerase gene expression in the MCF-7
Rin1 and GFP cell lines (Table 2.7). Telomerase gene expression for all cell samples was
normalized to that of the GAPDH housekeeping gene using the ΔCt method. A normalized
telomerase gene expression Ct value of 10.87 in response to IGF-1 stimulation was found
for the MCF7 cells overexpressing Rin1 (Table 2.7). The corresponding IGF-1 stimulated
GFP control cells displayed a normalized telomerase gene expression Ct value of 10.54
(Table 2.7). A 1.26 fold decrease in telomerase gene expression was observed for the cells
overexpressing Rin1 when compared to the GFP expressing cells (Table 2.7).
To assess telomerase activity, MCF7 cells expressing Rin1 or GFP were serum starved
for 24 hours and then treated with 100 ng/mL of IGF-1 for an additional 24 hours. The
IGF-1 treated cell samples and corresponding untreated samples were then lysed and
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prepared for the TRAP qPCR telomerase activity assay as described in 2.4, Telomerase
Activity Assay. The MCF7 cell samples expressing Rin1 resulted in an average Ct value of
24.63 following IGF-1 stimulation, while the average Ct value of the corresponding GFP
cell samples was 24.50 (Table 2.6). A 1.09 fold decrease in telomerase activity was
observed for the cells overexpressing Rin1 when compared to the activity of the control
GFP cells (Table 2.6). Fold change was calculated according to the ΔΔCt method. The heat
treated negative control and buffer only samples produced average values of 25.49 and
25.70 respectively (Table 2.6). All samples for telomerase gene expression and activity
were assayed in duplicate.
2.3

Discussion
The MDA-MB 231 breast cancer cell line was chosen to study the effect of IGF-1

induction on cellular proliferation given the strong proliferative and invasive properties of
this particular cell line. Two MDA-MB 231 control cell lines were used to compare the
effects of Rin1 overexpression on proliferation and viability. These control cell lines
consisted of virally unaltered (non-transduced) MDA-MB 231 cells as well as cells virally
altered to express GFP.
As expected, a linear increase in cellular proliferation was observed following the
exposure of non-transduced MDA-MB 231 cells to serum containing culture media (Figure
2.5). The increase in proliferation was significantly greater at higher cell concentrations
(1.0 x 105 and 2.0 x 105 cells/mL) when compared to the corresponding serum free
treatment cells. Additionally, the linear increase in proliferation as cell concentration
increased was also statistically significant for the serum treated cells (p<0.05) (Figure 2.5).
These baseline results indicated that MDA-MB 231 cells were capable of proliferation in
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response to serum-containing growth factor stimulation. A cell concentration of 2.0 x 105
cells/mL resulted in an 83% increase in cell proliferation over the serum free treatment and
was therefore deemed to be an optimal concentration to use for future experimentation on
cellular proliferation and viability.
Western blot analysis of virally transduced MDA-MB 231 cells indicates high levels of
GFP as well as Rin1 expression (Figure 2.3). Light micrograph imagery of the Rin1
overexpressing MDA-MB 231 cell line reveals a striking difference in morphology and
growth pattern. The Rin1 cells typically grow more slowly and in a clumped or island-like
pattern when compared to the GFP cell line and are more rounded in shape (Figure 2.2,
B.). The GFP cells, which express endogenous levels of Rin1, tend to grow more evenly
across the surface of the culture dish and have a more spindle-like appearance.
The reduced growth rate observed for the Rin1 overexpression cells could be a
consequence of the strong ability for Rin1 to compete for access to activated Ras and thus
attenuate signaling through the MAPK pathway. Confocal micrograph imagery reveals a
spatial difference in the distribution of Rin1 as well. Rin1 appears to be more concentrated
around the periphery of the cell in association with the plasma membrane, perhaps on
endocytic vesicles (Figure 2.2, A.).
All three MDA-MB 231 cell lines displayed a significant increase in cell proliferation
over the corresponding serum free condition (Figures 2.7, 2.8, and 2.9) following exposure
to IGF-1. As expected, all three MDA-MB 231 cell lines also displayed roughly equal low
levels of proliferation when serum starved and not exposed to IGF-1. However, in response
to IGF-1 stimulation alone, the Rin1 expressing cells only exhibited a modest 18% increase
in proliferation over the corresponding unstimulated cells (Figure 2.9). In fact, these cells
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displayed lower levels of cellular proliferation over a range of IGF-1 concentrations tested
in comparison to GFP cells (Figure 2.6). The viability of these cells was also 43% lower in
comparison to that of the non-transfected cells and 31% lower when compared to the GFP
cells. Taken together, these results support the idea of Rin1 exerting a modulating effect
on cellular proliferation and viability in MDA-MB 231 cells.
These results are in line with the results of the telomerase gene expression and activity
studies and suggest that Rin1 may be able to moderate signaling through mitogenic
pathways given its strong affinity for activated Ras. In order to assess the effect of Rin1 on
telomerase gene expression following IGF-1 stimulation, MDA-MB 231 cells
overexpressing Rin1 were compared to GFP expressing cells. RT-qPCR data reveal a 1.09
fold decrease in telomerase gene expression for the Rin1 cells after normalization to
expression of the GAPDH housekeeping gene (Table 2.3). Successful amplification of both
telomerase and GPADH is evident from the tight clustering of curves within the appropriate
range of Ct values for each gene as well as the presence of specific bands of the correct
amplicon sizes (Figure 2.13) and melting temperatures. The MDA-MB 231 cell lines
contain a constitutively active mutant form of Ras, and thus the overexpression of Rin1
may be modulating signaling from this protein as evidenced in the reduction of telomerase
gene expression by 1.09 fold (Table 2.3). Telomerase activity follows a similar trend as
gene expression for the MDA-MB 231 Rin1 cells. Here, a 1.56 fold decrease in telomerase
activity was observed for the Rin1 cells as compared to the GFP cells (Table 2.2). The
decrease in telomerase activity is evident upon PAGE gel analysis of the TRAP qPCR
products (Figure 2.12). The reduction in telomerase activity may be tied to the decrease in
telomerase gene expression observed in the MDA-MB 231 Rin1 cells.
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Telomerase gene expression and activity in the normal, non-tumorigenic MCF-12A
epithelial breast cell line appears to support a tumor suppressive role for Rin1 similar to
that observed for the MDA-MB 231 breast cancer cell lines. Here, a 2.55 fold decrease in
telomerase gene expression was recorded for the cells overexpressing Rin1 when compared
to control cells expressing GFP (Table 2.5). The decrease in telomerase gene expression is
much larger than the 1.09 fold decrease observed in the MDA-MB 231 cells expressing
Rin1. The greater decrease in telomerase gene expression exhibited by the MCF-12A cells
may be attributed to the ability of Rin1 to modulate MAPK signaling more strongly in a
normal, non-tumorigenic cell lines than in an invasive, tumorigenic cell line such as MDAMB 231 cells where telomerase expression and activity are strongly tied to cellular
proliferation and survival.
The effect of Rin1 on telomerase activity however is not as clear for the MCF-12A cells.
Generally, a tumor suppressor role is supported when comparing the telomerase activity of
MCF-12A cells overexpressing Rin1 to non-virally transduced cells. Here, a 1.23 fold
decrease in telomerase activity is observed for the cells expressing Rin1. The value is
similar to the 1.56 fold decrease in activity reported for the MDA-MB 231 Rin1 cells. On
the other hand, a 1.12 fold increase in telomerase activity is reported when comparing the
MCF-12A Rin1 cells to the corresponding GFP cells (Table 2.4). The increase in
telomerase activity exhibited by MCF-12A Rin1 cells also mirrors an increased level of
cellular proliferation for these cells. Higher levels of proliferation were observed for MCF12A Rin1 cells following IGF-1 exposure (41%) when compared to GFP cells. The
downregulation of telomerase gene expression observed in these cells appears to be
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independent and in contrast to the recorded increased levels of telomerase activity and
cellular proliferation.
The telomerase gene expression and activity data from the tumorigenic, non-invasive
MCF7 breast cancer cell line lends further support to a potential tumor suppressor role for
Rin1. Here, the 1.09 fold decrease in telomerase activity (Table 2.6) for cells expressing
Rin1 over GFP cells is similar to that of the 1.56 fold decrease in telomerase activity
observed for the MDA-MB 231 cells. A more interesting trend, however, is apparent when
examining the ability of Rin1 to downregulate telomerase gene expression across the three
different breast cell lines studied. The 1.26 fold reduction in telomerase gene expression
observed for the MCF7 cells expressing Rin1 (Table 2.7) is between that of the MDA-MB
231 and MCF-12A cells, which displayed fold decreases each of 1.09 and 2.55
respectively. Rin1 therefore has the least ability to attenuate cell signaling following IGF1 stimulation, and thus lower telomerase gene expression, in the MDA-MB 231 cells. The
result could be partially explained by the fact that these cells harbor a constitutively active
mutant form of Ras and, as a consequence, the MDA-MB 231 cells are highly tumorigenic
as well as invasive.
On the other hand, Rin1 has the greatest suppressive effect on telomerase gene
expression in the normal, non-tumorigenic/non-invasive MCF-12A breast cells. Here, in
the absence of a constitutively active form of Ras, Rin1 may have a stronger ability to
dampen cell signaling subsequent to growth factor stimulation and therefore have a larger
suppressive effect on telomerase gene expression. Finally, the ability of Rin1 to reduce
telomerase gene expression in the tumorigenic, non-invasive MCF7 cells is intermediate
(1.26 fold) between that of the MDA-MB 231 and MCF-12A cells. This result mirrors the
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26% increase in cellular proliferation observed for these cells that falls between the 18%
and 41% increases observed for the MDA-MB 231 Rin1 and MCF-12A Rin1 cells
respectively. Again, as with the MDA-MB 231 cells, background tumorigenic processes in
the MCF7 Rin1 cells may counteract the modulating influence of Rin1 on MPAK
signaling.
In summary, Rin1 may act to attenuate signaling through the MAPK pathway given its
strong interaction with activated Ras. This idea is supported by cellular proliferation data
as well as by telomerase gene expression and activity studies from the MDA-MB 231,
MCF7, and MCF12-A human breast cell lines. The tumor suppressive role of Rin1 in these
breast cell lines may be cell type specific, with lower levels of cellular proliferation and a
stronger reduction in telomerase activity being observed in the two tumorigenic cell lines
versus the non-tumorigenic cell line (Table 2.8).
2.4

Materials and Methods

Characteristics of Cell Lines
The MDA-MB 231 breast cancer cell line is a highly invasive and tumorigenic breast
epithelial (carcinoma) cell line that harbors a constitutively active mutant form of Ras,
KRAS (G13D) (Kim et al., 2015). These cells are also triple negative meaning that they
lack expression of the estrogen, progesterone, and HER2/Neu receptors and typically grow
well in DMEM culture media supplemented with 10% fetal bovine serum. The MCF7
breast cancer cell line is a tumorigenic, non-invasive breast epithelial cell line that also
grows well in DMEM culture media supplemented with 10% FBS (Kim et al., 2015). The
MCF-12A cell line is a normal breast epithelial cell line that grows optimally in a 1:1
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DMEM/F-12 culture media supplemented with 5% horse serum, insulin, cholera toxin,
EGF, and hydrocortisone (Kim et al., 2015).
Creation of Cell Lines
The MDA-MB 231 metastatic breast cancer cells were used to create cell lines
expressing GFP or Rin1. Lentiviral plasmid expression vectors for GFP (pLV[Exp]-PuroCMV>eGFP) and Rin1 (pLV[Exp]-Puro-CMV>hRIN1) were designed using the
VectorBuilder website (https://en.vectorbuilder.com/) powered by Cyagen Biosciences.
The protein coding open reading frame sequence of each vector was placed under the
control of a strong CMV promoter. A puromycin drug selection marker was included in
each vector to allow for selection of stably transduced cells at a concentration of 4 ug/mL.
The GFP and various Rin1 lentiviral vectors were then synthesized by Cyagen Biosciences
and each was accompanied with a maxiprep of plasmid vector DNA at a concentration of
approximately 1 ug/uL (500 uL total volume).
A lentiviral expression system (Lenti-X Packaging Single Shots) available from
Clontech Laboratories (Takara) was utilized to transduce native MDA-MB 231 cells to
express GFP or Rin1. Transduction was performed according to the manufacturer’s
instructions. Briefly, 2.0 x 106 Lenti-X 293T viral packaging cells were plated on a 6 cm
culture dish in 4 mL of complete growth media lacking tetracycline. The cells were plated
24 hours prior to transfection and allowed to grow at 37⁰C and 5% CO2 until they reached
approximately 80 to 90% confluency. On the day of transfection, 7 ug of plasmid DNA
was mixed with sterile water to a final concentration of 600 uL. The entire volume of
diluted DNA was then added to a single Lenti-X Packaging Single Shot tube and vortexed
for roughly 20 seconds. The DNA sample was then allowed to incubate for 10 minutes.
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Following incubation, 300 uL plasmid DNA sample was added to a culture dish containing
the Lenti-X 293T viral packaging cells. The protocol was followed for each of the four
lentiviral vector plasmid DNA samples and was performed in duplicate. The viral
packaging cells were then incubated for 48 hours at 37⁰C and 5% CO2. After 48 hours, the
viral containing supernatant was collected and filtered through a 0.45 um filter to remove
any cellular debris. Five hundred microliters of viral supernatant was then added to MDAMB 231 cells plated at a density of 3.0 x 105 cells per well on a 6 well plate in 2 mL of
complete growth media.
The native MDA-MB 231 cells were plated one day prior to viral transduction.
Polybrene was added to each well at a concentration of 6 ug/mL to enhance transduction.
Transduction was performed in triplicate (3 wells) for each plasmid DNA sample. Any
unused viral supernatant was aliquoted in 1.5 mL Eppendorf tubes and frozen at -80 ⁰C.
Viral transduction of the MDA-MB 231 cells occurred for 48 hours after which time the
viral containing media was aspirated and replaced with 3 mL of fresh complete growth
media. The cells were allowed to recover for an additional 48 hours prior to selection with
puromycin. After the recovery period, the complete growth media was changed for 3 mL
of selection growth media containing the antibiotic puromycin at a concentration of 4
ug/mL. The transduced MDA-MB 231 cells were selected for 72 hours before being
trypsinized and moved to a T75 tissue culture flask. The cells were subsequently grown in
selection media for a period of two weeks with media changes every three days until only
stably transduced cells survived. The stable cell lines expressing GFP or Rin1 were then
frozen in cryogenic tubes at -80 ⁰C until further use.
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Additionally, MCF-7 non-metastatic breast cancer cell lines and normal breast epithelial
MCF-12A cell lines were created to stably express Rin1 or GFP following the methodology
outlined above. Stable expression of Rin and GFP in these cell lines was achieved through
selection using a puromycin concentration of 2 µg/mL.
MTT Cell Proliferation Assay
An initial experiment to determine the optimal concentration of cells needed to observe
a statistically significant difference in proliferation was performed using MDA-MB 231
breast cancer cells expressing green fluorescent protein (GFP). The cells were obtained
from a cryopreserved stock culture and were grown in a T75 (75 cm2) tissue culture flask
containing 15 mL of complete growth media incubated at 37⁰ C with 5% CO2. The cells
were grown until approximately 80% confluent. The culture media consisted of 1X
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L of glucose with Lglutamine. Complete culture media was prepared by filtering 500 mL of 1X DMEM
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (10,000
U/mL penicillin and 10,000 ug/mL streptomycin) , 1% Minimal Essential Medium (MEM)
nonessential amino acid solution, and 1% sodium-pyruvate (100 mM). After reaching
approximately 80% confluency, the culture medium was aspirated and the cells were
washed once with 2 mL of cold 1X PBS-EDTA (1 mM) solution. The cellular monolayer
was then trypsinized in an incubator (37⁰ C and 5% CO2) to detach cells for 3 minutes with
2 mL of Trypsin-EDTA (0.25%) solution. Four milliliters of serum free DMEM starvation
medium was then added to the culture flask to suspend the trypsinized cells. The 4 mL cell
suspension was then transferred to a 15 mL conical centrifuge tube and spun at 5,000 RPM
in a centrifuge for three to five minutes until a cell pellet formed at the bottom of the tube.
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The entire volume of supernatant was then aspirated carefully so as to not disturb the pellet,
and the pellet was re-suspended in a fresh volume of 2 mL of serum free starvation medium.
A one hundred microliter sample of the re-suspended cells was then transferred to a 1 mL
Eppendorf microcentrifuge tube. An equal volume of 100 uL of Trypan blue cell viability
exclusion stain was added to the tube and gently mixed to permit detection of viable (live)
cells. A 10 uL sample of the stained cell suspension was then loaded into one chamber
(side A) of a Bio-Rad dual chamber cell counting slide. A second 10 uL sample was also
loaded into the second chamber (Side B) and the total number of viable cells per milliliter
in each chamber was counted using a Bio-Rad TC20 Automated Cell Counter. The average
number of live cells per milliliter was then calculated and used to perform dilutions of the
2 mL suspension to specific cell concentrations in order to test the effect of serum versus
serum free media on the proliferation of MDA-MB 231 eGFP cells. Serum free starvation
media was used to prepare all dilutions.
Concentrations of 5.0 x 104, 1.0 x 105, and 2.0 x 105 cells/mL were tested initially to
determine the optimal cell concentration needed to observe a meaningful, statistically
significant difference in cellular proliferation as measured by an MTT assay. Each of the
three concentrations tested were plated on separate 12 well plates (3 plates total, one for
each cell concentration) in a volume of 1 mL per well (5.0 x 104 cells/well, 1.0 x 105
cells/well, 2.0 x 105 cells/well), and incubated under serum free conditions at 37⁰ C with
5% CO2 for 24 hours to synchronize growth rates. After 24 hours, the culture media in half
of the wells (6) per plate was aspirated and replaced with 1 mL of complete growth media.
The other half of the wells (6) retained the serum free starvation media. The plates were
then incubated at 37⁰ C with 5% CO2 for another 24 hours. A 4 mL MTT (3-(4,592

dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution at a concentration of 5
mg/mL was prepared, and 50 uL was added to each well of each plate. The plates were
gently agitated to ensure thorough mixing of the MTT solution with the liquid in each well.
The plates were then wrapped in aluminum foil to prevent light exposure and were
incubated at 37⁰ C with 5% CO2 for 4 hours to allow for reduction of the yellow tetrazolium
dye. After 4 hours, the culture media in each well was carefully removed so as to not disturb
the formazan crystals produced by the reduction of the tetrazolium dye. Four hundred
microliters of dimethyl sulfoxide (DMSO) was then added to each well of each plate to
dissolve the formazan crystals and the plates were agitated for 5 minutes to promote
complete solubilization of the formazan product. The 400 uL of the purple fomazan-DMSO
solution from each well of each plate was then transferred to an individual microcuvette
and diluted with 1.1 mL of deionized water to a final volume of 1.5 mL. The absorbance
of each sample at a wavelength of 570 nm was recorded using an Ultrospec 2000 Pro
spectrophotometer. A Student’s t-Test was used to test for any statistically significant
difference in cell proliferation between serum exposed cells and those not exposed to serum
for each cell concentration. The three cell concentrations tested provided six replicates each
for serum and serum free conditions. Regression analysis was then used to detect any
statistically significant increase in proliferation as cell concentration increased. A
concentration of 2.0 x 105 cells/mL was determined to be the optimal concentration to
observe any possible significant difference between treatment groups. All future cell
proliferation and viability experiments were performed in triplicate.
A CCK8 cell proliferation assay similar to that of the MTT assay was performed on the
MDA-MB 231, MCF-7, and MCF-12A cells expressing GFP or Rin1 as well as on non93

transfected cells for each of these cell lines. In this assay, a WST8 (2-(2-methoxy-4nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt)
compound is reduced to an orange, water soluble formazan product that can be detected at
a wavelength of 450 nm. As with the MTT assay, the intensity of the absorbance of the
colored solution is directly proportional to the number of cells present. All experiments
were performed in triplicate for each of the three breast cell lines to determine the effect of
serum or IGF-1 stimulation on cellular proliferation. Cells were grown for 24 hours in
starvation media on a 12 well plate (9 wells in total) at a density of 1.0 x 105 cells per mL
with 1 mL per well. After 24 hours, the starvation media was aspirated from the appropriate
wells and replaced with serum containing growth media (3 wells) while other wells retained
the starvation media (3 wells) or were supplemented with 100 ng/mL of IGF-1 (3 wells).
The cells were grown for another 24 hours at 37°C with 5% CO2 and then treated with 25
µL per well of CCK8 solution. Following incubation for 4 hours with CCK8 solution, the
growth media was aspirated and its absorbance at 450 nm was measured. The viability each
of the cell samples remaining in the wells was then determined using trypan blue staining.
Trypan Blue Cell Viability Assay
Following the removal of the growth media and the measurement of its absorbance for
cellular proliferation, the cells in each well were washed once with 200 uL of cold 1X PBSEDTA (1mM) solution. The cells were subsequently detached with 200 uL of trypsinEDTA (0.25%) solution for 5 minutes in an incubator at 37⁰C with 5% CO2. One milliliter
of serum free media was added to each well to suspend the cells. A 100 uL sample from
each well was subsequently transferred to individual Eppendorf microcentrifuge tubes and
mixed with 100 uL of Trypan blue cell viability stain (2X dilution). A 10 uL sample of
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stained cell suspension from each tube was then loaded onto a Bio-Rad dual chamber cell
counting slide and the number of cells/mL (total and viable) was counted for each sample.
A Student’s t-Test was used to test for any statistically significant difference in cell
viability between serum free, serum exposed, or IGF-1 treated cells.
Western Blotting
Western blot analysis was performed on the various MDA-MB 231, MCF-7, and MCF12A cell lines prior to conducting any assays to confirm that each cell line expressed the
protein(s) of interest. Cells were grown to approximately 80% confluency in a T75 tissue
culture flask containing 15 mL of 1X DMEM complete culture media as described in the
MTT Cell Proliferation Assay. Cells were then washed once with 1 mL of cold 1X PBSEDTA (1mM) and subsequently trypsinized with 1 mL of Trypsin-EDTA (0.25%)
solution. One milliliter of 1X DMEM complete culture media was added to the tissue
culture flask to suspend the detached cells. A 100 uL sample of cell suspension was then
used to obtain a cell count according to the method outlined above. Following the
determination of the cell count per milliliter, 1 mL of the cell suspension was transferred
to a 1.5 mL Eppendorf microcentrifuge tube and spun (1000X g) for 5 minutes at 4⁰C to
obtain a cell pellet. The culture media was then removed and the pellet was washed three
times with cold 1X PBS-EDTA (1mM). One hundred microliters of cold RIPA buffer per
106 cells in the pellet was then added to the pellet to lyse the cells. The RIPA buffer was
supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific,
1X final concentration). Lysis was achieved by vortexing the pellet in the RIPA buffer for
approximately 15 seconds. The cell lysate was then kept on ice for 30 minutes with
vortexing every 10 minutes for approximately 15 seconds. After 30 minutes on ice, the cell
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lysate was spun at 10,000X g for 25 minutes at 4⁰C in order to pellet the cell debris. The
supernatant containing the extracted proteins was then transferred to a clean 1.5 mL
Eppendorf microcentrifuge tube from which it was aliquoted into smaller samples of 50 uL
each, and the samples were stored at -80⁰C. The cell lysate protocol described above was
obtained from Proteintech and is available at www.ptglab.com.
Prior to Western blotting, the protein concentration of the cell lysate was determined by
a bicinchoninic (BCA) protein assay using a kit supplied by Thermo Scientific. A 2X
Laemmli sample buffer was prepared by mixing 950 uL of 2X Laemmli sample buffer
(Bio-Rad) with 50 uL of β-mercaptoethanol (Bio-Rad). The cell lysate protein sample was
prepared for Western blotting by diluting 50 uL of the protein sample with 50 uL of the 2X
Laemmli sample buffer containing β-mercaptoethanol. The protein sample was then heated
for 5 minutes at 95⁰C and 20 uL of denatured protein sample was subsequently loaded onto
a 4-20% gradient polyacrylamide pre-cast gel (Bio-Rad) along with 10 uL of Precision Plus
Protein Dual Color Standards (Bio-Rad). Separation of proteins was achieved by running
the gel in 1X running buffer at 200V for 30 minutes. 1X running buffer was prepared by
mixing 100 mL of 10X electrophoresis buffer (25mM Tris, 192 mM glycine, 0.1% SDS)
with 900 mL of deionized water to a final pH of 8.3. A Bio-Rad Mini Protean Tetra cell
was used to perform the protein electrophoresis. Following electrophoresis, proteins were
transferred to a nitrocellulose membrane by running the gel in 1X transfer buffer for 45
minutes at 100V. A cold pack and stirring bar were added to the tank containing the transfer
buffer and gel cassette to reduce heat which might interfere with protein transfer to the
nitrocellulose membrane. Transfer buffer was prepared by mixing 100 mL of 10X
electrophoresis buffer and 200 mL of methanol with 700 mL of deionized water.
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The nitrocellulose membrane containing transferred proteins was then prepared for
Western blotting using the Pierce Fast Western Blot Kit (Thermo Scientific) according to
the manufacturer’s instructions. Briefly, the nitrocellulose membrane blot was washed in
1X Fast Western Wash Buffer to remove any transfer buffer. Ten microliters of primary
antibody at a concentration of 1 ug/uL was then added to 10 mL of Fast Western Antibody
Diluent to produce a final primary antibody dilution of 1:1000 or 1 ug/mL. The membrane
was then incubated in the primary antibody diluent solution overnight at 4⁰C. The
membrane was then incubated in 10 mL of Fast Western Optimized HRP Reagent working
dilution for 15 minutes and then subsequently washed four times with 1X Fast Western
Wash Buffer for 5 minutes each. The membrane was then incubated in 10 mL of Detection
Reagent working solution for 5 minutes after which it was prepared for imaging by
exposure to X ray film. The primary antibodies used were a rabbit polyclonal anti-Rin1
(human) antibody (Proteintech, 16388-1-AP) and a rabbit eGFP tag antibody (Pierce
Thermo Scientific, CAB4211). A GAPDH antibody (Pierce Thermo Scientific,
MA516034) was used as a loading control.
Immunofluorescence
MDA-MB 231 breast cancer cells expressing GFP or Rin1 were seeded onto coverslips
submerged in 1 mL of selection media within the wells of a 12 well plate. The cells were
incubated overnight at 37⁰C and 5% CO2 in order to attach to the coverslips. The following
day the growth media was aspirated from each well and replaced with a 4% formaldehyde
solution. The samples were allowed to fix in the formaldehyde solution for 15 minutes at
room temperature. The fixative was then removed and the samples were washed three times
in 1X PBS for 5 minutes each. The cell samples were then blocked for one hour in blocking
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buffer containing 5% normal goat serum and 0.3% Triton-X 100. Following the blocking
step, the samples were incubated overnight at 4⁰C in primary antibody diluted in antibody
buffer containing 1% BSA and 0.3% Triton-X 100. The Rin1 and GFP primary antibodies
used were the same as those utilized for Western blotting and were diluted at a ratio of 1
uL IgG/200 uL buffer. The following day the samples were washed three times in 1X PBS
for 5 minutes each and then incubated in an Alexafluor488 conjugated secondary antibody
(goat anti-rabbit) for one hour at room temperature in the dark. The secondary antibody
was diluted at a ratio of 1 uL IgG/300 uL buffer. The coverslips containing the cell samples
were then mounted to glass microscope slides using Prolong Gold Antifade reagent with
DAPI. The samples were allowed to cure overnight at room temperature in the dark. The
samples were then stored at 4⁰C until imaged with an Olympus confocal microscope.
Telomerase Activity Assay
The MDA-MB 231 human breast cancer cells expressing GFP and Rin1 as well as nontransfected cells were serum starved for 24 hours at 37°C and 5% CO2 on a 12 well plate
at a density of 1.0 x 105 cells per well in 1 mL of serum free growth media. Each MDAMB 231 cell line was plated in duplicate. After 24 hours, 100 ng/mL of IGF-1 was added
to half of the total samples- one well per cell type. The other half of the samples did not
receive IGF-1 treatment. The samples were then incubated for another 24 hours, after
which time the culture media in each well was removed and the cells were subsequently
prepared for the telomeric repeat amplification protocol (TRAP) assay as per the
manufacturer’s instructions. The TRAPeze Telomerase Detection Kit (EMD Millipore,
S7700) was utilized to determine the telomerase activity in each of the IGF-1 treated and
untreated samples for the three MDA-MB 231 cell types mentioned above.
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Briefly, cells were lysed for 30 minutes in cold 1X CHAPS lysis buffer supplemented
with 10 uL/mL of protease and phosphatase inhibitor to extract the telomerase enzyme.
The cell lysate was then centrifuged at 10,000 rpm for 15 minutes at 4°C. Protein extract
from each cell sample was then added to a qPCR master mix containing a telomerase
substrate (TS) molecule which was subsequently extended by the telomerase enzyme to
create a ladder of DNA products of various lengths starting at 50 bp. The qPCR master mix
consisted of the following per reaction: 10X TRAP reaction buffer (5 uL), 50X DNTP mix
(1 uL), TS primer (1 uL), TRAP primer mix (1 uL), Taq polymerase (2 units, 0.4 uL),
EvaGreen dye (2.5 μL) and dH2O (40 uL). The telomerase extended DNA products were
then amplified and quantified by qPCR. The qPCR amplification protocol consisted of the
following steps: 1) 30°C for 30 minutes, 2) 95°C for 2 minutes, 3) 94°C for 15 seconds, 4)
59°C for 30 seconds, 5 ) 72°C for 1 minute and 6) plate read. Steps three through six was
repeated for a total of 40 cycles. The DNA products were visualized by ethidium bromide
staining (0.5 ug/mL) using a FotoDyne imager with an ethidium bromide filter. The gel
was stained for 30 minutes in 200 mL of the ethidium bromide solution and then de-stained
for 30 minutes in deionized H2O prior to imaging. The water was changed every 10 minutes
during the de-staining process. The telomerase activity of MCF-7 and MCF-12A cell lines
expressing either GFP or Rin1 as well as non-transfected cells was determined in the same
manner as described above for the MDA-MB 231 cell lines.
Telomerase Gene Expression
Telomerase gene expression levels in the MDA-MB 231, MCF-7, and MCF-12A breast
cell lines expressing GFP and Rin1 were measured by reverse transcriptase qPCR (RTqPCR). Cells were plated on a 24 well plate at a density of 2.0 x 105 cells per mL in one
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mL of serum free DMEM culture media. A total of two wells were plated for each breast
cell line. After 24 hours of incubation at 37 °C with 5% CO2, 100 ng/mL of IGF-1 was
added to one of the wells while the other well received no IGF-1 treatment. The cells were
then incubated for another 24 hours and then lysed according to the manufacturer’s
instructions to extract total RNA using the Invitrogen PureLink RNA Mini Kit (catalog#
12183018A). The RNA concentration of each cell sample was then determined by
established spectrophotometric methods using the A260/A280 and A260/A230 ratios.
cDNA synthesis to measure gene expression levels of telomerase and GAPDH (control)
was then performed in duplicate according to the manufacturer’s instructions using the
SuperScript III RT-PCR system from Invitrogen (catalog# 18080093). Briefly, a qPCR
master mix was prepared consisting of the following per reaction: 2X reaction mix (25 μL),
forward and reverse primers (1 μL each), SuperScript III RT/Platinum Taq Mix (2μL),
RNA template (0.1 μg), EvaGreen dye (2.5 μL), and PCR grade water to a final volume of
50 μL. The RT-qPCR protocol consisted of the following steps: 1) 55°C for 30 minutes, 2)
94°C for 2 minutes, 3) 94°C for 15 seconds, 4) 53°C for 30 seconds, 5) 68°C for 1 minute,
and 6) plate read. Steps three through six were repeated for a total of 40 cycles. A final
extension step of 68°C for 5 minutes was carried out before a melt curve analysis. The
GAPDH and telomerase qPCR products were then separated on a 12% acrylamide gel run
at 125V for one hour in 1X TBE buffer and subsequently visualized by ethidium bromide
staining using a Fotodyne digital imager.
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Figure 2.1: Lentiviral vector used to create the MDA-MB 231 cell line expressing Rin1.
The Rin1 gene sequence is inserted directly downstream of the CMV promoter. An
identical vector with the GFP gene sequence inserted was used to create the MDA-MB
231 cell line expressing GFP. Also labeled are the various elements necessary for
lentivirus production and cell selection.
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Figure 2.2: A) Confocal micrograph image of MDA-MB 231 cells expressing
Rin1. Rin1 tends to localize near the plasma membrane (red arrows). B) Light
micrograph image illustrating the clumped growth pattern of MDA-MB 231 cells
expressing Rin1 (red circle).
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Figure 2.3: Western blot image of the A) MDA-MB 231 GFP cell line expressing GFP
and endogenous levels of Rin1. B) MDA-MB 231 cell line overexpressing Rin1.
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Figure 2.4: The effect of cell number on cellular proliferation in serum exposed MDAMB 231 cells. Error bars represent the standard error of the mean.
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Figure 2.5: Regression analysis of the effect of cell number on cellular proliferation in
serum exposed MDA-MB 231 cells.
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Figure 2.6: The effect of IGF-1 concentration on cellular proliferation in MDA-MB 231
cells expressing GFP or Rin1. Values represent the percent increase in cellular
proliferation over an unstimulated (0 ng/mL) control. All experiments were conducted
in triplicate. Error bars represent standard error of the mean.
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Figure 2.7: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
non-transduced MDA-MB 231 cells. Values represent the percent increase normalized
to the serum free/no IGF-1 treatment group. All experiments were conducted in
triplicate. Error bars represent the standard error of the mean.
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Figure 2.8: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
MDA-MB 231 cells expressing GFP. Values represent the percent increase normalized
to the serum free/no IGF-1 treatment group. All experiments were conducted in
triplicate. Error bars represent the standard error of the mean.
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Figure 2.9: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
MDA-MB 231 cells expressing Rin1. Values represent the percent increase normalized
to the serum free/no IGF-1 treatment group. All experiments were conducted in
triplicate. Error bars represent the standard error of the mean.
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Figure 2.10: Telomerase activity assay demonstrating the presence of telomeric repeat
amplification protocol PCR products. 1. 25 bp DNA ladder. 2. HeLa cell telomerase
positive control. 3. HeLa cell heat treated telomerase negative control. Red box is the
36 base pair internal control.
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Figure 2.11: Amplification curves of the qPCR telomerase activity products for the
serial dilution of a HeLa cell telomerase positive control sample. Red circle is undiluted
sample, green triangle is 10X dilution, orange square is 100X dilution, blue cross is
1,000X dilution, and brown diamond is buffer only.
Serial Dilution of HeLa Cell Telomerase Positive Control
Average Ct Value ± Standard Error
Undiluted

26.28 ± 0.02

10X

26.50 ± 0.11

100X

26.70 ± 0.03

1,000X

26.78 ± 0.10

Buffer

27.02 ± 0.37

Table 2.1: Average cycle threshold (Ct) values of the qPCR amplification of telomerase
activity products for the serial dilution of a HeLa cell telomerase positive control
sample. All experiments were conducted in duplicate.
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Figure 2.12: PAGE gel analysis of the telomerase activity qPCR TRAP products for the
MDA-MB 231 cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24
hours or no stimulation (-). 1. 25 bp ladder. 2. Telomerase positive control. 3.
Telomerase heat treated negative control. 4. GFP (+) IGF-1. 5. GFP (-) IGF-1. 6. Rin1
(+) IGF-1. 7. Rin1 (-) IGF-1. 8. Buffer. Red boxes indicate reduced telomerase activity
in cells expressing Rin1 when compared to cells expressing GFP following IGF-1
stimulation.
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MDA-MB 231 Telomerase Activity
Average Ct Value ± Standard Error

Telomerase positive control

19.92 ± 0.13

Telomerase negative control

20.16 ± 0.15

GFP (+) IGF-1

20.49 ± 0.01

GFP (-) IGF-1

20.41 ± 0.04

Rin1 (+) IGF-1

21.14 ± 0.02

Rin1 (-) IGF-1

20.68 ± 0.01

Buffer

20.23 ± 0.09
21.14-20.49= 0.65
-0.65

2 = 0.64
1/0.64= 1.56
1.56 fold decrease in telomerase activity for cells
expressing Rin1 as compared to cells expressing GFP.
Table 2.2: Cycle threshold values (Ct) for the qPCR products of telomerase activity in
MDA-MB 231 cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24
hours or no stimulation (-). All experiments were conducted in duplicate.
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Figure 2.13: PAGE gel analysis of the RT-qPCR GAPDH and telomerase gene
expression products in the MDA-MB 231 cell lines following stimulation with 100
ng/mL of IGF-1 (+) for 24 hours or no stimulation (-).
MDA-MB 231 Telomerase Gene Expression
ΔCt
(TelomeraseGAPDH)

GAPDH

Telomerase

Average Ct Value ±
Standard Error

Average Ct Value ±
Standard Error

GFP (+)

14.94 ± 0.02

25.68 ± 0.11

10.74

GFP (-)

15.32 ± 0.01

26.54 ± 0.05

11.22

Rin1 (+)

17.08 ± 0.06

27.95 ± 0.13

10.87

Rin1 (-)

15.70 ± 0.63

26.19 ± 0.04

10.49

Buffer

38.55 ± 0.75

39.12 ± 0.58

0.57

10.87-10.74= 0.13
2-0.13= 0.91
1/0.91= 1.09
1.09 fold decrease in telomerase gene expression for cells
expressing Rin1 as compared to cells expressing GFP.
Table 2.3: Cycle threshold values (Ct) for the RT-qPCR of telomerase gene expression
in MDA-MB 231 cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24
hours or no stimulation (-). All experiments were conducted in duplicate.
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Figure 2.14: Western blot image of the A) MCF-12A GFP cell line expressing GFP
and endogenous levels of Rin1. B) MCF-12A cell line overexpressing Rin1.
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Figure 2.15: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
non-transduced MCF-12A cells. Values represent the percent increase normalized to
the serum free/no IGF-1 treatment group. All experiments were conducted in triplicate.
Error bars represent the standard error of the mean.
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Figure 2.16: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
MCF-12A cells expressing GFP. Values represent the percent increase normalized to
the serum free/no IGF-1 treatment group. All experiments were conducted in triplicate.
Error bars represent the standard error of the mean.
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Figure 2.17: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
MCF-12A cells expressing Rin1. Values represent the percent increase normalized to
the serum free/no IGF-1 treatment group. All experiments were conducted in triplicate.
Error bars represent the standard error of the mean.
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MCF-12A Telomerase Activity
Average Ct Value ± Standard Error

Telomerase positive control

25.56 ± 0.11

Telomerase negative control

25.70 ± 0.15

GFP (+) IGF-1

25.92 ± 0.22

GFP (-) IGF-1

25.57 ± 0.02

Rin1 (+) IGF-1

25.76 ± 0.12

Rin1 (-) IGF-1

25.74 ± 0.14

Buffer

26.06 ± 0.18

25.76-25.92= -0.16
-(-0.16)

2
= 1.12
1.12 fold increase in telomerase activity for cells
expressing Rin1 as compared to cells expressing GFP.
Table 2.4: Cycle threshold values (Ct) for the qPCR products of telomerase activity in
MCF-12A cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours or
no stimulation (-). All experiments were conducted in duplicate.
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MCF-12A Telomerase Gene Expression
ΔCt
(TelomeraseGAPDH)

GAPDH

Telomerase

Average Ct Value ±
Standard Error

Average Ct Value ±
Standard Error

GFP (+)

18.13 ± 0.08

22.36 ± 2.41

4.23

GFP (-)

18.72 ± 0.37

24.70 ± 0.08

5.98

Rin1 (+)

18.06 ± 0.05

23.64 ± 1.23

5.58

Rin1 (-)

18.18 ± 0.35

24.89 ± 0.35

6.71

Buffer

33.33 ± 0.71

31.90 ± 0.85

-1.43

5.58-4.23= 1.35
2-1.35= 0.39
1/0.39= 2.55
2.55fold decrease in telomerase gene expression for cells
expressing Rin1 as compared to cells expressing GFP.
Table 2.5: Cycle threshold values (Ct) for the RT-qPCR of telomerase gene expression
in MCF-12A cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours
or no stimulation (-). All experiments were conducted in duplicate.
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Figure 2.18: Western blot image of the A) MCF7 GFP cell line expressing GFP and
endogenous levels of Rin1. B) MCF7 cell line overexpressing Rin1.
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Figure 2.19: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
non-transduced MCF7 cells. Values represent the percent increase normalized to the
serum free/no IGF-1 treatment group. All experiments were conducted in triplicate.
Error bars represent the standard error of the mean.
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Figure 2.20: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
MCF7 cells expressing GFP. Values represent the percent increase normalized to the
serum free/no IGF-1 treatment group. All experiments were conducted in triplicate.
Error bars represent the standard error of the mean.
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Figure 2.21: The effect of IGF-1 stimulation (100 ng/mL) on cellular proliferation of
MCF7 cells expressing Rin1. Values represent the percent increase normalized to the
serum free/no IGF-1 treatment group. All experiments were conducted in triplicate.
Error bars represent the standard error of the mean.
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MCF7 Telomerase Activity
Average Ct Value ± Standard Error

Telomerase positive control

24.53 ± 0.29

Telomerase negative control

25.49 ± 0.08

GFP (+) IGF-1

24.50 ± 0.26

GFP (-) IGF-1

24.97 ± 0.15

Rin1 (+) IGF-1

24.63 ± 0.04

Rin1 (-) IGF-1

25.46 ± 0.33

Buffer

25.70 ± 0.16

24.63-24.50= 0.13
-0.13

2 = 0.91
1/0.91=1.09
1.09 fold decrease in telomerase activity for cells
expressing Rin1 as compared to cells expressing GFP.
Table 2.6: Cycle threshold values (Ct) for the qPCR products of telomerase activity in
MCF7 cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours or no
stimulation (-). All experiments were conducted in duplicate.

123

MCF7 Telomerase Gene Expression
ΔCt
(TelomeraseGAPDH)

GAPDH

Telomerase

Average Ct Value ±
Standard Error

Average Ct Value ±
Standard Error

GFP (+)

16.44 ± 0.44

26.98 ± 0.48

10.54

GFP (-)

17.04 ± 0.10

27.63 ± 0.03

10.59

Rin1 (+)

16.53± 0.00

27.40 ± 0.13

10.87

Rin1 (-)

17.61 ± 0.57

28.92 ± 0.12

11.31

Buffer

36.68± 1.13

34.40 ± 0.56

-2.28

10.87-10.54= 0.33
2-0.33= 0.79
1/0.79= 1.26
1.26 fold decrease in telomerase gene expression for cells
expressing Rin1 as compared to cells expressing GFP.
Table 2.7: Cycle threshold values (Ct) for the RT-qPCR of telomerase gene expression
in MCF7 cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours or
no stimulation (-). All experiments were conducted in duplicate.
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Comparison of the Effect of Rin1 Expression in Breast Cell Lines
MDA-MB 231

MCF-12A

MCF7

+

+

+

(18%)

(41%)

(26%)

-

-

-

(1.09)

(2.55)

(1.26)

Telomerase Activity

-

+

-

(fold change)

(1.56)

(1.12)

(1.09)

Cellular Proliferation
(percent change)
Telomerase Gene
Expression
(fold change)

Table 2.8: The effect of Rin1 expression on cellular proliferation, telomerase gene
expression, and telomerase activity in different breast cell lines.
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CHAPTER 3
The Effect of Rin1 Constructs on Telomerase Protein Expression and Activity in
Breast Cancer Cells
3.1

Introduction
Telomeres are the regions of DNA that exist at the very tips or ends of linear

chromosomes in eukaryotic cells. Recent evidence suggests that the telomere regions of
chromosomes play vital roles in regulating normal cellular processes such as proliferation,
aging, and senescence/apoptosis (Ramlee et al., 2016). However, a large body of research
also implicates telomeres in the unlimited replicative capacity of many types of cancer
cells. The telomeric regions of chromosomes set a replicative limit on the number of cell
divisions a normal cell can undergo before the induction of senescence and/or apoptosis
occurs (Chung Low and Tergaonkar, 2013). The finite replicative capacity, which is
approximately 50 to 70 rounds of cell division for most normal somatic cells, is largely due
to the progressive loss of telomeric DNA with each round of cell division (Zvereva et al.,
2010). The loss of telomeric DNA that accompanies each cycle of cell division is a
consequence of incomplete DNA replication at the telomeres.
There are however certain populations of somatic stem cells as well as germ line stem
cells that can prevent the gradual loss of DNA from their telomeres through the activity of
an enzyme known as telomerase. Telomerase is only expressed and active in a relatively
small population of somatic stem cells where the depletion of telomeric DNA and resulting
onset of senescence or apoptosis would interfere with the normal functioning of specific
tissues (Chung Low and Tergaonkar, 2013). On the other hand, the immortal replicative
phenotype that is characteristic of the vast majority of cancer cells is attributed to high
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levels of telomerase activity. In fact, roughly 85% of all cancers display telomerase activity
and the activation of telomerase activity in these cells is a key step in the tumorigenic
process (Zhu et al., 2010). Consequently, the selective inhibition of telomerase activity in
cancer cells has emerged as an attractive therapeutic target (Holysz et al., 2013; Buseman
et al., 2012). A better understanding of telomerase structure, function, and regulation will
shed light on the importance of this enzyme in cancer biology.
The telomere regions of vertebrate chromosomes are defined by a distinct structure that
distinguishes telomeres from other areas of chromosomal DNA. In humans, a highly
repetitive sequence of TTAGGG approximately 5 to 15 kb in length is tightly associated
with a complex of six telomeric DNA binding proteins termed a shelterin complex (Stewart
et al., 2012). The majority of telomeric DNA is double stranded with the exception of a
guanine rich 3’ overhang of single stranded DNA roughly 100 nucleotides in length. The
looping of this single stranded DNA into the double stranded regions produces a structure
known as a T-loop. The shelterin complex, which assists in the formation of T-loops of
telomeric DNA, functions as a protective cap that prevents the activation of cellular DNA
damage responses that would otherwise recognize the telomeres as double stranded DNA
breaks (Stewart et al., 2012; Buseman et al., 2012). The major role of telomeres is to
maintain genomic stability by acting as a buffer for the gradual erosion of DNA that
accompanies each cycle of cell division. Once telomeric DNA has shortened beyond a
particular threshold, genomic instability as a result of chromosomal fusions and
translocations will typically induce senescence followed by apoptosis (Buseman et al,
2012). The mechanism is believed to be a normal part of the aging process.
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The shelterin protein complex is critical for maintaining genomic stability at the
telomeres and consists of the following six proteins: TRF1, TRF2, TIN2, TPP1, POT1, and
RAP1 (Stewart et al., 2012). TRF1 and TRF2 (telomeric repeat factor-binding protein)
each form separate homodimers that bind to the double stranded DNA regions of telomeres.
Both TRF1 and TRF2 act as negative regulators of telomere length and are linked to each
other by the TIN2 linker protein (Walker et al., 2012). The POT1 (protection of telomeres)
binds to the 3’ single stranded guanine rich overhang and mainly functions to inhibit the
activation of DNA damage response pathways at the telomeres. The POT1 is connected to
the other shelterin complex proteins through the linker protein TPP1 which binds to both
POT1 and TIN2 (Heidenreich and Kumar, 2017). The RAP1 is a small protein that binds
to TRF2 and aids TRF2 in preventing non-homologous end joining and chromosomal
fusions (Stewart et al., 2012). The TIN2 maintains the stability of the shelterin complex
given its interactions with both TRF1 and TRF2 as well as with TPP1-POT1 (Heidenreich
and Kumar, 2017). The interaction between POT1 and TPP1 is essential for the regulation
of telomerase activity by enhancing the processivity of the telomerase enzyme (Zaug et al.,
2010). Besides the recruitment of telomerase to telomeres, TPP1 is also involved in
monitoring the length of telomeres and provides feedback regulation to telomerase (Sexton
et al., 2014). Phosphorylation of TPP1 at serine residue 111 is important for the cell cycle
dependent recruitment and activation of telomerase activity (Zhang et al., 2013). Each
shelterin complex protein plays a clear role in telomere maintenance and the loss of any
one protein will result in reduced telomere protection (Bandaria et al., 2016; Erdel et al.,
2017).

128

Normal somatic cells lose approximately 50 nucleotides of telomeric DNA with each
cycle of cell division as a result of incomplete DNA replication during the S phase.
Incomplete replication of the lagging daughter strand occurs because of the inability of
DNA polymerase to access the very 3’ end of the template DNA strand (Zvereva et al.,
2010). The replication problem is overcome in certain cells by extension of the 3’ end of
the template DNA strand by the telomerase enzyme. Telomerase is a ribonucleoprotein that
functions as a reverse transcriptase by adding sequential repeats of the hexameric sequence
TTAGGG to the 3’ end of the template DNA strand; and once extended by telomerase,
DNA polymerase α-primase (PαP) can then complete replication of the lagging daughter
strand (Hockemeyer and Collins, 2015).
The functional telomerase holoenzyme consists of two essential parts: an enzymatic
protein component known as TERT that acts as a reverse transcriptase and an RNA
template component known as TR (Heidenreich and Kumar, 2017). The assembly of
functional telomerase holoenzyme proceeds through distinct stages. The TERT mRNA is
first synthesized and processed in the nucleus and then exported to the cytoplasm for
translation into protein. Newly synthesized TERT enzyme is then imported back into the
nucleus where it is localized to the nucleolus (Hockemeyer and Collins, 2015; Podlevsky
and Chen, 2012). Meanwhile, TR precursor RNA is transcribed by RNA polymerase II in
the nucleus and is capped on the 5’ end with trimethylguanosine. Two copies of a protein
complex containing dyskerin, NOP10, NHP2, and GAR1 associate with the TR at the
H/ACA motif and are required for 3’ end modification. The RHAU RNA helicase binds to
the 5’ end of TR and resolves the G-quadruplex while the TCAB1 protein binds to the CAB
box motif and directs the TR to nuclear Cajal bodies (Hockemeyer and Collins, 2015;
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Podlevsky and Chen, 2012). The TERT is subsequently moved into the Cajal bodies where
it assembles with TR to form the final functional telomerase holoenzyme. The active
telomerase enzyme will then be recruited to the telomeres at the appropriate time for
telomeric DNA synthesis (Hockemeyer and Collins, 2015; Podlevsky and Chen, 2012).
The regulation of telomerase activity occurs mainly at the level of TERT transcription
as TERT mRNA synthesis is highly regulated in most somatic cells. The synthesis of TERT
mRNA appears to be the rate limiting step in the regulation of telomerase activity as TERT
gene transcription is highly repressed in most somatic cells (Zhu et al., 2010). The
telomerase RNA template (TR) however is ubiquitously expressed in many cell types
(Daniel et al., 2012). The TERT core promoter contains binding sites for several key
transcription factors known to regulate TERT transcription- these include: c-Myc, SP1,
ER, Ets, AP1, and NF-κB (Zhu et al., 2010). The c-Myc binds to two E-box consensus
sequences within the TERT promoter and is strongly linked to activation of TERT
transcription. Similarly, SP1 plays a critical role in activating TERT transcription as
mutation of SP1 binding sites in the TERT promoter significantly reduces TERT
expression (Cifuentes-Rojas and Shippen, 2012). There is evidence that SP1 may in fact
interact with c-Myc to promote TERT expression and that SP1 may also potentially interact
with another protein known as MCAF-1 to stimulate TERT expression. Two estrogen
response elements are located within the TERT promoter upstream of the transcription start
site and enhance TERT expression when bound by ERα (Daniel et al., 2012).
On the other hand, TERT expression is negatively regulated by the binding of tumor
suppressor proteins such as the Wilm’s tumor-1 (WT1) protein. Additionally, p53
expression acts to inhibit TERT transcription. The p53 tumor suppressor protein has been
130

shown to interact with both human telomerase associated protein 1 (hTEP1) and SP1 to
inhibit TERT promoter activity (Lu et al., 2013). The overexpression of TERT
transcriptional activators such as c-Myc and the loss of tumor suppressor proteins such as
p53 or Rb are common mechanisms in the malignant transformation of cells (Zhu et al.,
2010).
Telomerase activity can also be regulated to a lesser extent by post-translational
modifications of the catalytic TERT subunit such as phosphorylation and ubiquitination.
Multiple protein kinases like c-Abl, protein kinase B, and protein kinase C are able to
influence telomerase activity (Wojtyla et al., 2010). Tyrosine phosphorylation of TERT by
c-Abl tends to reduce TERT activity while phosphorylation of serine/threonine residues by
PKB (Akt) tends to stimulate TERT activity. Protein phosphatase 2A has been shown to
reduce telomerase activity in specific cell types as TERT phosphorylation is necessary for
its import into the nucleus. The TERT stability and half-life in the cytoplasm is controlled
by E3 ubiquitin ligases that can target TERT for proteolytic degradation and thus prevent
its entry into the nucleus (Cifuentes-Rojas and Shippen, 2012). Several splice variants of
human TERT are known to exist each with differing levels of activity. The hTERTα splice
variant contains a 183 base pair deletion that results in reduced telomerase activity and thus
functions as a dominant negative inhibitor of telomerase activity (Cifuentes-Rojas and
Shippen, 2012).
Epigenetic regulation of the TERT promoter figures prominently for TERT expression
as the TERT promoter is located within a region of highly condensed chromatin (CifuentesRojas and Shippen, 2012). Core histones within the TERT promoter are usually
hypoacetylated and this contributes to the repression of TERT expression observed in most
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somatic cells. CpG island methylation is also commonly associated with the silencing of
TERT expression. Conversely, methylation of lysine 9 of histone 3 (H3K9) increases
TERT expression as does the hyperacetylation of other core histones through the inhibition
of histone deacetylase complexes (HDACs) (Zhu et al., 2010). Several transcription factors
are known epigenetically regulate TERT expression through the recruitment of histone
acetyltransferases (HATs) or HDACs to the TERT promoter (Lu et al., 2013).
Telomerase expression and activity can be modulated by various signal transduction
pathways. The Wnt/β-catenin pathway is widely known for its important role during
embryonic development, however it has also been implicated in tumor formation. A
positive feedback mechanism exists in which β-catenin can upregulate TERT expression
through its interaction with the TERT promoter. The TERT subsequently forms a complex
with the BRG1 Wnt transcription factor to stimulate expression of both cyclin D and cMyc (Wu et al., 2013). The c-Myc is a well documented activator of TERT expression.
Inflammation is commonly associated with many different cancers and NF-κB is a primary
regulator of chronic inflammation linked with tumorigenesis and cancer progression.
Recent evidence suggests that a reciprocal relationship may exist between NF-κB activity
and TERT expression. NF-κB can bind upstream of the TERT transcription start site to
stimulate TERT expression. The TERT, on the other hand, can reinforce NF-κB activity
by binding to the p65 subunit of NF-κB to enhance transcription of inflammatory genes
such as IL-6 and TNF-α (Ghosh et al., 2012). Additionally, the RAP1 shelterin complex
protein is a key regulator of NF-κB activity (Martinez and Blasco, 2011).
Other signal transduction pathways such as the PI3K/Akt and MAPK pathways also
contribute significantly to the regulation of TERT expression and activity. The Akt132

mediated phosphorylation of specific effector proteins promotes the proteolytic
degradation of p53 and the c-Myc competitor protein MAD1 (Peek and Tollesfbol, 2016).
Additionally, the PI3K/Akt pathway has been tied to NF-κB activation as well as the
inhibition of TGF-β signaling through Jab1 activation and SMAD4 degradation (Daniel et
al., 2012). The TGF-β signaling pathway is an important inhibitory pathway that mediates
cell growth, differentiation, and proliferation. TGF-β signaling can suppress c-Myc
expression but is susceptible to inhibition by estrogen (Peek and Tollefsbol, 2016). Heeg
et al. (2010) report that EGFR overexpression in OKF6 oral-esophageal cells enhances
TERT transcription via the Hif1-α transcription factor and directly stimulates telomerase
activity through an Akt-dependent phosphorylation of TERT. Similarly, estradiol (E2) is
reported to increase telomerase activity in endometrial cancer cells through MAPK
induction of TERT transcription. Inhibition of either MEK or ERK resulted in decreased
luciferase activity from a reporter plasmid containing the TERT promoter following
treatment with E2 (Zhou et al., 2013).
In summary, abnormal telomerase expression and activity is a defining hallmark
observed in many different cancers. The immortal replicative phenotype conferred by the
enzyme is critical to the survival and proliferation of malignant cancer cells. The regulation
of telomerase activity occurs primarily at the level of transcription and typically becomes
disordered during the tumorigenic process. The fact that the enzyme is not expressed in
most normal somatic cells makes selective telomerase inhibition an attractive
chemotherapeutic target. Further research into the oncogenic properties of telomerase is
needed to reveal novel therapeutic approaches.
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3.2

Results
Lentiviral vectors encoding Rin1 Y561F and Rin1 delta were designed using the

VectorBuilder online platform (https://en.vectorbuilder.com/). These lentiviral vectors
(Figure 3.1) were used in the creation of the Rin1 Y561F and Rin1 delta MDA-MB 231
breast cancer cell lines as described in 3.4, Creation of Cell Lines. Light micrograph images
of the MDA-MB 231 cell lines overexpressing the Rin1 Y561F or Rin1 delta constructs
reveal similarities in morphology and growth rate (Figures 3.2 and 3.3, B.) The cells of
each cell line displayed a flattened, spindle type shape and grew fairly evenly across the
surface of the culture dish. The growth rate of each was similar to that of MDA-MB 231
cells expressing GFP. Additionally, confocal imagery indicates a roughly uniform
distribution of Rin1 Y561F and Rin1 delta throughout the cytoplasm of these cells (Figures
3.2 and 3.3, A.) while Western blotting analysis reveals strong expression of the different
Rin1 constructs (Figures 3.4 and 3.5).
An experiment to determine the effect of different IGF-1 concentrations on the cellular
proliferation of MDA-MB 231 cells was performed using IGF-1 concentrations of 20, 60,
and 100 ng/mL. The MDA-MB 231 cell lines overexpressing Rin1 Y561F and Rin1 delta
each displayed an increase in cellular proliferation for every IGF-1 concentration tested
when compared to the corresponding untreated (0 ng/mL) control cells (Figure 3.11). The
same result was observed for the GFP control cell line (Figure 3.11). The effect of IGF-1
concentration on proliferation was statistically significant for all cell lines tested (p <0.05,
ANOVA), and stimulation with as little as 20 ng/mL of IGF-1 resulted in an increase in
cellular proliferation as compared to untreated cells (Figure 3.11). The MDA-MB 231 Rin1
Y561F and Rin1 delta cell lines displayed an optimal increase in cellular proliferation when
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stimulated with 100 ng/mL of IGF-1. All proliferation experiments were conducted in
triplicate using a concentration of 2.0 x 105 cells/mL.
An experiment to determine the effect of IGF-1 concentration on telomerase protein
expression in MDA-MB 231 GFP cells was conducted using IGF-1 concentrations of 0,
10, and 50 ng/mL. Telomerase protein expression increased as the IGF-1 concentration
increased and peaked in response to stimulation with an IGF-1 concentration of 50 ng/mL
for 12 hours (Figure 3.6). An ImageJ analysis of the intensity of telomerase protein
expression at 50 ng/mL of IGF-1 indicates an approximately 13 fold increase over
unstimulated cells and a roughly 2 fold increase over cells stimulated with 10 ng/mL
(Figure 3.6). The effect of IGF-1 stimulation on telomerase protein expression was
subsequently evaluated in MDA-MB 231 cells expressing Rin1, Rin1 Y561F, and Rin1
delta. The cells were induced with 50 ng/mL of IGF-1 for 24 hours and the intensity of
telomerase protein expression was normalized to that of GFP cells using ImageJ analysis
(Figure 3.7). Increases in telomerase protein expression of 3 fold and 2 fold respectively
were observed for the MDA-MB 231 Rin1 Y561F and Rin1 delta cell lines, while the Rin1
cell line exhibited a 0.7 fold decrease in telomerase protein expression (Figure 3.7).
In order to study the effects of the amino (R2N) and carboxyl (R3C) terminal regions
of Rin1 on signaling through the MAPK pathway, MDA-MB 231 cells expressing these
Rin1 constructs were stimulated with 100 ng/mL of IGF-1 for 24 hours. Levels of total
p44/42 and phospho-p44/42 protein expression were then determined through Western
blotting (Figure 3.8) and the ratio of phospho-p44/42 to total p44/42 was calculated by
ImageJ analysis (Figure 3.8). A 16 fold increase in the ratio of phospho-p44/42 to total
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p44/42 was observed for the cells expressing the amino terminus of Rin1 when compared
to the cells expressing the carboxyl terminus (Figure 3.8).
A time course experiment to investigate the effect of Rin1 on signaling through the
MAPK pathway was performed on the MDA-MB 231 cells expressing GFP, Rin1, the
amino (R2N), and the carboxyl (R3C) terminal regions of Rin1. The expression of various
MAPK pathway proteins and other associated proteins as well as their phosphorylation
status was determined by Western blotting following IGF-1 stimulation with 25 ng/mL for
either 0, 5, or 10 minutes (Figures 3.9 and 3.10). The R3C cell line exhibited reduced levels
of p44/42 phosphorylation over the 10 minute time period when compared to the GFP and
R2N cell lines (Figures 3.9, A. and 3.10, A.). The Rin1 cells also display delayed p-44/42
phosphorylation as well as delayed phosphorylation of the Ets2 transcription factor (Figure
3.9, B.). Additionally, low levels of phosphorylated STAT3 and Ets2 transcription factors
were observed for the R3C cell line (Figure 3.10, B.).
Telomerase activity was also examined in various MDA-MB 231 breast cancer cell lines
expressing different constructs of the Rin1 protein following treatment with IGF-1. These
cell lines include the MDA-MB 231 human breast cancer cell lines expressing Rin1 Y561F
and Rin1 delta as well as the amino (R2N) and carboxyl (R3C) terminal regions of Rin1.
Each cell line was virally transduced and selected for stable Rin1 construct expression as
described previously (2.4, Creation of Cell Lines). Telomerase activity following exposure
to 100 ng/mL of IGF-1 for 24 hours was determined by the telomeric repeat amplification
protocol (TRAP) assay for each of the MDA-MB 231 cell lines expressing the various Rin1
constructs (Table 3.1).
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The MDA-MB 231 breast cancer cell lines overexpressing Rin1 Y561F and Rin1 delta
displayed elevated telomerase activities of approximately 1 fold each over GFP cells when
treated with 100 ng/mL of IGF-1 for 24 hours (Table 3.1). The MDA-MB 231 GFP cells,
which express endogenous levels of Rin1, resulted in an average Ct value of 25.94 while
the Rin1 Y561F and delta cell lines produced average Ct values of 25.88 and 25.92
respectively (Table 3.1). The corresponding IGF-1 untreated samples for each cell line
were also run for comparison (Table 3.1). A known telomerase positive HeLa cell control
sample was run as a positive control and telomerase negative controls consisted of a heat
inactivated HeLa cell sample as well as a buffer only sample (Table 3.1). In contrast to the
Rin1 Y561F and delta cell lines, the MDA-MB 231 cell lines expressing the amino (R2N)
and carboxyl (R3C) regions of Rin1 exhibited 1.06 and 1.11 fold reductions in telomerase
activity when compared to GFP cells. The MDA-MB 231 cell lines expressing the R2N
and R3C regions of Rin1 resulted in average Ct values of 26.03 and 26.09 respectively
(Table 3.1).
3.3

Discussion
Abnormal telomerase protein expression and activity are commonplace for a number of

different cancers. The fact that telomerase activity is virtually absent in most normal
somatic cells but present in roughly 85% of all cancers highlights the importance of the
enzyme for cancer cell survival and replication. Strategies to inhibit telomerase activity are
therefore attractive chemotherapeutic targets. One such strategy is the potential use of the
Rin1 protein to modulate signaling through the MAPK pathway and thus suppress
telomerase activity. To this end, several Rin1 constructs were expressed in MDA-MB 231
breast cancer cells to investigate the ability of Rin1 to moderate telomerase activity.
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Cells virally transduced to express GFP were used as a control to compare the effect of
overexpression of particular Rin1 constructs (Y561F, delta, amino terminus, carboxyl
terminus) on telomerase activity for the MDA-MB 231 breast cancer cell line. The GFP
cells express endogenous levels of Rin1 and therefore would be most similar to nontransduced cells in terms of Rin1 expression. However, the GFP cells are virally transduced
which permits meaningful comparisons with the cell lines that are virally transduced to
express the various Rin1 constructs. The expression of GFP has no influence on telomerase
activity.
As discussed previously (1.3, The MAPK Pathway and Cancer), Rin1 is able to compete
strongly with RAF1 for access to activated Ras. Thus, is it possible that Rin1 may act to
dampen mitogenic signaling through the MPAK pathway and consequently affect the
activity of a downstream MAPK effector such as telomerase. If so, the potential tumor
suppressive role of Rin1 would be evidenced in reduced telomerase activity. Conversely,
overexpression of the Rin1 Y561F and Rin1 delta constructs should not impede telomerase
activity as these Rin1 isoforms do not bind as strongly to activated Ras (1.3, The MAPK
Pathway and Cancer). Similarly, it is hypothesized that overexpression of the Rin1 amino
terminal region (R2N) should allow for enhanced MAPK signaling given that the R2N
region of Rin1 lacks the Ras association (RA) domain. Conversely, the carboxyl terminal
region (R3C) of Rin1 contains the Ras association domain and its overexpression should
therefore dampen signaling through the MAPK pathway.
The effect of the Rin1 Y561F and Rin1 delta constructs on cellular proliferation in
MDA-MB 231 cells underscores the tumorigenic properties of these particular forms of
Rin1 when compared to cells that overexpress Rin1 (Figures 3.11 and 2.6). For instance,
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fold increases in proliferation of 1.2, 1.7, and 9.3 were observed respectively for MDAMB 231 cells expressing Rin1 Y561F across the range of IGF-1 concentrations (20, 60,
and 100 ng/mL) tested when compared to cells expressing Rin1 (Figure 2.6). Similarly,
fold increases in proliferation of 1.5, 2.0, and 9.2 were observed respectively for the cells
expressing Rin1 delta over the Rin1 cells when stimulated with the same range of IGF-1
concentrations (Figures 3.11 and 2.6). These data, in conjunction with the observable
differences in growth patterns and rates as well as increased telomerase activity, point to
heightened MAPK signaling in MDA-MB 231 cells expressing the Rin1 Y561F and delta
constructs following IGF-1 stimulation- most likely as a consequence of reduced binding
to activated Ras. The Rin1 cells consistently displayed the least amount of increase in
proliferation over the corresponding unstimulated cells for each of the IGF-1
concentrations examined, probably owing to increased competition with RAF1 for access
to activated Ras (Figure 2.6).
The enhanced MAPK signaling in MDA-MB 231 cells expressing the Rin1 Y561F and
Rin1 delta constructs is also evident in telomerase protein expression and correlates well
with telomerase activity for these cell lines. Stimulation of GFP cells, which express low
endogenous levels of Rin1, results in a steady increase in telomerase protein expression
over a range (0, 10, and 50 ng/mL) of IGF-1 concentrations (Figure 3.6). When normalized
to telomerase protein expression in GFP cells, there is a clear reduction in telomerase
protein expression of 0.7 fold for the MDA-MB 231 cells overexpressing Rin1 versus
either Rin1 Y561F or Rin1 delta, that display fold increases of 3 and 2 respectively (Figure
3.7). As a downstream MAPK effector, changes in telomerase protein expression mirror
the ability of Rin1 or its constructs to moderate signaling through the pathway.
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When examining the expression and phosphorylation status of key MAPK proteins over
time subsequent to IGF-1 stimulation, the ability of Rin1 to attenuate signaling is evident
for p-44/42 (ERK). There is suppressed phosphorylation of p-44/42 over a 10 minute time
period for the MDA-MB 231 cells overexpressing Rin1 as compared to the cells expressing
the Rin1 amino (R2N) terminus (Figures 3.9, B. and 3.10, A.). Additionally, appreciable
phosphorylation of p-44/42 is not evident for the cells expressing the Rin1 carboxyl (R3C)
terminus (Figure 3.10, B.). In a separate experiment, a 16 fold increase in the ratio of
phosphorylated p-44/42 to total p-44/42 was observed for the Rin1 R2N cells as compared
to the R3C cells (Figure 3.8). Again, the prevalence of the Ras association (RA) domain
in the Rin1 and R3C cells could explain the differences and correlates well with the reduced
telomerase activity observed in both the Rin1 and R3C cell lines.
The MDA-MB 231 Rin1 cells exhibit suppressed phosphorylation of the Ets2
transcription factor, which is a key activator of telomerase protein expression (Figure 3.9,
B.). A similar reduction in STAT3 phosphorylation is also apparent in these cells as well
as in the R3C cells (Figure 3.10, B.). Taken together, the data highlight a potential tumor
suppressor role for Rin1 in MDA-MB 231 breast cancer cells. The decrease in telomerase
activity observed for the Rin1 and R3C cells (Tables 2.2 and 3.1) is particularly interesting
given that the MDA-MB 231 cell line contains a constitutively active mutant form of Ras;
therefore, overexpression of Rin1 in these cells appears to effectively counter the
heightened signaling through the MAPK pathway.
In summary, telomerase activity in MDA-MB 231 breast cancer cells is modulated by
the form of Rin1 that is expressed. While Rin1 Y561F and Rin1 delta do not bind as
strongly to activated Ras when compared to Rin1, the deletion of 62 amino acids from Rin1
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delta and the Y561F point mutation appear to affect their ability to bind with activated Ras
and thus permit enhanced signaling through the MAPK pathway. The inhibitory effect of
Rin1 on telomerase activity may be partially explained by the interaction of its Ras
Association (RA) domain with Ras. The RA domain of Rin1 is located in the carboxy
terminus of Rin1 and overexpression of the Rin1 carboxy terminal region (R3C) in MDAMB 231 cells reduces telomerase activity by 1.11 fold. Although Rin1 Y561F and Rin1
delta each contain the RA domain, the altered structures of these Rin1 constructs due to
point mutation and deletion prevents efficient binding to active Ras and may therefore
allow for enhanced MAPK signaling over that of Rin1 as evidenced by increased
telomerase activity.
3.4

Materials and Methods

Creation of Cell Lines
The MDA-MB 231 cell lines stably expressing the Rin1 Y561F and Rin1 delta
constructs were created using the same protocol as described previously in 2.4, Creation
of Cell Lines. Lentiviral plasmid expression vectors for Rin1 Y561F (pLV[Exp]-PuroCMV>hRIN1Y561F) and Rin1delta (pLV[Exp]-Puro-CMV>hRIN1 delta) were designed
using the VectorBuilder website (https://en.vectorbuilder.com/) powered by Cyagen
Biosciences. The Rin1 gene sequence was mutated to produce the open reading frame
sequences for Rin1 Y561F and Rin1 delta. MDA-MB 231 cell lines expressing the amino
(R2N) or carboxyl (R3C) terminal regions of Rin1 were generously provided by Wei
Zhang, a fellow graduate student from the Barbieri lab at Florida International University.
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Western Blotting
Western blotting analysis of the MDA-MB 231 R2N and R3C cell lines to confirm the
expression of the Rin1 amino and carboxyl terminal regions, as well as the Rin1 Y561F
and Rin1 delta constructs, was performed in the same manner as described previously in
2.4, Western Blotting. Additionally, Western blotting analysis was utilized to determine the
effect of the various MDA-MB 231 Rin1 constructs (Rin1, Rin1 Y561F, Rin1 delta, and
GFP) on telomerase protein expression following IGF-1 stimulation (50 ng/mL) for 24
hours. The effect of stimulation with different IGF-1 concentrations (0, 10, or 50 ng/mL)
for 12 hours on telomerase protein expression was performed using MDA-MB 231 GFP
cells.
Determination of the cellular mechanism underlying the regulation of telomerase
activity by Rin1 was performed in MDA-MB 231 cell lines expressing either GFP, Rin1,
the amino terminal (R2N), or the carboxyl terminal (R3C) of Rin1. Briefly, 2.0 x 105 cells
for each MDA-MB 231 construct were grown in 1 mL starvation media for 24 hours. The
starvation media for each cell sample was then replaced with 1mL of chilled Krebs-Ringer
buffer supplemented with 25 ng/mL of IGF-1. The cell samples were immediately chilled
at 4°C with rocking for 30 minutes to allow for IGF-1 receptor binding. The IGF-1
induction (25 ng/mL) was then performed by incubating the cell samples at 37°C for either
0, 5, or 10 minutes. The samples were lysed at these respective times and prepared for
Western blotting analysis according to the protocol discussed previously in 2.4, Western
blotting. Cell samples were assessed for changes in the levels of protein expression over
time for key signaling proteins such as p44/42, phospho-p44/42, STAT3, phospho-STAT3,
Ets2, and phospho-Ets2. The effect of the Rin1 amino (R2N) and carboxyl (R3C) regions
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on the ratio of phopho-ERK/ERK was also determined by Western blotting. Cells were
stimulated with IGF-1 (100 ng/mL) for 24 hours and then prepared for Western blotting
analysis as described previously in 2.4, Western Blotting.
IGF-1 Assay
In order to assess the effect of insulin-like growth factor 1 (IGF-1) concentration on the
proliferation of MDA-MB 231 cells, cells expressing GFP, Rin1, Rin1 Y561F, and Rin1
delta were exposed to various concentrations of IGF-1. The cells were initially grown under
the same conditions as described in 2.4, MTT Cell Proliferation Assay. The cells were
plated on a 12 well plate at a concentration of 2.0 x 105 cells per mL with one mL per well
and cultured for 24 hours under serum free conditions. After 24 hours, the cells were
exposed in triplicate to four different concentrations of IGF-1: 20 ng/mL, 60 ng/mL, and
100 ng/mL. A control group of cells was not exposed to IGF-1 (0 ng/mL). Human IGF-1
(20 ug) was purchased from Shenandoah Biotechnology and diluted in sterile, deionized
water to a concentration of 1 ng/uL. After 24 hours of exposure to the various IGF-1
concentrations, the effect of the growth factor on cell proliferation was determined by an
MTT assay in the same manner as described under the 2.4, MTT Cell Proliferation Assay.
An ANOVA was utilized to detect any statistically significant difference in cell
proliferation as a function of IGF-1 concentration.
Telomerase Activity Assay
The MDA-MB 231 human breast cancer cells expressing Rin1 Y561F and Rin1delta as
well as the amino (R2N) and carboxyl (R3C) terminal regions of Rin1 were serum starved
for 24 hours at 37°C and 5% CO2 on a 12 well plate at a density of 1.0 x 105 cells per well
in 1 mL of serum free growth media. Each of the four MDA-MB 231 cell types were plated
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in duplicate. After 24 hours, 100 ng/mL of IGF-1 was added to half of the total samplesone well per cell type. The other half of the samples did not receive IGF-1 treatment. The
samples were then incubated for another 24 hours, after which time the culture media in
each well was removed and the cells were subsequently prepared for the telomeric repeat
amplification protocol (TRAP) assay as per the manufacturer’s instructions and as
previously described in 2.4, Telomerase Activity Assay.
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Figure 3.1: Lentiviral vector used to create the MDA-MB 231 cell line expressing Rin1
Y561F. The Rin1 Y561F gene sequence is inserted directly downstream of the CMV
promoter. An identical vector with the Rin1 delta gene sequence inserted was used to
create the MDA-MB 231 cell line expressing Rin1 delta. Also labeled are the various
elements necessary for lentivirus production and cell selection.
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Figure 3.2: A) Confocal micrograph image of MDA-MB 231 cells expressing Rin1
Y561F. Rin1 Y561F tends to localize throughout the cytoplasm. B) Light micrograph
image illustrating the even growth pattern of MDA-MB 231 cells expressing Rin1
Y561F.
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Figure 3.3: A) Confocal micrograph image of MDA-MB 231 cells expressing Rin1
delta. Rin1 delta tends to localize throughout the cytoplasm. B) Light micrograph image
illustrating the even growth pattern of MDA-MB 231 cells expressing Rin1 delta.
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Figure 3.4: Western blot image of the A) MDA-MB 231 Rin1 Y561F cell line
40X
expressing Rin1 Y561F. B) MDA-MB 231 Rin delta cell line overexpressing Rin1
delta.

Rin1
carboxy
region

GAPDH

Figure 3.5: Expression of the carboxyl terminal region of Rin1 in the MDA-MB 231
R3C cell line.
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Figure 3.6: Effect of IGF-1 concentration on telomerase protein expression in MDAMB 231 GFP cells. Cells were stimulated with 0, 10, or 50 ng/mL of IGF-1 for 12
hours.
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Figure 3.7: Effect of Rin1 constructs on telomerase protein expression in MDA-MB
231 cells. Cells were stimulated with 50 ng/mL of IGF-1 for 24 hours. Values
represent the percent increase normalized to GFP cells.
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Figure 3.8: Effect of Rin1 amino (R2N) and carboxyl (R3C) terminal regions on the
ratio of p-ERK/ERK in MDA-MB 231 GFP cells following IGF-1 stimulation (100
ng/mL) for 24 hours.
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Figure 3.9: Western blot image of the effect of Rin1 on the expression and
phosphorylation status of various proteins in the MDA-MB 231 GFP and Rin1 cell lines
following IGF-1 induction (25 ng/mL) for the times indicated (minutes).
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Figure 3.10: Western blot image of the effect of Rin1 on the expression and
phosphorylation status of various proteins in the MDA-MB 231 amino (R2N) and
carboxyl (R3C) cell lines following IGF-1 induction (25 ng/mL) for the times indicated
(minutes).

153

MDA-MB 231 Telomerase Activity of Rin1 Constructs
Average Ct Value ± Standard Error
Telomerase positive control

25.03 ± 0.20

Telomerase negative control

25.40 ± 0.10

GFP (+) IGF-1

25.94 ± 0.10

GFP (-) IGF-1

25.82 ± 0.21

Rin1 Y561F (+) IGF-1

25.88 ± 0.16

Rin1 Y561F (-) IGF-1

25.82 ± 0.23

Rin1 delta (+) IGF-1

25.92 ± 0.13

Rin1 delta (-) IGF-1

25.82 ± 0.43

Rin1 R2N (+) IGF-1

26.03 ± 0.13

Rin1 R2N (-) IGF-1

25.74 ± 0.27

Rin1 R3C (+) IGF-1

26.09 ± 0.24

Rin1 R3C (-) IGF-1

27.48 ± 1.73

Buffer

25.80 ± 0.15

Table 3.1: Cycle threshold values (Ct) for the qPCR of telomerase activity in MDAMB 231 Rin1 construct cell lines following stimulation with 100 ng/mL of IGF-1 (+)
for 24 hours or no stimulation (-). Rin1 Y561F and Rin1 delta cells display 1.04 and
1.01 fold increases in telomerase activity compared to GFP cells. Rin1 R2N and Rin1
R3C cells display 1.06 and 1.11 fold decreases in telomerase activity compared to GFP
cells.
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Effect of IGF-1 Concentration on Cellular Proliferation
20 ng/mL
60 ng/mL
100 ng/mL

Proliferation (% Increase over Control)

80
70
60
50
40
30
20
10
0
GFP

Rin1 Y561F

Rin1 delta

Figure 3.11: The effect of IGF-1 concentration on cellular proliferation in MDA-MB
231 cells expressing Rin1 Y561F or Rin1 delta. Values represent the percent increase
in cellular proliferation over an unstimulated (0 ng/mL) control. All experiments were
conducted in triplicate. Error bars represent standard error of the mean.
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CHAPTER 4
The Effect of Rin1 on Telomerase Activity in Human Glioblastoma and Melanoma
Cells
4.1

Introduction
Small GTPases have recently come to the forefront of cell biology as important

regulators of numerous cellular processes. Key cellular events such as extracellular signal
transduction, proliferation, cell motility, and cytoskeletal rearrangements are all regulated
to some extent by the action of small GTPases (Carvalho et al., 2015). Cellular small
GTPases encompass a large and diverse group of proteins ranging from the heterotrimeric
G-proteins associated with plasma membrane G-protein coupled receptors to the small and
mostly cytosolic monomeric G-proteins (Csepanyi-Komi et al., 2012). The latter category
of small GTPases has garnered much attention lately for their ability to function as
molecular switches in the control of a variety of cellular processes, particularly those
related to signal transduction, cell survival/proliferation, and cell motility.
The Ras superfamily of small monomeric GTPases are perhaps the best understood and
most extensively studied in terms of their structure and function. The discovery of the Ras
(rat sarcoma) small GTPase almost twenty years ago has since led to the identification of
a multitude of other small GTPases with similar structure and function to that of Ras. The
Ras superfamily of small GTPases can be broadly divided into five distinct groups: Ras,
Rho, Rab, Arf, and Ran (Carvalho et al., 2015). Each group within the Ras superfamily of
small GTPases share a similar protein structure but can regulate separate and distinct
cellular processes via their subcellular locations and interactions with downstream
effectors (Bos et al., 2007). Additionally, the activity of each member of the Ras GTPase
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superfamily is controlled by a specific set of regulators known as guanine nucleotide
exchange factors (GEFs) and GTPase activating proteins (GAPs).
In terms of their cellular roles, members of the Ras small GTPases are principally
involved in extracellular signal transduction as well as in regulating cell differentiation and
proliferation (Simanshu et al., 2017). The Arf and Rab family members are known to
coordinate vesicle formation and intracellular vesicle trafficking as well as exocytosis,
while Rho GTPases are known regulate cell motility and migration through control of
cytoskeletal dynamics (Bos et al., 2007). The import and export of nuclear cargo as well as
nuclear envelope and mitotic spindle formation are regulated by the Ran GTPases (Bos et
al., 2007). Regardless of their individual roles, all Ras superfamily small GTPases have in
common a highly conserved guanine nucleotide binding domain that consists of a six
stranded β sheet surrounded by five α helices (Cherfils and Zeghouf, 2013). Also contained
within this domain are two switch regions referred to as Switch 1 (residues 30-38) and
Switch 2 (residues 59-76) that change conformation when GTP is hydrolyzed as well as a
phosphate binding loop (P-loop) (Carvalho et al., 2015). The two switch regions and the
P-loop are involved in interactions with the phosphates of the bound guanine nucleotide
and an essential magnesium ion that is necessary for strong binding of the nucleotide to the
GTPase. Additionally, the carboxy terminus of most small GTPases is often modified by
the attachment of prenyl groups such as farnesyl or geranylgeranyl that help to localize the
G-protein to specific membranes. (Bos et al., 2007).
Most small GTPases are approximately 20-25 kDa in size and all are capable of GTP
hydrolysis (Csepanyi-Komi et al., 2012). Small GTPases function as molecular switches
by alternating between an active and an inactive state. The binding of GDP to the protein
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favors the inactive state while the binding of GTP results in activation of the G-protein
(Bos et al., 2007; Carvalho et al., 2015; Csepanyi-Komi et al., 2012). The exchange of GDP
for GTP, and thus protein activation, is facilitated by multidomain proteins known as
guanine nucleotide exchange factors (GEFs). Each member of the Ras superfamily of small
GTPases is regulated by a specific group of GEFs with distinct structures (domains) and
subcellular locations. For example, all GEFs for the Ras small GTPases contain a CDC25
homology domain along with a Ras exchange motif (REM) while most Arf family GEFs
contain a Sec7 domain. The GEFs for Rho family GTPases typically contain a DH-PH
domain while Vps9, Sec2, and Mss4 domains are characteristic of Rab family GEFs. The
Ran GTPases are activated by the RCC1 GEFs (Bos et al., 2007; Cherfils and Zeghouf,
2013). Other domains involved in protein interaction such as SH2, SH3, PH, and C1 are
commonly found in GEFs besides the necessary GEF domains listed above (CsepanyiKomi et al., 2012). Upon activation by their respective GEFs, small GTPases then interact
with unique sets of downstream effector proteins to perform the specific cellular functions
associated with that particular family of small GTPases.
While GEFs are responsible for the activation of small GTPases by helping to exchange
GDP for GTP, GTPase activating proteins (GAPs) promote the hydrolysis of GTP to GDP
and thus result in G-protein inactivation. All small GTPases display intrinsic GTPase
activity, however this activity is often very slow and not useful on a biological timescale.
The GAPs therefore increase the rate of GTP hydrolysis by several orders of magnitude
(Cherfils and Zeghouf, 2013). Like GEFs, most GAPs are multidomain proteins that
interact with high specificity towards a particular family of small GTPases.
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The mechanisms of GEF activation and GAP inactivation are best understood for the
Ras small GTPases. The activation of Ras typically occurs upon binding of growth factors
such as epidermal growth factor (EGF) or insulin-like growth factor 1 (IGF-1) to their
respective plasma membrane receptors. Growth factor activation of these receptor tyrosine
kinases (RTKs) promotes the binding of adaptor proteins such as Grb2 to phospho-tyrosine
residues on the activated RTK (Erijman and Shifman, 2016). A Ras GEF known as SOS
binds to Grb2 and then activates Ras by stimulating the exchange of GDP for GTP. The
GEF activity of SOS involves conformational changes in the two switch regions of Ras as
well as in the P-loop. Specifically, the CDC25 GEF domain of SOS interacts with the
switch 2 region and opens up the nucleotide binding site of Ras through the insertion of an
α helix (Erijman and Shifman, 2016; Kiel et al., 2004). The interaction ultimately disturbs
the magnesium ion within the nucleotide binding site of Ras and results in a decreased
affinity of the G-protein for the phosphate groups of the bound GDP nucleotide. The GDP
nucleotide is therefore displaced from Ras beginning with the release of the phosphate
groups first while the incoming GTP nucleotide binds first through its base. High
intracellular levels of GTP favor binding of GTP over re-binding of GDP once GDP is
released from the G-protein (Erijman and Shifman, 2016; Kiel et al., 2004).
The inactivation of the Ras small GTPase occurs through the hydrolysis of the terminal
(γ) phosphate group of GTP through a mechanism involving stimulation by a Ras-GAP.
The Ras-GAP promotes GTP hydrolysis through the insertion of a specific arginine residue
(arginine finger) of the Ras-GAP that stabilizes the transition state by reducing the negative
charge on the terminal phosphate group of GTP (Erijman and Shifman, 2016; Kiel et al.,
2004). The actual hydrolysis of GTP is then accomplished by the coordination of a water
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molecule by a glutamine residue within Ras. The Ras-GAP helps to orient this glutamine
residue for optimal GTP hydrolysis (Erijman and Shifman, 2016; Kiel et al., 2004).
While the general mechanisms of GEF and GAP activity are similar across the Ras
superfamily of small GTPases, there do exist subtle differences in function depending on
the particular G-protein family. For instance, the Vps9 domain of the Rab5 GEF known as
Rin1 activates Rab5 through the insertion of a group of α helices into the nucleotide binding
site of Rab5. Here, an aspartate residue rather than an arginine residue, interacts with the
P-loop of Rab5 to promote the exchange of GDP for GTP (Cherfils and Zeghouf, 2013;
Barr and Lambright, 2010). Similarly, the Rabex5 GEF activates Rab21 by using its Vps9
domain to pry open the switch 1 region and then inserts an aspartate residue to interfere
with the magnesium and phosphate binding sites (Barr and Lambright, 2010). Second
messenger molecules such as cAMP are also known to activate the Rap small GTPases
involved in cell adhesion. cAMP directly activates the Rap GEF Epac1 as well as protein
kinase A (PKA), which in turn can phosphorylate Rap1 on its C-terminus and affect its
subcellular localization. In another point of divergence with Ras, the RapGAP itself
provides an asparagine residue to coordinate the attacking water molecule rather than the
glutamine residue provided by Ras (Gloerich and Bos, 2011).
A growing body of evidence also implicates small GTPases in certain aspects of
tumorigenesis (McFarlin et al., 2003). One of the defining hallmarks of most malignant
cancers is the ability to spread or metastasize to new locations within the body and establish
new tumors at sites distant from the primary tumor. In order for metastasis to occur, cancer
cells must acquire an increasingly mobile phenotype that can lead to cell migration. The
series of changes in cell morphology that accompany increased cell motility are often
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referred to as the epithelial to mesenchymal transition (EMT). The EMT is characterized
by changes in epithelial cell polarity and loss of contact with neighboring cells. The Rho
small GTPases figure prominently in the EMT given their normal roles of regulating
cytoskeletal dynamics (Jansen et al., 2018).
The Rho family of small GTPases is quite large and can be broadly divided into three
main subfamilies (Rho, Rac, and Cdc42) with each consisting of various related members.
The most extensively studied and best understood Rho G-proteins are RhoA, Rac1, and
Cdc42 (Wertheimer et al., 2012). Like other small, monomeric GTPases, Rho protein
activity is regulated by GEFs and GAPs. Most Rho GEFs contain a Dbl homology (DH)
domain where the GEF activity resides and a pleckstrin homology (PH) domain that is
capable of binding the membrane phospho-inositol lipid PI(3,4,5)P3. The binding of
RhoGEF to PI(3,4,5)P3 following RTK or GPCR activation releases the autoinhibition of
the DH domain. The RhoGEF is then free to activate a specific Rho G-protein and thus a
specific group of downstream effectors that control rearrangement of the actin cytoskeleton
(Hanna and El-Sibai, 2013). Unlike most RhoGAPs that stimulate GTP hydrolysis, the
Rac1 GAP known as IQGAP1 is unusual in that it binds to GTP-Rac1 but does not exhibit
GAP activity. Instead, IQGAP1 appears to interfere with the stability of adherens junctions
by possibly interacting with β-catenin (Jansen et al., 2018).
The Rho dependent control of cell migration is illustrated in the regulation of focal
adhesion formation by focal adhesion kinase (FAK). Focal adhesions are defined by
interactions of integrins with ECM proteins and are typically found at the leading edge of
migrating cells. In a proposed model of focal adhesion regulation, FAK binds to and
phosphorylates the p190RhoGAP. This phosphorylation step activates the p190RhoGAP
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and results in the inhibition of RhoA (Tomar and Schlaepfer, 2009). A push/pull
mechanism of cell movement occurs at the leading edge of the cell in which a reciprocal
relationship between RhoA and Rac1 is the driving force. Elevated RhoA activity
(pull/increased contractility) can inhibit Rac1 activity whereas decreased RhoA activity
(push/decreased contractility) permits increased Rac1 activity. FAK mediated
phosphorylation of the p190RhoGEF known as Rgnef activates RhoA and thus balances
the p190RhoGAP activity as well as the migratory push/pull dynamic (Tomar and
Schlaepfer, 2009).
The antagonistic relationship between RhoA and Rac1 is further illustrated in the type
of cell movement governed by each protein. The RhoA activity tends to promote a
cytoskeletal organization that results in a more generalized, amoeboid type of movement
needed for cells to move through the ECM. In contrast, Rac1 activity is associated with a
more directed type of movement such as lamellipodia formation (Kutys and Yamada, 2014;
Parri and Chiarugi, 2010). In this example, increased Rac1 activity leads to the generation
of reactive oxygen species (ROS) that oxidize and inactivate the low molecular weight
protein tyrosine phosphatase (LMW-PTP) responsible for p190RhoGAP regulation. As a
consequence, the p190RhoGAP remains phosphorylated and in an active state capable of
downregulating RhoA activity through enhanced GTP hydrolysis (Parri and Chiarugi,
2010). The Rac1 activity also negatively influences RhoA activity through the downstream
WAVE-2 effector complex. Conversely, low ROS levels activate LMW-PTP and therefore
inactivate p190RhoGAP through its dephosphorylation. As a result, RhoA activity
increases and begins to inhibit Rac1 through activation of the Rac1GAP known as
ARHGAP2 (Parri and Chiarugi, 2010).
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The Rac1 activity is often very high in breast cancer cells and further underscores the
importance of Rac GTPases in the malignant transformation of cells. The RacGEF P-Rex1
has been identified as an important activator of Rac1 and its expression is frequently
upregulated in many breast cancers. The R-Rex1 is activated by signal inputs received from
both the ErbB family of tyrosine kinase receptors as well as from GPCRs such as CXCR4
(Sosa et al., 2010). In the case of ErbB transactivation of CXCR4, the βγ subunit of CXCR4
activates PI3Kγ which in turn produces PI(3,4,5)P3 at the plasma membrane. The P-Rex1
is then activated upon binding of its PH domain to PI(3,4,5)P3 and consequently promotes
Rac1 activation (Wertheimer et al., 2012). Additionally, Dillon et al. (2015) report that PRex1 may be able to create a positive feedback loop where P-Rex1 can activate the IGF-1
receptor as well as PI3K/AKT and MAPK signaling.
Inhibition of PI3K has also been shown to reduce MAPK signaling in breast cancer cells
overexpressing HER2 (ErbB2) or expressing a constitutively active mutant form of PI3K.
Here, PI3K inhibition suppresses Rac1 activation and thus limits the Rac1 mediated
activation of its p21 protein activated kinase (PAK) effector. As a consequence, this
subsequently reduces c-RAF1 activity and ultimately leads to lowered MAPK activity (Ebi
et al., 2013). Hyperactive Rac3, like Rac1, is also associated with persistent p21 PAK and
c-Jun N-terminal kinase (JNK) activation in certain breast cancer cell lines (Mira et al.,
2000). In breast cancer cells overexpressing the IGF-1 receptor, knockdown of Rac1
greatly reduced resistance to the Trastuzumab anti-HER2 monoclonal antibody (Zhao et
al., 2011).
Inappropriate regulation of small GTPases by GEFs and/or GAPs is a common
mechanism in tumorigenesis. This is true for most members of the Ras superfamily of small
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G-proteins, but especially true for the Rho family of G-proteins where gain-of-function or
loss-of-function mutations in GEFs or GAPs can lead to increased cell motility. There are
however examples of where the Rho protein itself may be mutated and thus contribute to
cancer development, such as the Rac1 P29L mutation observed in certain cases of
melanoma. The activating mutation affects the switch 1 region and may help to stabilize
the binding of GTP (Alan and Lundquist, 2013).
Unlike other members of the Ras superfamily, Ras proteins themselves are typically
mutated with high frequency in a majority of cancers. The three major isoforms of Ras (KRas, N-Ras, and H-Ras) contain activating mutations in 15% to 30% of all cancers (Alan
and Lundquist, 2013). Most of these mutations occur at positions 12, 13, and 61 and
interfere with the ability of a RasGAP to stimulate GTP hydrolysis. Mutations at positions
12 and 13 specifically block the insertion of the RasGAP arginine finger while a mutation
at position 61 interferes with the coordination of the water molecule needed for GTP
hydrolysis (Simanshu et al., 2017).
In addition to the common mutations directly affecting Ras itself, mutational loss of
RasGAP function can also contribute significantly to tumor development. For instance,
loss of the RasGAP known as neurofibrimin is common in glioblastomas and contributes
to the development of neurofibromatosis type 1 disease (Vigil et al., 2010). Mutational loss
of another RasGAP called RHEB (Ras homology enriched in brain) is associated with a
disorder known as tuberous sclerosis complex. Functional Rheb consists of a complex of
two proteins known as tuberin and harmartin that are encoded by the TSC1 and TSC2 genes
respectively (Vigil et al., 2010). Mutation of either gene can result in constitutive activation
of the Rheb small GTPase and its effector mTORC1, with mTORC1 activity being strongly
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linked to increased cell growth and proliferation. The Rheb GAP activity is normally
regulated by inactivation of tuberin through an Akt mediated phosphorylation. Therefore,
mutations that activate PI3K or inactivate PTEN are also associated with oncogenic Rheb
activation (Vigil et al., 2010). Similarly, the Rag small GTPases can also regulate mTORC1
activity through the sensing of cellular amino acid concentrations. Loss of the GATOR1
RagGAP results in hyperactive mTORC1 activity that is insensitive to amino acid depletion
(Bar-Peled et al., 2013).
Epigenetic regulation of RasGAPs has recently been identified as an important
mechanism in tumor formation. As an example, overexpression of the histone
methyltransferase EZH2 subunit of the polycomb repressor complex 2 (PRC2) in prostate
cancer cells results in transcriptional silencing of the DAB2IP RasGAP gene. The loss of
DAB2IP RasGAP may represent a critical step in prostate cancer development and
subsequent metastasis (Maertens and Cichowski, 2014). Epigenetic silencing of the
RASAL2 RasGAP promoter via methylation has also been observed in certain metastatic
breast cancer cell lines exhibiting reduced RASAL2 expression (Maertens and Cichowski,
2014; McLaughlin et al., 2013). The importance of RasGAPs in the regulation of Ras
activity and tumor formation is highlighted in hepatocellular carcinoma cells. Here,
transcriptional silencing via promoter methylation of either NF1, DAB2IP, or RASAL2
results in hyperactivity of wild type Ras and increased tumor aggressiveness (Calvisi et al.,
2011).
In summary, the Ras superfamily of small GTPases mediate a number of important
cellular processes related to cell survival and proliferation. Events such as signal
transduction, cytoskeletal dynamics, and cell motility are all regulated by small G-proteins.
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Direct mutation of small GTPases or mutations in the GEFs/GAPs that regulate their
activity are commonplace in many cancers. Further research specifically into the
mechanisms of small GTPase regulation will undoubtedly reveal novel therapeutic
approaches for cancer treatment.
4.2

Results
The U87 and U118 MG human glioblastoma cell lines overexpressing GFP and Rin1

were virally transduced (Figure 4.1) and selected for stable GFP and Rin1 expression
(Figure 4.2) as described in 4.4, Creation of Cell Lines. The Yusik melanoma cell lines
overexpressing GFP and Rin1 were also created and selected for stable GFP and Rin1
expression as described in 4.4, Creation of Cell Lines. Light micrograph images of the U87
MG human glioblastoma cell lines expressing GFP or Rin1 reveal stark differences in
cellular morphology and growth patterns. The U87 MG cells that overexpress GFP
(endogenous Rin1 levels) appear to grow more quickly and form distinct, irregularly
clumped tumors (Figure 4.3, A.) when compared to cells expressing Rin1 (Figure 4.3, B.).
The cells that express Rin1 tend to have a steady growth rate and are more evenly dispersed
across the surface of the culture dish (Figure 4.3, B.).
Both the U87 and U118 MG cell lines displayed appreciable telomerase activity
following IGF-1 stimulation (100 ng/mL) for 24 hours. With respect to the GFP cells, the
U87 MG Rin1 cells displayed an increase in telomerase activity of 1.3 fold (Table 4.1).
Similarly, a 1.1 fold increase in telomerase activity was observed for the U118 MG Rin1
cells when compared to the GFP cells (Table 4.2). Although a similar trend in telomerase
activity following IGF-1 induction was observed for the U87 and U118 MG human
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glioblastoma cell lines, the average Ct values for the respective Rin1 cells differed by
approximately 2 cycles, 26.13 versus 28.03 (Tables 4.1 and 4.2).
The Yusik human melanoma cell line was also utilized to investigate the effect of Rin1
expression on telomerase activity. Here, the Rin1 cells displayed a 1.49 fold decrease in
telomerase activity when compared to the GFP cells (Table 4.3). The decrease in
telomerase activity for Yusik melanoma cells overexpressing Rin1 closely mirrors that
observed in the MDA-MB 231 Rin1 breast cancer cells (Table 2.2).
4.3

Discussion
The effect of Rin1 on telomerase activity was examined in two human glioblastoma cell

lines, U87 and U118 MG, and one human melanoma cell line, Yusik, in order to clarify if
the influence of Rin1 on telomerase activity is cell type specific. The telomerase activity
profiles for the MDA-MB 231 Rin1 breast cancer and Yusik Rin1 melanoma cell lines
were remarkably similar. Overexpression of Rin1 reduced telomerase activity in each of
these cell lines in comparison to the corresponding GFP expressing cells. Overexpression
of Rin1 resulted in an approximate 1.50 fold reduction in telomerase activity for both cell
lines following IGF-1 induction (Tables 2.2 and 4.3). The competition of Rin1 with RAF1
for binding to activated Ras may partially explain this result. The decrease in telomerase
activity observed for the MDA-MB 231 Rin1 cells is particularly interesting given that the
cell line contains a constitutively active mutant form of Ras; therefore, overexpression of
Rin1 in these cells appears to effectively counter the heightened signaling through the
MAPK pathway. Similarly, a mutation in the BRAF gene (V600E) is present in the Yusik
melanoma cell line and contributes significantly to malignancy in these cells through a
constitutively active form of BRAF. Surprisingly, the ability of Rin1 to attenuate MAPK
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signaling, and thus telomerase activity, in these cells was unexpected given that BRAF is
constitutively active and not dependent upon competition with Rin1 to be activated by Ras.
The ability of Rin1 modulate telomerase activity through MAPK signaling is largely
dependent on the particular isoform of Rin1 expressed and the cell type it is expressed in.
A potential tumor suppressive role for Rin1 is supported by its effect on telomerase activity
in the human MDA-MB 231 breast cancer and human Yusik melanoma cell lines, while an
oncogenic effect is apparent in the U87 and U118 MG human glioblastoma cell lines. A
comparison of light micrograph images of U87 MG cells expressing either GFP or Rin1
reveals a more even, steady growth pattern for cells overexpressing Rin1 versus the more
clumped, tumorigenic appearance of the control (endogenous Rin1) GFP expressing cells
(Figure 4.3, A. and B.). The observed differences in growth pattern and rate may be partly
attributed to increased telomerase activity in the cells overexpressing Rin1. In fact,
telomerase activity in the U87 MG Rin1 cells was 1.3 fold greater than in the corresponding
GFP cells (Table 4.1). Additionally, a 1.1 fold increase in telomerase activity over the GFP
cells was observed for the U118 MG Rin1 cells (Table 4.2). The heightened tumorigenicity
of the U87 MG Rin1 cells is further evidenced by an average Ct value that is roughly 2
cycles lower than that of the corresponding U118 MG Rin1 cells.
In contrast to the MDA-MB 231 breast cancer and Yusik melanoma cell lines, Rin1
appears to promote telomerase activity in both the U87 and U118 MG glioblastoma cell
lines. The exact mechanisms underlying cell specific differences in the effect of Rin1 on
telomerase activity are unclear and remain an area for future research.
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4.4

Materials and Methods

Creation of Cell Lines
The U87 MG and U118 MG human glioblastoma cell lines as well as the Yusik human
melanoma cell line stably expressing GFP and Rin1, were created using the same protocol
as described previously in 2.4, Creation of Cell Lines. However, these cell lines were
selected using a puromycin concentration of 1µg/mL to account for the increased
sensitivity of these cells to puromycin.
Telomerase Activity Assay
The human U87 MG and U118 MG glioblastoma cell lines as well as the human Yusik
melanoma cell line expressing GFP and Rin1 were serum starved for 24 hours at 37°C and
5% CO2 on a 12 well plate at a density of 1.0 x 105 cells per well in 1 mL of serum free
growth media. All samples for each of the cell types were plated in duplicate. After 24
hours, 100 ng/mL of IGF-1 was added to half of the total samples- one well per cell type.
The other half of the samples did not receive IGF-1 treatment. The samples were then
incubated for another 24 hours, after which time the culture media in each well was
removed and the cells were subsequently prepared for the telomeric repeat amplification
protocol (TRAP) assay as per the manufacturer’s instructions and as previously described
in 2.4, Telomerase Activity Assay.
Western Blotting
Western blotting analysis of the U87 MG, U118 MG, and Yusik cell lines to confirm
the expression of GFP and Rin1 was performed in the same manner as described previously
in 2.4, Western Blotting.
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Figure 4.1: Lentiviral vector used to create the U87 MG, U118 MG, and Yusik cell lines
expressing Rin1. The Rin1 gene sequence is inserted directly downstream of the CMV
promoter. An identical vector with the GFP gene sequence inserted was used to create
the U87 MG, U118 MG, and Yusik cell lines expressing GFP. Also labeled are the
various elements necessary for lentivirus production and cell selection.
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Figure 4.2: Western blot image of the A) U87 MG glioblastoma cell line expressing
GFP and endogenous levels of Rin1. B) U87 MG glioblastoma cell line overexpressing
Rin1.

A.

B.

Figure 4.3: Light micrograph images of the A) U87 MG GFP cells growing in a
clumped, irregular pattern and B) U87 MG Rin1 cells growing in an even, uniform
pattern.
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U87 MG Telomerase Activity
Average Ct Value ± Standard Error
Telomerase positive control

25.16 ± 0.27

Telomerase negative control

25.69 ± 0.33

GFP (+) IGF-1

26.47 ± 0.44

GFP (-) IGF-1

25.80 ± 0.15

Rin1 (+) IGF-1

26.13 ± 0.04

Rin1 (-) IGF-1

26.18 ± 0.01

Buffer

26.19 ± 0.49

26.13-26.47= -0.34
-(-0.34)

2
= 1.3
1.3 fold increase in telomerase activity compared to GFP cells.
Table 4.1: Cycle threshold values (Ct) for the qPCR products of telomerase activity in
U87 MG cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours or
no stimulation (-). All experiments were conducted in duplicate.
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Figure 4.4: Western blot image of the A) U118 MG glioblastoma cell line expressing
GFP and endogenous levels of Rin1. B) U118 MG glioblastoma cell line overexpressing
Rin1.
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U118 MG Telomerase Activity
Average Ct Value ± Standard Error
Telomerase positive control

27.34 ± 0.14

Telomerase negative control

28.38 ± 0.09

GFP (+) IGF-1

28.20 ± 0.16

GFP (-) IGF-1

28.07 ± 0.12

Rin1 (+) IGF-1

28.03 ± 0.02

Rin1 (-) IGF-1

27.88 ± 0.10

Buffer

28.20 ± 0.18

28.03-28.20= -0.17
-(-0.17)

2
= 1.1
1.1 fold increase in telomerase activity compared to GFP cells.
Table 4.2: Cycle threshold values (Ct) for the qPCR products of telomerase activity in
U118 MG cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours or
no stimulation (-). All experiments were conducted in duplicate.
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Figure 4.5: Western blot image of the A) Yusik melanoma cell line expressing GFP and
endogenous levels of Rin1. B) Yusik melanoma cell line overexpressing Rin1.
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Yusik Telomerase Activity
Average Ct Value ± Standard Error

Telomerase positive control

25.37 ± 0.06

Telomerase negative control

25.99 ± 0.26

GFP (+) IGF-1

26.41 ± 0.11

GFP (-) IGF-1

26.35 ± 0.13

Rin1 (+) IGF-1

26.99 ± 0.18

Rin1 (-) IGF-1

26.73 ± 0.24

Buffer

25.85 ± 0.20

26.99-26.41= 0.58
-0.58

2 = 0.67
1/0.67=1.49
1.49 fold decrease in telomerase activity compared to GFP cells.
Table 4.3: Cycle threshold values (Ct) for the qPCR products of telomerase activity in
Yusik cell lines following stimulation with 100 ng/mL of IGF-1 (+) for 24 hours or no
stimulation (-). All experiments were conducted in duplicate.
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CHAPTER 5
Conclusions and Future Work
The telomere regions of eukaryotic chromosomes are vital to the maintenance of
genome stability. The gradual loss of telomeric DNA that occurs with each round of cell
division acts like a molecular clock to set a finite limit on the number of times a population
of cells can undergo cell division. The replicative limit is often reached when the telomeric
DNA has become eroded to the point that genomic instability begins to occur as a
consequence of chromosomal translocations and fusions. The replicative limit is bypassed
in certain populations of cells that express the telomerase enzyme. In fact, activation of
telomerase activity is a common mechanism by which many cancer cells acquire the
immortal replicative phenotype that is frequently associated with malignant
transformation.
The Ras and Rab interactor 1 protein (Rin1) may be able to regulate telomerase activity
in cancer cells given its ability to modulate signaling through the MAPK pathway.
Attenuation of MAPK is believed to occur as a result of the direct competition between
Rin1 and RAF1 for binding to activated Ras. The hypothesis was examined in different
cancer cell lines engineered to overexpress Rin1 or other Rin1 constructs such as Rin1
Y561F and Rin1 delta. Three specific aims were developed in order to determine if Rin1
can indeed function as a tumor suppressor in various cancer cell lines. The first aim of the
research investigated the effect of Rin1 expression on cellular proliferation and viability as
well as on telomerase gene expression and activity in three different human breast cell
lines. The cell lines consisted of the tumorigenic and highly invasive MDA-MB 231 breast
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cancer cells, the tumorigenic but non-invasive MCF7 breast cancer cells, and the normal,
non-tumorigenic/non-invasive MCF12A breast epithelial cells.
The Rin1 protein appears to function as a potential tumor suppressor in MDA-MB 231
breast cancer cells by downregulating telomerase activity. Reduced telomerase activity was
also observed in the MCF7 cells. Downregulation of telomerase gene expression, a
downstream target of the MAPK pathway, was observed in the MDA-MB 231 cells
overexpressing Rin1. Similarly, the MCF-7 and MCF12A cells also exhibited reductions
in telomerase gene expression as a consequence of Rin1 expression. Interestingly, Rin1
had the least suppressive effect on telomerase gene expression in the MDA-MB 231 cells
while the strongest effect was observed in the MCF-12A cells. The result may be partially
explained by the fact that the MDA-MB 231 cells harbor a constitutively active mutant
form of Ras that may counteract the tumor suppressive effect of Rin1. The ability of Rin1
to suppress telomerase gene expression in the MCF7 cells is intermediate between that of
the MDA-MB 231 and MCF-12A cells. The finding may be attributed to the tumorigenic
but non-invasive nature of these cells.
In line with reduced telomerase gene expression and activity, MDA-MB 231 breast
cancer cells overexpressing Rin1 generally display lower levels of cell proliferation and
viability following IGF-1 stimulation when compared to non-transfected or GFP
expressing cells. The result was also observed for the MCF-12A cells and to a lesser extent
for the MCF7 cells. The MDA-MB 231 Rin1 cells grew more slowly and in a distinct
clumped pattern in comparison to the GFP cells.
Growth factor receptors such as the insulin-like growth factor 1 receptor (IGF-1R) and
the epidermal growth factor receptor (EGFR) play a prominent role in the development of
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breast cancer. The stimulatory effect of mitogens like IGF-1 or EGF on cellular
proliferation and migration is well documented, as are the abnormalities in these receptors
that often contribute to the unrestrained cell growth that is characteristic of so many
different types of cancers. Besides growth factor receptors, the estrogen receptor (ER) also
figures predominantly in breast cancer tumorigenesis. The signaling pathways activated by
both types of receptors are an intense area of research and have shed light on the
mechanisms of action by which various mitogens exert their oncogenic effects.
Therefore, in line with the importance of cell signaling to cancer cell growth and
survival, the second aim of the research examined the effect of Rin1 expression on MAPK
signaling and telomerase protein expression in MDA-MB 231 cells. Western blotting
analysis of key MAPK pathway proteins following IGF-1 stimulation reveals reduced
phosphorylation of the p-44/42 and Ets2 transcription factors. A strong inhibition of p44/42 phosphorylation as well as reduced telomerase activity were also observed in the
MDA-MB 231 cells overexpressing the carboxyl terminal region of Rin1 containing the
Ras association domain. Similarly, overexpression of Rin1 in MDA-MB 231 breast cancer
cells reduces telomerase protein expression in comparison to cells expressing either the
Rin1 Y561F and Rin1 delta constructs. The Y561F and delta forms of Rin1 do not bind as
strongly to activated Ras when compared to the wild type form of Rin1. As such, they have
a lesser ability to modulate MPAK signaling and thus display increased levels of
telomerase activity following IGF-1 stimulation. Additionally, the Y561F and delta forms
of Rin1 display increased levels of cellular proliferation across a range of IGF-1
concentrations when compared to cells expressing Rin1. Taken together, the data support
a possible tumor suppressive role for Rin1 in MDA-MB 231 breast cancer cells.
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The third aim of the research sought to investigate the effect of Rin1 expression on
telomerase activity in cell lines other than breast cells. The cell lines utilized were the
human Yusik melanoma cells as well as the U87 MG and U118 MG human glioblastoma
cells. The effect of Rin1 on telomerase activity and thus its potential role as a tumor
suppressor is not as clear in those cell lines as it is for the breast cell lines studied. In the
Yusik melanoma cells that express a constitutively active mutant form of BRAF (V600E),
Rin1 appears to function as a tumor suppressor by lowering telomerase activity in a manner
very similar to that of the MDA-MB 231 breast cancer cells. However, its role in the U87
MG and U118 MG glioblastoma cells appears to be that of a possible oncogene through
upregulation of telomerase activity. The results suggest that Rin1 is able to moderate
telomerase activity in cancer cells in a manner that is largely dependent upon cell type.
A clearer picture of the potential tumor suppressor role of Rin1 will be obtained through
future experimentation in a few key areas. Firstly, while the current research focused on
the full length Rin1 protein as well as the amino and carboxyl terminal regions of Rin1, it
would be beneficial to investigate what effect, if any, other domains of Rin1 might have
on cellular proliferation/viability, telomerase gene and protein expression, and telomerase
activity. For instance, the Vps9 domain of Rin1 is a known GEF for the Rab5 protein
involved in the sorting of early endocytic vesicles. Could overexpression of the Vps9
domain or mutants of this specific domain affect signaling in other cancer cells besides
MDA-MB 231 cells?
Another critical area for future research would be to determine if Rin1 or specific
domains of Rin1 can influence the expression and/or phosphorylation status of MAPK
signaling proteins in cell lines other than the MDA-MB 231 cells. Specifically, the carboxyl
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terminal region of Rin1 is a potent inhibitor of the phosphorylation of certain MAPK
signaling proteins and can reduce telomerase activity. Would the same effects be observed
in different cancer cell lines as well as normal cell lines? Also, what effect might the Rin1
Y561F and delta constructs have on telomerase gene expression and activity in cell lines
other than the MDA-MB 231 cells? Lastly, the effect of Rin1 expression on telomerase
gene expression and activity in response to stimulation by other growth factors such as
EGF should also be examined.
In summary, the research findings indicate a novel molecular mechanism of action for
Rin1 in specific cancer cell lines. Future experimentation to further elucidate the potential
tumor suppressive role for Rin1 is needed and will expand upon the findings reported here.
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